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Abstract 
The majonty of d iabetics develop neuropathy, wh ich can be debi l itati ng , but the 
underlying pathophysiolog ica l mechanisms are poorly understood . Diabetic 
neuropathy progresses in a d istal to proximal manner. Previous studies have shown 
that g l utamate, the most common excitatory neurotransmitter, plays a role in the 
pathogenesIs of neuropathy. The reason why the role of g lutamate in  nociception 
becomes a problem in  d iabetes and the mechanisms that are i nvolved are unknown . 
Based on the pre l im inary data, the hypothesis was that g lutamate pathways are 
l ikely to be involved in  d iabetic neuropathy particu larly neuropathic pa in .  Pathways 
were investigated to look for changes that might reflect neuropathic pain and fit with 
previously establ ished pharmacolog ical evidence. The aim of this project was to 
identify changes in expression of genes and thei r prote in products that are i nvolved 
in  g lutamate signa l l ing in  d iabetes .  This wil l help to further the understanding of the 
mechanisms of d iabetic neuropathy. In d iabetic rats, there were cons istent changes 
in  expression,  part icu larly i n  the lumbar  and sacra l dorsal root gangl ia  of the spina l  
cord and in  the sympathetic gangl ia .  The changes were consistent between the 
different g roups of an imals as wel l  as between adjacent groups of gangl ia .  The most 
prominent changes in both the G K  g roups included marked upregu lation of Gria4 
( ionotropic AMPA receptor) , downregulat ion of Grik3 and Grik4 (both ionotropic, 
ka in ite receptors) and Grin 1 and Grin2A (both ionotropic, NMDA receptors) ,  
activation of a l l  of which has been shown to induce hypera lgesia ;  downregulation of 
S Ic1  a6 (excitatory amino acid transporter 4 )  and upregu lation of S Ic1  a 1  (excitatory 
amino acid transporter 3) ,  both of which mediate neural reuptake of g lutamate from 
the synapt ic cleft; and upreg ulation of Gclc (g lutathione synthase), which reflects a 
response to protect against oxidat ive damage.  
vii  
Despite many theories eXist ing about the pathogenesis of d iabetic neuropathy, there 
is  no un ify ing hypothes Is .  It is possible that changes in g l utamate s ignal l ing can 
contribute to these other mechanisms and possibly un ify these d ifferent theories.  A 
better understanding of the role that g l utamate plays in deve lopment of d iabetic 
neuropathy may pave the way for future therapeutic intervention. 
Keywords: Diabetes, Diabetic Neuropathy, G lutamate Signal l ing ,  Dorsal Root 
Gangl ia ,  Sympathetic Gangl ia .  
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Chapter 1: Introduction 
1 . 1 D i a betes M e l l itus 
The term Diabetes mel l itus comprises a group of metabol ic d isorders 
characterized by the presence of excess blood g lucose; hyperg lycaemia (A. D. 
Associat ion,  201 4) .  The defect in  d iabetes is characterized by defects in insu l in  
secretion or act ion,  or a combination of both .  Th is d isturbs the carbohydrate, fat and 
prote in  metabol ism.  The result ing hyperg lycaemia leads to long-term damage, 
dysfunction and consequent fa i lu re of severa l organs .  These compl ications are 
debi l itat ing enough that affect the qua l ity of l ife and mortal ity (Albert i ,  Zimmet, & 
Consultat ion,  1 998). Compl icat ions and their consequences occur such as 
ret inopathy lead to b l indness, nephropathy to renal  fa i lure ,  neuropathy to foot u lcers 
or amputation ,  autonomic dysfunction and its variety of manifestations .  D iabetics 
are prone to cardiovascular, peri pheral vascular and cerebrovascu lar d isease. 
Patients with d iabetes often present with characteristic symptoms such as 
excessive th i rst, the passing of excessive urine (polyuria) ,  b lurred vis ion and loss of 
weight .  Some patients present in  the ketoacidosis or non-ketot ic hyperosmolar state 
that can lead to stupor, coma and in extreme cases death. Un less dramatic, the 
absence of symptoms or una larm ing symptoms can go unchecked and lead to the 
development of compl ications before d iabetes is  d iagnosed. These symptoms are 
usual ly  because of the presence of hyperglycemia (Albert i ,  1 998) . 
1 . 2 Statistics a n d  Dia betes 
Diabetes and other forms of g lucose into lerance; impaired g lucose tolerance 
( IGT) and impaired fasting  g lucose ( I FG) ,  are now found in  every populat ion and 
there is  epidemiological evidence suggesting the burden of d iabetes is  increasing 
g lobal ly and cont inu ing to do so.  Diabetes places a heavy tol l  on the socioeconomic 
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fabric of society due to the large number of people affected (Wi ld, Rog l ic, Green, 
S icree, & King,  2004) .  From 1 75 mi l l ion d iabetics in  2000 (Yach , Stuckler, & 
Brownel l ,  2006) to 371  m i l l ion currently affected ( I DF 201 4) ,  d iabetes is a pandemic 
of  ep ic  prop0rtions.  
Worldwide rank wise, Kuwait 3rd , Qatar 6th , Saudi Arabia 7th , Bahra in 8th and 
U nited Arab Emirates 1 0th a l l  have places in  the top 1 0  countries with prevalence of 
d iabetes at 20-79 years of age in 201 1 .  These positions are expected to ascend by 
2030 considering the current prevalence rate (D .  Chen & Wang) .  
In  the U n ited Arab Emirates the ENDCAD study in 2000,  1 9 .6% of the total 
population was found to be d iabetic; 24% locals and 1 7 .4% expatriates (ENCAD 
UAE, 2009). Diabetes is one of the major causes of mortal ity in UAE , causing 2 -
3% of deaths (Ministry of Health strategic plan till 201 0, 2000) . 
1 . 3 C lass ification of D i a betes M e l l i tus:  
This often depends on how the patient presents at the t ime of d iagnosis and 
although some do not easi ly f i t  into a s ingle category, the classificat ion is important 
from a therapeutic point of view. This a l lows better understanding of the 
pathogenesis of the hyperg lycemia and leads towards better treatment options.  
Although the majority of the d iabetic i nd iv iduals fa l l  i nto two broad 
etiopathogenetic categories, as d iscussed below, assig n ing a type of d iabetes to an 
ind iv idual  depends on the circumstances present at the t ime of diagnosis .  Many 
d iabetic ind iv iduals do not eas i ly  fit i nto any single c lass .  For example ,  a female 
patient who has gestationa l  d iabetes mel l itus may continue to be hyperg lycaemic 
after del ivery and in fact have type 2 d iabetes .  An indiv idual who acqu i res d iabetes 
because of large doses of steroids may become normog lycaemic when the steroids 
are d iscontinued but later on deve lop d iabetes after instances of pancreatit is. 
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Another example IS a person treated with thiazides who develops d iabetes years 
later and It could be because the person had type 2 diabetes exacerbated by the 
drug . For the c l in ician and the patient , having the correct label for the type of 
d iabetes leads to better understanding of the pathogenesis of the hyperg lycaemia 
and effective treatment strateg ies. 
One of the earl iest formal  attempts to classify d iabetes un iformly was by the 
1 964 World Health Organization Expert Committee .  I t  was recognized that clear 
class ification would a id epidemiological  approaches and advance cl in ica l research in 
developing of evidence based therapies. A symptomatic classification was adopted 
and the age of onset was an addit iona l  criteria . The age characterization was as 
fol lows (Me l l itus & Organization ,  1 965) :  
1 .  I nfanti le or chi ldhood d iabetes (0- 1 4  years of age) 
2. Young diabetes ( 1 5-24 years of age) 
3 .  Adult d iabetes (25-64 years of age) 
4. Elder ly d iabetes (65 and above years of age) 
However ,  the terms type 1 d iabetes and type 2 d iabetes emerged fol lowing 
the National Diabetes Data Group (N DDG) in  the USA and the second report of the 
WHO Expert Committee on Diabetes Mel l itus .  
Two main classes of d iabetes were suggested:  insu l in-dependent d iabetes 
mel l itus (100M/type 1 )  and non- insu l in  dependent d iabetes mel l itus ( N I DDM/type 2) .  
'Other types' and gestat ional  d iabetes mel l itus were a lso added to  the l ist .  The 
condit ion of impai red g lucose tolerance ( IGT) also appeared , replacing 'borderl ine' 
d iabetes ("WHO Expert Committee on Diabetes Mel l i tus: second report ," 1 980) . 
The 1 999 classificat ion reta ined the main groups of type 1 ,  type 2 ,  other 
specific types, and gestat ional  d iabetes, but the terms ' insu l in  dependent' and 'non­
insul in dependent' were presumed to be confusing and so dropped (Albert i ,  1 998) 
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Currently ("WHO, Diabetes report" 201 3) d iabetes is genera l ly classified into 
Type 1 ,  Type 2 and other types of d iabetes. Type 1 resu lts from the destruction of 
beta cel ls of pancreas leading to total insu l in  deficiency. Type 2 is a combination of 
progressive secretory defect combined with insu l in  resistance. Other types include 
gestat ional d iabetes and diabetes occurring due to genetic defects of beta cel l  
function or insu l in  act ion or d iseases of the pancreas itself or due to chemicals or 
drugs (Gabir, 2000).  
1 .4 Physio logy of I n s u l i n  and G l u cose control 
I nsu l in 's name is derived from the Latin insula for " island". I nsu l in  is 
produced by the beta cel ls that l ie in  the middle of the pancreatic is lets.  These is lets, 
which range from one mi l l ion to three m i l l ion ,  form the 2% endocrine part of the 
pancreas - a predominant ly exocrine g land .  With in the islets, the beta ce l ls  
constitute 65-80% of a l l  the ce l ls .  The beta ce l ls  also secrete amyl in (Hal l ,  201 1 ) .  
The pancreatic islets are a lso where the a lpha,  delta and P P  cel ls  reside. 
The alpha cel ls  secrete g l ucagon ,  the delta cel l s  secrete somatostat in and the PP 
cel ls  secrete pancreatic polypeptide.  These cel ls are closely related and the 
proxim ity a l lows d i rect control of hormone secretion by the other hormones. Such as 
insu l in  i nh ibit ing the secretion of g lucagon,  amyl in  inh ibit ing insu l in  and somatostatin 
i nh ibit ing insu l in  and g lucagon (Ha l l ,  201 1 ) . 
I nsu l in  is  the main hormone for food derived energy storage and is coded for 
on chromosome 1 1 .  I nsu l in  is a prote in and in humans has a molecu lar weight of 
5808. It cons ists of two amino acid chains bound by disu lfide bonds. I nsu l in  is first 
made by the endoplasmic reticu lum as prepro insu l in  which is cleaved to form 
pro insu l in  and cleaved i nto the A and B chain that are bound together and the C 
chain that is separated in  the Goig i  a pparatus. The insu l i n  and C peptide are packed 
into secretory g ranules.  When insu l in  is re leased into the blood it is an unbound 
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form and has a plasma half- l i fe of s ix m inutes. With in fifteen minutes it is cleared 
from the circulation The port ion of insu l in  that is not bound to receptors is degraded 
by insu l inase. I n  the liver, 50% of It is degraded, the rest is cleared by the kidneys 
(Ha l l ,  20 1 1 )  
The l iver achieves a constant level of g lucose despite variations of food 
intake and energy usage by processes such as g lucose storage and 
g luconeogenesis .  Tissue specific g lucose uti l ization requ i res g lucose transporters 
which ord inar i ly depend on insu l in .  The bra in  however does not need insu l in  
although i t  i s  the ma in  consumer of the body's g lucose. M uscle and fat t issues are 
facultative g lucose consumers (Barrett E K ,  201 2; Cahi l l ,  Rossin i ,  & Aok i ,  1 974; 
Rodney A.  Rhoades , 20 1 4 ; Ross in i ,  L ike ,  Ch ick,  Appel ,  & Cahi l l ,  1 977) .  
The insu l in  receptor is a combination of four  subunits that are l inked with 
each other by d isu lfide bonds. The two a lpha subun its are extracel lu lar  and the two 
beta subunits are transmembrane. I nsu l in  binds to the a lpha subunits and 
consequently the beta sUbunits are activated and become autophosphory lated . This 
activates a local tyrosine k inase which causes phosphorylates other enzymes 
including a g roup cal led insu l in-receptor substrates .  Different types of these 
substrates are expressed in  d ifferent t issue. Act ivati ng these, in  turn, activates some 
enzymes wh i le inact ivati ng others . I nsu l in  d i rects the metabol ic machinery in ce l ls to 
bring about the desired effects on carbohydrates, fat and proteins .  
After insu l in  b inds,  the cel ls  increase their  uptake of g lucose. This is  of 
particu la r  importance for muscle cel ls and adipose cel ls .  The increase of g lucose 
leve ls in the cel ls  leads to phosphorylation and provid ing a substrate for the 
carbohydrate metabol ic funct ions. The g lucose is taken up by the increased 
ava i labi l ity of intrace l lu lar  vesicles to the cel l  surface . Insu l in  causes cel ls to become 
permeable to amino acids ,  potassium and phosphate ions.  I nsu l in  also affects 
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translation of messenger RNAs at the ribosomes for new prote in production and 
also alters rate of DNA transcript ion.  I nsu l in thus remolds much of the cel lu lar  
enzymes to ach ieve its metabol ic goals (Ha l l ,  201 1 ) . 
The resting muscle membrane is only s l ight ly g lucose permeable but on 
Insu l in  stimu lation g lucose is a l lowed to enter the muscle. During exercise and when 
large amounts g lucose is avai lable after a meal ,  the extra insu l in  secreted by the 
pancreas stimu lates the muscle to take up g lucose. During much of the day, muscle 
depends on fatty acids rather than g lucose for its energy requ i rements. 
In muscle, especia l ly  during periods of inactiv ity, the g lucose that is  taken up 
is  stored as g lycogen or broken into lactate which fuels hepatic g luconeogenesis .  I n  
fat ,  g lucose is a source of energy and a substrate for trig lyceride synthesis (Gale 
EAM, 2002) . 
One of the most important effects of insu l in  is to cause the l iver to store 
g lucose that is avai lable after a meal .  I nsu l in  bri ngs a bout these act ions by 
enhancing the activity of enzymes such as g l ucokinase and g lycogen synthase . This 
he lps form g lycogen. I nsu l in  suppresses activity of enzymes such as phosphorylase 
and g lucose phosphatase. The net effect of these actions increases the g lycogen 
content in  the l iver. I nsu l in  also prevents g l uconeogenesis by suppressing enzymes 
and amino acid re lease from extra hepatic t issues such as the l iver. However, hours 
after a meal  the levels of insu l in  and g l ucose fa l l  i n  the blood and l iver g lycogen 
breaks down to provide the requ i red g lucose . I f  the l iver cel ls  cannot store more 
g lycogen,  insu l in  promotes convert ing the excess g lucose to fatty acids. After the 
l iver g lycogen content reaches approximately five to six percent, further g lycogen 
synthesis is  inh ibited and a l l  addit ional g lucose forms fatty acids and trig lycerides to 
store. I nsu l in  a lso encourages fat storage into adipose cel ls by enhancing g lucose 
transport into cel l s  and inh ibit ing l ipase. The lack of insu l in  causes l ipolysis of stored 
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fats and release of fatty acids ,  increases plasma cholesterol levels and in extreme 
cases can lead to ketosis and acidosis The effect of prote in  metabol ism by insu l in  
Includes stimulat ing amino ac id transport into cel ls ,  increasing messenger RNA 
translat ion, Increasing the rate of transcription of selected DNA genetic sequences 
to a l low more RNA and thus protein to form and inh ibit ing protein catabol ism (Ha l l ,  
201 1 ) .  
Glucose transporters are classed as the GLUT fami ly and  have dist inct 
substrate specificit ies , coding genes kinetic propert ies, and t issue d istributions 
determin ing roles and expression.  GLUT -4 is  the main insu l in  responsive g lucose 
transporter and is main ly located in muscle ce l ls and adipocytes. I nsu l in  binds to the 
receptor, activat ing tyrosine k inase phosphorylat ion and a series of ce l lu lar  events 
ensue a l lowing g lucose inside the cell (Shepherd & Kahn ,  1 999) .  A member of the 
g lucose transporter (GLUT 2) is  found in  beta cel ls and a l low a rate of g lucose to 
enter these cel ls that is proport iona l  to the blood concentration in  the physio logica l  
range.  Once inside the beta cel ls ,  g lucose is converted to g lucose-6-phosphate by 
g lucokinase. Th is is the rate l im it ing step for g lucose metabol ism in the beta ce l l  and 
is thought to be the main mechanism for g lucose sensing and adjustment of the 
amount of secreted insul in to g lucose levels (Ha l l ,  201 1 ) . 
1.5 Type 1 D i a betes 
Type 1 Diabetes affects 5-1 0% of d iabetics and arises from the immune 
mediated destruct ion of the beta cel ls  and is commonly associated with other 
autoimmune d isorders (Amer D iabet, 201 1 ) . In some cases there may be an 
inherited tendency for beta cel l  degeneration without the involvement of v i ra l  
infect ions or auto immune d isorders (Ha l l ,  201 1 ) . 
The commonest form of d iabetes is Type 2 with u p  to 90% of d iabetics 
having th is type, although Type 1 is a lso on the i ncrease (Patterson, 2002). 
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Type 1 d iabetes stems from the immune mediated destruction of the beta 
cel ls Markers of th is destruction include autoantibodies such as;  islet ce l l  
autoantIbodies,  insu l in  autoantibodies,  and autoantibodies to  GAD and tyrosine 
phosphatasE's IA-2 and IA-2b. Most d iabetics have one or more of these 
autoantibodies upon d iagnosis .  These patients are a lso more prone to other 
autoimmune disorder such as Graves' d isease, viti l igo ,  myasthenia gravis and so 
forth .  
Type 1 d iabetes has strong H LA associations ,  with l i nkage to  DOA and DOB 
genes and is a lso under the inf luence of ORB genes. These H LA-DRIDO al leles can 
be either pred ispos ing or protective of d iabetes (A. D. Association ,  201 4) .  
The term Type 1 d iabetes however does not encompass the forms of beta 
cel l  destruction or fa i lure to which specific causes can be attributed such as cystic 
fibrosis (Alberti ,  1 998). There are other forms of Type 1 diabetes that have unknown 
etio logies.  Some of these d iabetics have permanent lack of insul in and are at 
increased risk of deve loping ketoacidosis but have on indication of autoimmun ity. 
These ind iv iduals are ra re and more often of African or Asian descent. They 
experience ketoacidosis at i nterva ls and have vary ing degrees of i nsu l in  deficiency. 
The requ i rement for insu l in  to be replaced in  their bod ies may come and go (A. D. 
Association ,  201 4) .  This form is often classed as Type 1 B  - a ra rer form of Type 1 
d iabetes. Type 1 A  is the commoner form , result ing from the auto immune destruction 
of beta cel is  (Daneman 2004) .  
The auto immun ity of type 1 d ia betes is  a concept that has been backed by 
several important research studies and one of the most persuasive evidence was 
provided by case reports of d iabetes developing in people who received bone 
marrow from type 1 d iabetics. The recipients first underwent bone marrow ablation 
as treatment for condit ions such as haematological cancers to remove a l l  immune 
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cel ls  To bnng back their Immune system they received bone marrow donations from 
s ib l ings with type 1 d iabetes. However, they themselves developed type 1 d iabetes 
sever years later. This provides evidence for the theory that immune cel ls were 
transferred In the bone marrow destroyed the beta cel ls (Wass A H  J ,  201 1 ) . 
Autoreactive T cel ls  aga inst the pancreatic ce l ls  are produced and expand . 
Due to the deficient regulation of T cel l  response, clonal expansion of these 
particular T cel l s  cont inues unchecked and triggers a response of beta antigen 
specific (T cel l )  immune and other i nflammatory responses that destroy the beta 
cel ls .  Ord inari ly ,  T cel ls the react against se lf-ant igens are checked and halted 
during development and eventual ly  e l im inated by clonal delet ion.  However in type 1 
diabetes, as in  other autoimmune condit ions, th is censoring process is not effective. 
One of the methods to interrupt and reverse the autoimmunity of type 1 
d iabetes before end organ damage occurs has been the advent of bone marrow 
transplant as a treatment opt ion.  However, th is has its own compl ications and 
d ifficult ies (Domen ick & I Idstad ,  200 1 ) .  
Auto immun ity does not exist i n  a l l  forms of type 1 d iabetes , I n  some patients 
th is is lacking as is the WHO d iabetes class ification of the type 1 B category .  I n  
Japan,  th is  form o f  d iabetes h a s  been described as affecting 1 5-20% of type 1 
d iabetes and marked in  the absence of insu l it is and d iabetes-related antibod ies, an 
abrupt onset with preced ing of common cold l i ke and gastro intest ina l  symptoms, a 
surpris ing ly near normal leve l of HbA 1 c despite the h igh levels of g lucose, and h igh 
leve ls  of  serum pancreatic enzyme concentrations ( I magawa , Hanafusa,  M iyagawa, 
& Matsuzawa, 2000) .  
The mechanism of beta cel l  death appears to d iffer in  th is  part icular type of 
d iabetes compared to the autoimmune category. Whi le the beta cel ls  are destroyed 
in auto immune d iabetes over a span of t ime, often severa l years - this destruction is 
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extremely rapid in  the fulm inant form of type 1 d iabetes. This process is postulated 
to be triggered by viral infection (Wi l lcox, 2008) .  
In  the 1 980s, E isenbarth proposed the current model to expla in the 
development of Type 1 A  diabetes and today the basic idea of this model pers ists. 
The model hypothesizes that every person has a susceptibi l ity to develop this type 
of d iabetes but some more so than others. Suscept ibi l ity is inherited , resid ing in the 
HLA genotypes DR and OQ and to a lesser extent in other genetic loci termed 1 00M 
susceptibi l ity genes.  50% of the genetic susceptibi l i ty stems from the H LA  focus and 
1 5% from two genes;  1 00M2 and IOOm 1 2  with minor part ic ipation from the other 
1 00M genes. The suscept ib i l ity genes are thought to be invo lved in the regu lation of 
immune response. 
Exposure to an envi ronmental tr igger that a lters immune function leads to 
beta cell destruct ion.  Triggers such as viruses; enteroviruses, coxsackie, congenital 
rube l la) ,  environmental tox ins such as n itrosamines or food such as early exposure 
to cow mi lk  prote ins and g luten have been l inked to varying degrees. The over 
activation of the T cel l  med iated immune system in those ind iv iduals with increased 
susceptib i l ity experience insu l it is and a B cel l  response the produces antibodies to 
beta cel l  ant igens. As the beta cel ls are destroyed, insu l in  levels drop t i l l  below a 
critica l leve l a state of absolute insu l in  deficiency ensues. The so ca l led 
'honeymoon' period occurs after in it iation of insu l in  therapy beg ins  when some 
insul in  is secreted by few of the last remain ing beta cel ls but these eventua l ly  fa i l  as 
wel l .  
The connection to  auto immunity a lso arises from evidence that these 
patients are also more prone to developing other autoimmune d iseases such as 
Graves' d isease, Addison's d isease, myasthenia g ravis and so on .  There is one 
centra l theory of cause of type 1 d iabetes and occasional ly interest ing hypotheses 
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have cropped up such a s  the hyg iene hypothesis that postu lates early exposure to 
Infections In chi ldren bui lds immun ity and prevents type 1 d iabetes. Another 
Interesting hypothesis is the accelerator hypothesis where the two types of d iabetes 
are only dlstl'lgu ished by the rate of beta ce l l  loss. Three accelerators are postu lated 
In the accelerator hypothesis;  the h igh rate of beta ce l l  apoptosis, insu l in  resistance 
that stresses the col laps ing beta cel l s , immunological ly vulnerable beta ce l ls in  
genet ica l ly  susceptible ind iv iduals .  However these hypotheses need more 
invest igat ion (Oaneman 2004) .  
U nderstanding the a l le l ic  architecture i . e .  identify ing disease associated 
gene variants, how frequently these occur and the risk attached to each variant, of 
type 1 d iabetes wi l l  he lp identify new targets for treatment .  I ndiv iduals are able to 
manage with 20% of the beta cel l  mass and th is offers a window of opportun ity for 
interventions before the d iabetes sets in (Wass A. H J, 201 1 ) . 
Type 1 d iabetes is i ncreasing ,  a recent study by the EU ROOIAB Study g roup 
that assessed 20 populat ion based reg istries in  1 7  European countries,  showed that 
there has been a 3 .9% increase of incidence between 1 989 and 2003 in chi ldren 
aged 5 - 1 5  and a 5 .4% r ise per year in  the under 5 age group. 
Type 1 d iabetes resu lts from a complex interact ion of several genes and 
environmental factors ,  which can promote the d isease and occasional ly protect from 
it. At least four  chromosomal  reg ions are impl icated to contribute to the risk of 
developing type 1 d iabetes ,  the H LA reg ion on chromosome 6p2 1 IOOM 1 , the 
insu l in  gene region at 1 1  p 1 5 1 00M2,  the CTLA4 locus at 2q33 I OOM 1 2  and the 
PTPN22 locus at 1 p 1 3 . There is however no standard for defin ing what is or i s  not a 
risk locus for developing type 1 d iabetes but there is  consistent evidence that 
supports a role for the genes in  these regions to impl icate them as confe rring an 
1 2  
I ncreased risk of developing type 1 d iabetes in  ind iv iduals (Concannon,  Rich, & 
Nepom , 2009) 
The pancreatic patholog ical lesion that is characteristic of type 1 diabetes is 
Insu l it ls .  This term describes the immune cel l  infi ltration surrounding the is lets with 
addit ional immune cel ls scattered around them . Th is appears to increase as the 
beta cel ls  die off. I n  later stages, th is  infi ltrat ion subsides. The beta cel l  prol iferative 
capacity appeared to be unchanged despite the ongoing destructive processes. 
I nsu l it is is commonly observed in  new-onset patients with d iabetes of new onset but 
It does not affect all insu l in  conta in ing is lets equal ly .  Th is is  perhaps due to the 
d ifferences in is let function ;  factors including sensit ivity to g lucose, insu l in  release 
and so on could play a role .  This a lso suggest that during periods of physiologic 
demand for increased insu l in  such as during puberty or  under the influence of h igh 
sugar intake, there might be a population of  is lets more vulnerable to dysfunction 
and cel l  death that attract APCs and promote insu l it is i n  certa in  genetica l ly  
susceptible patients. These funct ional d ifferences between the is lets could expla in 
why autoreactive lymphocytes target some is lets more than others (Rowe A .  Patrick, 
201 1 ) . 
Analysis of the immune cel l  i nfi ltrate in  T 1  0 is lets show that during the in i t ia l  
period of beta cel l  death ,  the most abundant immune cel ls  are the CD8+ cytotoxic T 
cel ls .  
Once the decl ine in  beta cel ls is establ ished , the larger share of population 
consists of the CD20+ cel ls .  However, once the beta ce l ls are complete ly destroyed, 
immune cel ls decrease dramatical ly in the is lets and th is suggests that their role is 
only whi le viable beta cel ls  exist. The stimu lus for i nsu l it is decl i nes after the death of 
beta cel ls .  G lucagon sta in ing is  normal in such is lets and this shows that a lpha cel ls  
are unaffected (Wi l lcox, 2008) , 
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Type 1 d iabetes mel l itus develops in  stages 0Nass A . H  J ,  201 1 ) : 
Stage 1 - In  this stage , a trigger a l lows the T lymphocytes to develop the abi l ity to 
recogn ize � cel l  autoantigens that emerge from the thymus. This lets the periphera l  
Immune system from birth conta in  adaptive immune cel ls  with the abi l ity to attack 
the beta cel ls .  Immunogenetic studies on type 1 d iabetes have backed this 
Information.  H LA genes that increase r isk of developing type 1 d iabetes could 
possibly involve the ineffective functions of the thymus such as reducing the abi l ity 
of it to delete beta cel l  specific T lymphocytes .  
Stage 2 - inflammation damages the beta cel ls .  Autoantigens to  beta ce l ls are 
released and absorbed by dendrit ic cel ls which migrate to the pancreatic lymph 
nodes and,  in combination with defective thymic funct ion, the islet proteins are 
presented to naIve beta cel l  specific T lymphocytes with the re levant T cel l  
receptors . Viruses have often been thought to  be  culprits in  the  in it iat ion.  
Stage 3 - the imbalance in  immune regu lation a l lows the beta cel l  specific T 
lymphocytes to activate and mature to form the pro-i nflammatory phenotype .  This 
resu lts in  a g reater propensity to activate the harmful T lymphocytes .  
Stage 4 - autoreactive T lymphocytes migrate to  the inflamed islets, further adding 
to the inflammation and beta cel l  damage. Autoreact ive B lymphocyte recruitment is 
also a feature and autoantibod ies may help the i nflammation by form ing immune 
complexes. The beta cel ls  are systematica l ly destroyed from islet to is let . 
Stage 5 - chron ic i nflammation settles and in  this stage the presence of 
autoantibodies are establ ished. Relapses and remissions also occurs in  th is stage 
and these could be inf luenced by events i rre levant to the i n it ia l  trigger. The beta cel l  
destruct ion spreads t i l l  the d isease is  fu l ly  establ ished .  
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1 . 6 Type 2 d i a betes 
Type 2 diabetes is the result of the compl icated i nteractions of genetic and 
environmental factors. Although changes such as an increasingly sedentary l ifestyle 
and excessive consumption of ca lories seem to be triggering factors, genetic 
elements are Involved (Stumvol l ,  Goldstein ,  & van Haeften ,  2005). One of the 
hal lmarks of type 2 d iabetes is insu l in  resistance; which is the inab i l ity of insu l in  to 
be effective at its normal circu lat ing concentrations (Wass A . H .  J ,  20 1 1 ) . The 
presence of hyperg lycaemia ,  characteristic of d iabetes ,  adds to insu l in  resistance in  
skeletal muscle by g lucose toxicity (Rossett i ,  G iaccari , & DeFronzo, 1 990) and 
impairs insu l in-stimu lated g lucose ut i l ization and g lycogen synthesis i n  ske letal 
muscle (Tomas,  2002). 
I nsu l in  and g lucagon act for opposing goals. Glucagon increases the g lucose 
output from the l iver to increase circulat ing g lucose by increasing g luconeogenesis 
and g lycogenolysis .  An excessive or  imbalanced amount of g lucagon contributes to 
the post meal hyperg lycaemia present in  type 2 d iabetes since g lucagon is not 
suppressed normal ly (Dunn ing & Gerich, 2007) .  The incret in effect, observation that 
g ut derived factors enhance g lucose stimu lated insu l in  secretion from the pancreatic 
beta cel ls  more than parenteral g l ucose infusions, is  a lso s ign ificantly b lunted in type 
2 d iabetics which could be due to the decrease in  sensit iv ity of is lets to the incretin  
hormones. G lycaemic control part ia l ly compensates for th is defect (Drucker & 
Nauck).  
Type 2 d iabetes is  the qu intessentia l  mu lt ifactoria l  trait ,  where indiv idual  r isk 
is  determ ined by compl icated interactions of genet ic and environmental factors. 
Although changes such as an increasingly sedentary l ifestyle and excessive 
consumption of calories seem to be tr iggering factors, genetic elements are a lso 
i nvolved in the pathogenesis of th is disorder. A positive fami ly h istory increases the 
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r isk to develop type 2 d iabetes by 2 .4  fold .  1 5-25% of first degree relatives of 
patients with type 2 d iabetes develop d iabetes or the state of impaired g lucose 
tolerance. If  one parent has type 2 d iabetes, the l ifetime risk for the offspring is 
calcu lated to be 38% and this Increases to 60% if both parents are affl icted . 
Twin  studies have also added to this knowledge. D izygotic twins share 50% 
of their genes, un l ike monozygotic twins .  Concordance rates in the latter twins have 
been used to d ifferentiate between genetic and non-genetic contribut ions. In people 
older than 60 years of age , concordance rates for d iabetes were 35-58% in 
monozygotic twins and 1 7-20% in  d izygotic twins (Stumvol l ,  2005) .  
This is based on the 'equa l  environment assumption' s ince twins share 
s imi lar  environments, the increased concordance rates for d isease in  monozygotic 
twins compared with d izygotic twins ind icate the importance of genetic factors that 
contribute to type 2 d iabetes .  The understanding of the molecular basis of th is 
complex disease is h i ndered at several leve ls . Several features of th is compl icated 
disease is at root such as the variable age of onset, the varying degrees of severity 
that makes phenotyping difficult , locus and a l le l ic heterogene ity which impl icates 
several genes across mu lt iple bio log ica l pathways i nteract with the environment to 
confer risk or offer protection aga inst the disease. Each suscept ib i l ity gene and 
environmental factor contributes to the d isease with vary ing resu lts in d ifferent 
populations so repl icating these results in other populations is d ifficult . Also severa l 
minor contributing genes make trad itional  l i nkage based approaches difficult and 
large studies are needed to fi nd these genes. 
L inkage studies in  type 2 d iabetes have encountered lack of repl ication of 
peaks of l ineage and difficult ies i n  identifying the underly ing genes. I n  fact, the only 
type 2 d iabetes gene identified us ing l inkage and posit ion c loning is  cal pain 1 0  and 
th is too has not been widely accepted .  The doubt a rises because l inkage to 
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CAPN 1 0  on chromosome 2q was only detected in Mexican Americans.  SNPs 
associated with type 2 diabetes were a set of functional ly unclear variants . the 
orig ina l  fi nd ings with CAP N 1  0 were not repl icated in  other populations and i ts actual 
function and mechanism in  relat ion to d iabetes was unclear. Some loci have been 
Identified and found to be in d ifferent populations as wel l ;  however none have strong 
evidence in  their favour. Study of the intermediate phenotypes of type 2 d iabetes, 
rather than when the disease is fu l ly  establ ished. has uncovered other loci .  
Association studies have a lso been employed,  especia l ly of the candidate 
gene type, in studying the genetics of type 2 d iabetes .  These studies have often 
focused on genes encoding pathways of g lucose i nduced insu l in  secretion from beta 
cel ls ,  peripheral insu l in  led uptake of g lucose by fat and muscle and also the 
inf luence of insu l in  on the l iver's g luconeogenic pathways. These studies have 
revealed certa in  genes and polymorph isms such as the common Pr0 1 2  al le le which 
has a frequency range 80-90% in d ifferent populat ions of the Pr0 1 2Ala 
polymorphism in PPARG, the E23K variant of KCNJ 1 1 and late ly the involvement of 
the H N F4A gene (Barroso, 2005). 
Type 2 d iabetes has proven to be very heterogeneous and genetic stud ies 
have shown very d iverse results .  Two of the most popu lar methods used to study 
genetic factors involved in  d isease include the candidate gene approach and the 
genome wide scan approach. The candidate gene approach examines specific 
genes with a p laus ible role in the disease process. This is done by test ing the 
statistica l association of a g iven a l le le  and a phenotype in unrelated people. The 
genome wide scan or l i nkage basis approach locates genes through their genomic 
posit ion and rat ionales that re lated i ndiv iduals sharing a specific phenotype wi l l  a lso 
share chromosomal reg ions surrounding the gene involved (Stumvo l l ,  2005) . 
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However, the candidate gene approach has not had very much success. 
There are several reasons for th is which includes l im itations inherent to the method 
but a lso to the era in  which th is type of research was being widely used. A 
fundamental requ i rement is to have a detai led knowledge of the d isease when 
candidate genes are being selected and since type 2 d iabetes is an incred ibly 
complex disease, any s ing le cand idate gene will have a low chance in  affecting 
susceptibi l ity to the d isease. Also study designs us ing th is technique depend on the 
sample s ize and phenotypic characterizat ion of the studied sample.  Thousands of 
samples are needed and statistics are often appl ied to compensate for the lack of 
sample sizes. Mete-analysis is often used but th is is subject to publ ication bias 
where negative reports often go  unpubl ished and so skew meta-ana lysis and other 
biases and heterogeneity can inf luence the outcome. Variables such as ethn icity, 
age, gender also contribute to heterogeneity ryvass & Stewart, 201 1 ) . 
One major goal  for e lucidating the genetic backdrop of type 2 diabetes is to 
improve treatment by identify ing patients more l i kely than others to benefit from 
specific therapeutic agents. Neonatal d iabetic patients with the KCJ N 1 1  mutat ion,  
when switched from insul in to su lfonylurea showed improved symptoms especial ly 
their  neurological man ifestations that are often severe (Ridderstra le & Groop, 2009). 
Type 2 d iabetes is general ly characterized by four major metabol ic 
abnormalit ies. These are obesity, the impai red action of insu l in ,  dysfunction of 
insu l in  secretion and the increased output of g lucose. The first three are present in 
most patients before onset of the disease , the sequence of development and the 
contributions to the progress from normal to impaired g lucose tolerance to fu l l  blown 
d iabetes has been d ifficult to ascerta in .  People who develop d iabetes may manifest 
primary defects in both insu l in  action and secretion which predispose them to 
d iabetes .  These defects occur early during development towards establ ished 
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d iabetes and worsen as g lucose tolerance deteriorates. The inabi l ity to  compensate 
for either defective Insu l in  action or secret ion dist inguishes i ndividuals who develop 
d iabetes than those who maintain normal  g lucose tolerance CWeyer, Bogardus, 
Mott , & Pratley, 1 999). 
I nsu l in  resistance is a strong ind icator of type 2 d iabetes but eventual 
development of the disease and hyperglycemia associated with d iabetes is 
associated with deficient insul in secretion .  This defect appears to be determined by 
genetics. I nsu l in  resistance is the inab i l ity of insu l in  to be effective at i ts normal 
circu lat ing concentrat ions. In relation to g lucose, it leads to impai red suppression of 
endogenous g lucose production , in  the basal state and after food consumption, 
when insu l in  rises accord ing the g l ucose absorption from g ut and stop further 
g lucose production by l iver. 
In muscle and ad ipocytes, insu l in  resistance reduces the uptake of g lucose 
and local ized storage of g lycogen and trig lycerides. For the l iver cel ls ,  insu l in  
resistance results i n  a decrease in  the synthesis of g lycogen and g lycogen storage. 
Also g lucose production i s  no longer repressed by the ineffective insul in and more 
g lucose i s  present in the blood. The term I nsu l in  resistance usual ly refers to the 
reduced g lucose-lowering effects of insu l in .  
I nsu l in  res istance has t issue specific consequences. Reduced abi l ity of 
insu l in  to suppress VLDL (very low density l ipoprote in)  production from the l iver 
i ncreases serum trig lycerides,  which leads to a decrease i n  HDL  cholesterol and 
helps form LDL (low density l ipoprote in)  that contributes to atherosclerosis .  I n  
ad ipose t issue, insu l in  resistance increases the flux of non-esterified fatty acids 
( I sh iyama, Taguchi ,  Yamamoto, & Murakami)  to the l iver and skeletal muscle and 
impairs the action of insu l in  on the g lucose metabol ism with in these tissues (Wass 
A . H . J, 201 1 ) . 
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The most Important site of insu l in  resistance appears to be the peripheral 
tissues (OeFronzo, Ferrann in i , Hendler, Fel ig , & Wahren,  1 983). When insul in is 
appl ied as therapy, hepatic insul in sensitivity, as measured d irectly by insul in 's 
ab i l ity to suppress production of g lucose by the l iver, s ign ificantly i ncreases. FFA 
concentrations and rates of l i pid oxidation decrease. Based on the assumption that 
insu l in  inh ibits l ipolys is ,  observat ions that l iver fat reduces and hepatic insu l in  
sensitivity increases could be due to the reduced FFA movement through the l iver 
(Juurinen,  Ti ikkainen, Hakkinen,  Hakkara inen,  & Yki-Jarv inen,  2007). 
I nsu l in  resistance affects the l iver d ifferently during the overn ight fast periods 
and in the postprandia l  state . After an overn ight fast, normal ly ,  insu l in  inh ib its 
endogenous g lucose product ion .  In type 2 d iabetics, the insu l in  resistance adds to 
the increase in basal endogenous product ion .  Excess blood g lucose and increased 
levels of insu l in  normal ly  inh ibit endogenous g lucose production so insu l in  
resistance is  impl icated i n  increasing production of basal  endogenous g lucose 
(Wass A .H .  J, 201 1 ) . 
Once the l iver is insu l in  resistant, the act ion of insu l in  is impa i red and leads 
to hyperg lycaemia accompanied by stimu lat ion of insu l in  secretion .  Addit iona l ly, the 
more the level of res istance at the l iver, the h igher is  the need for endogenous and 
exogenous insu l in .  
I t  i s  postu lated that one of the reason for indiv idual  variation i n  insu l in  
requ i rements i n  type 2 d iabetes is the variation in  insu l in  act ion .  The variat ion in  
hepatic fat content may influence the need for insu l in  by inf luencing the sensitivity of 
endogenous g lucose product ion to insu l in  (Ryysy , 2000) .  
In  the postprand ia l  state, under normal  condit ions, the endogenous g lucose 
production is suppressed due to the increase in insu l in  and decrease in  g lucagon. 
The major effect of insu l in  in  l iver is  the suppression of g lucose output. In type 2 
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diabetics , the g lucose production is not effective ly suppressed due to hepatic 
res istance , deficiency In insu l in  and the presence of excess g lucose. Continual  
production of g lucose by the l iver adds to the post meal hyperg lycaemia.  The rate 
of g lucose usage in type 2 d iabetics is normal  because the presence of 
hyperg lyacemia compensates for the impai red action of insu l in  to increase g lucose 
uptake into t issues 0/Vass A. H .  J, 201 1 ) . 
I nsu l in is an  important regulator of several aspects of adipocyte biology since 
adipocytes are one of the most insu l in  responsive ce l ls .  I nsu l in  promotes trig lyceride 
storage in  adipocytes by assisting the d ifferentiation of preadipocytes to adipocytes 
and, in mature adipocytes ,  by stimu lat ing the transport of g lucose, l ipogenesis and 
inh ibit ing l ipolysis . Functional  defects i n  type 2 d iabetes affects adipocyte regu lation 
and these defects, in  adipocytes ,  can occur from downregulation of the major insu l in  
responsive g lucose transporter; GLUT 4 .  Also insu l in  b inding to i ts receptor, 
phosphorylation of the receptor and consequent tyrosine k inase activity and IRS 
phosphorylation are a l l  reduced.  Th is  occurs in muscle and adipose t issue. 
Particularly i n  ad ipose t issue,  type 2 d iabetics have adipocytes that have reduced 
I RS-1  expression that leads to decreased P 1 3K activity and P I 3  turns to depend on 
I RS-2 as the ma in  docking prote in .  In muscle cel ls ,  a lthough the levels of I RS 1 and 
2 are normal , P I3K  activity is impai red (Kahn & F l ier ,  2000) .  
I nsu l in  resistance i n  adipose t issue is important because l ipolysis is sensit ive 
to insu l in  leve ls .  Adipose t issue is  a lso affected by insu l in  resistance as is evidenced 
by observat ions that there is increased trig lyceride breakdown and h igher fatty acid 
concentrations in  type 2 diabetics compared to normal subjects at s imi lar  insu l in  
levels .  The increased rate of  post meal  free fatty oxidation could a lso lead to 
impai red g lucose output by the l iver and defective stimulat ion of g l ucose oxidat ion.  
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Excessive l ipolysIs lead ing to ketoacidosis does not occur i n  type 2 d iabetes 
because the Insu l in  deficiency is not profound enough to do so (Groop C L , 1 989). 
1 . 7 D i a g n o s i s  of D i a betes 
Correct diagnosis and confirmation of the diagnosis is requ i red especial ly 
considering the impact on the ind iv idual  is considerable and l ifelong . The 
requ i rements for d iagnostic confirmation differ from indiv idual to individual and are 
often based on the presenting symptoms such as severe symptoms and gross 
hyperg lycemia to patients presenting with blood g lucose values j ust above the cut 
off va lue .  Severe g lycaemia detected under condit ions such as acute traumatic or 
infective stress could be transitory and cannot be considered as d iagnostic of 
d iabetes. A s ing le abnormal blood g lucose value in  patient experiencing no 
symptoms is also not enough for a concrete d iagnosis of d iabetes. I n  such cases, 
one addit ional blood g lucose test with a value in  the d iabetic range [fasting/random] 
or  from the oral g lucose tolerance test (OGTT) is  requ i red for d iagnostic 
confi rmat ion.  In the face of unclear d iagnosis ,  period ic re test ing is  advisable t i l l  the 
situation is clarified (Alberti ,  1 998;  Consultat ion, 1 999) 
1 .7 . 1  D iag nostic C rite ria Va l ues:  
A 1 C 2! 6 . 5% OR FPG 1 26 mg/dl [7 .0 mmol/I] . Fasting is defi ned as no caloric 
intake for at least 8 h but p la in water is  a l lowed OR 2-h plasma g lucose 2! 200mg/d l  
( 1 1 . 1  mmol/I) during an  OGTT OR I n  a patient with classic symptoms of 
hyperg lycemia or hyperg lycemic cris is , a random plasma g lucose 2! 200 mg/dl ( 1 1 . 1  
mmol/I) (A. D. Associat ion,  201 4) 
The OGTT test, for a l l  i ntents and purposes, should be resorted to only if the 
blood g lucose values are between levels estab l ish ing or  excluding the d iagnosis of 
d iabetes and fast ing are below d iabetic d iagnostiC values. If  this test is performed it 
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IS enough to  measure the blood g lucose values wh i le fasting and thereafter 2 hours 
after a 75 gm ora l g l ucose load by d issolving anhydrous g lucose in  water. For 
chi ldren this is calcu lated accord ing to body weight: 1 . 75 gm/kg a lthough the 
d iagnostic cr'teria remain the same as for adults. It should be g iven in the morning 
after 3 days of unrestricted eating .  The overn ight fast is usual ly for 8 - 1 4  hours with 
water perm itted (Albert i ,  1 998) 
Although previously thought to be an  unre l iable diagnostic tool for d iabetes 
d ue to lack of standard ization and avai labi l ity (Alberti , 1 998; Consultation, 1 999) 
g lycated haemog lobin (HbA 1 C) is now considered to be a diagnostic tool that 
closely resembles other d iagnostic tools currently used for the correct d iagnosis of 
d iabetes .  Current recommendations and data show that the A 1 C cutoff of 6.5% is 
h igh ly specific and reasonably sensitive in d iagnosing diabetes .  Repeating fasting 
g l ucose tests can min im ize incorrect d iagnosis of d iabetes,  the high re l iab i l ity of A 1 C 
suggests a s ing le measurement is enough for d iagnosis (Selv in ,  Steffes, Gregg ,  
Brancat i ,  & Coresh ,  201 1 ) . 
An I nternat ional Expert Committee,  compris ing members from the European 
Association for the Study of Diabetes, the I nternational  D iabetes Federation and the 
American Diabetes Association reported va lues of HbA 1 c � 6.5% (48 mmol/mol)  as 
the cut-off point for d iagnosing d ia betes . The Un ited Kingdom Department of Health 
recommends using algorithms for d iabetes screen ing in high-r isk ind iv iduals that 
include tradit ional g lucose d iagnostic criteria or, a lternatively, HbA 1 c measurements 
combined or not with g lucose measurements. In non-symptomatic patients , a 
confirmed HbA 1 c ± 6 .5% (48 mmol/mol) is enough to d iagnose Type 2 d iabetes. But 
patients with HbA 1 c levels � 6.0% (42 mmol/mol)  a nd < 6 .5% (48 mmol/mol) should 
undergo  the OGTT to determ ine the diagnosis of d iabetes. However, no further 
testing i s  requ i red for patients with HbA 1 c < 6.0% (42 mmol/mol) .  Unt i l  recently, the 
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lack of  HbA 1 c standardization prevented the  use  of  HbA 1 c as part o f  a potential 
screening and d iagnostic program.  The I ntroduct ion of a new reference method 
improved H bA 1 c assay standard ization worldwide and its role in the screening and 
d iagnosis of Type 2 d iabetes (Hu ,  201 0 ;  WHO, 201 1 ) . 
1 . 8 Dia betic C o m p l ications 
Several serious compl ications are associated with long term diabetes of 
either type which increases morbid ity and mortal ity in d iabetics , whether acute or 
chronic.  In terms of the t issues affected , compl ications can be div ided into 
microvascu lar and macrovascu lar, based on arterial s ize affected (Hermans,  2007) .  
The level of hyperg lycaemia increases the risk of microvascular damage 
such as ret inopathy, nephropathy and neuropathy. I ncidences of macrovascular 
compl ications such as ischaemic heart d isease, stroke and periphera l  vascular 
d isease are also increased . 
Although some compl ications are more specific to the different types of 
d iabetes, most chronic compl ications affect both types of d iabetes (Gale EAM ,  
2002). 
There are several wel l  studied mechanisms by which hyperg lycaemia infl icts 
damage such as the polyol pathway, Advanced g lycat ion end product formation,  
Protei n  k inase C activat ion (PKC) ,  overactive hexosam ine pathway and oxidative 
stress .  
I n  the polyol pathway, the enzyme a ldose reductase shunts the extra 
g lucose into forming sorbitol that is later oxid ized to fructose . Th is consumes 
NADPH which is  critical for regenerat ing intrace l lu lar  oxida nts such as g lutath ione 
wh ich defends against oxidative stress, another critical contributor to cel l  damage. 
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The precursors of AGE products damage cel ls  by modifying Intracel lu lar  
prote ins that regu late gene transcription , modifying nearby extracel lu lar  matnx 
molecu les and proteins leading to ce l lu lar  dysfunction and activation of inflammatory 
pathways. I n  the prote in k inase C pathway, the cel lu lar hyperg lycaemia i ncreases 
product ion of d iacylg lycerol that activates PKC and has varying effects on gene 
expression.  
Hyperg lycaemia also leads to increased fl ux through the hexosamine 
pathway which a lso has damaging consequences (Brown lee, 2005) .  The 
hexosam ine pathway is impl icated in  g lucose toxicity that contributes to insul in 
res istance in  the muscle, an important pathological mechanism in  Type 2 d iabetes 
(Shepherd & Kahn ,  1 999). 
1 .9 D i a betic N e u ropathy 
Diabetic neuropathy (ON)  i s  one of the most common compl ications of 
d iabetes ,  with up to 50% of patients developing it and a ltering patients' qual ity of l ife , 
mental ly and physica l ly  (M .  J .  Young ,  Boulton. Macleod , Wi l l iams, & Sonksen, 
1 993) .  
An internationa l ly  accepted definit ion of d iabetic polyneuropathy for c l in ical 
practice is the "presence of and/or s igns of periphera l  nerve dysfunction in  people 
with d iabetes after the exclus ion of other causes". 
Factors such as poor control of blood g lucose levels ,  aberrant l ipid levels ,  
hypertension and obesity can be l inked to the development of  ON (Solomon 
Tesfaye, 201 0; Thomas, 1 997) .  
Patients experience numbness, t ing l ing ,  pa in ,  or weakness that often beg in  
in  the feet and spread proximal ly  in  a length-dependent manner leading to  chronic 
pa in ,  u lcer formations, amputat ions,  balance issues and fa l ls .  Although ON can 
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manIfest a t  a n y  stage of the d iabetes , the prevalence increases with age and 
duratIon of d iabetes with the h ighest rates appearing amongst diabetes of twenty 
five years (Boulton, 2005b). 
Diabetic neuropathy IS  characterized by d iffuse or local ized damage to 
autonomic or peripheral nerve fibres .  Broad ly,  d iabetic neuropathy is classed into 
two major groups as shown in Table 1 based on Bou lton and Thomas (Boulton, 
2005b; Solomon Tesfaye . , 201 0). 
G e n e ra l ized symmetric Focal and m u ltifoca l neu ropathies 
polyne u ropathies 
Acute sensory Cran ia l  
Chronic sensorimotor Truncal 
Autonomic Focal  l imb 
Proximal motor amyotrophy 
Coexisting Chron ic I nflammatory Demye l inat ing 
Polyneuropathy (C l OP) 
Table 1 :  C lass ification of d iabetic neuropathy 
The typical pattern, and the most common,  is of a symmetrical and length­
dependent sensorimotor polyneuropathy; d ista l  sensory polyneuropathy (DSPN) 
(Thomas,  1 997) . Focal  neuropathies are less common.  As the duration and severity 
of d iabetes progresses, in periphera l  neuropathy,  there is a 'stocking-g love' 
d istriiJution of sensory deficits ahead of any motor dysfunction observed. The signs 
and symptoms depend on the type of fibers involved and their funct ions. Large fiber 
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Involvement affects l ight touch sensation and proprioception (Kleggetveit & Jl2l rum,  
20 1 0) whi le sma l l  fiber Involvement affects pain and temperature leading to 
paresthesias, dysesthesias and neuropathic pain (Aminoff, 2006) .  With more 
advanced neuropathy, compl ications such as u lceration and diabetic arthropathy 
emerge.  Diabet iC arthropathy, also known as Charcot neuroarthropathy, affects the 
bones, jo ints and soft t issues of the ankle and foot . Charcot first described the 
relat ionship between loss of sensation and arthropathy in 1 868 (Kumar, Asl in ia ,  
Yale,  & Mazza , 201 1 ) . Although i t  can occur because of various peripheral 
neuropathies, d iabetes appears to be the commonest cause. The interaction of 
d iabetes,  sensory-motor neuropathy, autonomic and sensory-motor neuropathy, 
metabol ic derangements of the bones and trauma result in the acute local ized 
condit ion that leads to bone destruction, subluxation ,  d is locat ion,  and deformity 
(Rogers ,  201 1 ) . 
Many d iabetics develop foot u lcers that are neuropathic in  orig in ,  often 
accompanied by cel lu l it is or osteomyel it is .  Poor wound heal ing often provides the 
background for severe infections to set in  which could compl icate to gangrene and 
often surg ical amputation is requ i red to conserve viable tissue (Ramsey, 1 999). 
Neuropathy also a contributor to d iabetic mortal ity (Coppin i ,  Bowtel l ,  Weng,  Young , 
& Sonksen, 2000). 
D iabetic autonomic neuropathy (DAN) is  a form of d iffuse d iabetic 
neuropathy and can target sympathetic and parasympathetic functions that 
encompass gen itour inary ,  card iovascular and gastrointest inal  dysfunct ions. DAN 
h igh ly prevalent yet poorly understood and has a negative impact on qual ity of l ife 
and mortal ity (Coppin i ,  2000; Freeman,  2005) . 
I n  the more focal forms of d iabetic neuropathy, the damage can be to s ingle 
or mult iple peripheral nerves, cran ia l  nerves or reg ions of plexuses or nerve roots. 
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The most common are the s ingle nerve damage, or peripheral nerve 
mononeuropath ies , affect ing the media l  and u lnar nerves. Carpal tunnel syndrome 
IS more common in  d iabetics (Chammas, 1 995) with approximately 30% of d iabetics 
demonstratinG some evidence of this on e lectrophysiological test ing (Dyck, 1 993). 
Focal d iabetic neuropathies often have an  acute onset, are self- l im it ing and 
relatively uncommon.  The occulomotor nerve is most commonly affected amongst 
the cran ia l  neuropathies and man ifests as un i lateral headache, d ip lopia , and ptosis 
without pupi l la ry involvement. 
This is termed as d iabetic ophtha lmoplegia and often coexistences with other 
d iabetic compl ications and card iovascu lar risk factors (Greco , Gambina,  & Magg io, 
2009). 
Nerve plexus and nerve root involvement in  d iabetics often manifests 
lumbosacra l plexopathy and polyrad iculopathy and is termed d iabetic amyotrophy. It 
is more prevalent in elderly patients with type 2 d iabetics and is associated with 
un i lateral th igh pain innervated by L2 to L4 (L .  Smith ,  Burnet ,  & McNei l ,  2003). 
Thoracic rad icu lopathy often man ifests as sharp pains experienced i n  the thoracic or 
abdominal  area (Chokroverty, Reyes, Rubino,  & Tonaki ,  1 977) .  
Overa l l ,  d iabetic polyneuropathy and d iabetic autonomic neuropathy are 
common,  most often d iffuse and often progress ive. The foca l neuropathies are qu ite 
often rare, appear  suddenly and have a se lf-l im it ing course (Thomas, 1 997;  Vin ik ,  
Mehrabyan ,  Colen,  & Boulton ,  2004) .  
The criteria requ i red to d iagnose d iabetic periphera l  neuropathy is  based on 
the presence of neuropathic symptoms, s igns and is reinforced by the presence of 
abnormal  e lectrophysiolog ical resu lts - a lthough the latter is more important for 
d isease progression rather than d iagnosis (Eng land ,  2005). 
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I t  i s  apparent that peripheral neuropathy is h igh ly preva lent in d iabetics and 
appears to increase with the duration of the d isease and g lycaemic control . Tight 
g lycaemlc control reduces the incidence and progression of neuropathy (Dyck, 
1 993; S Tesfaye , 1 996; M . J. Young ,  1 993) Whi le d iabetic periphera l  neuropathy 
affects at least 50% of older type 2 d iabetic patients, its pathogenesis is not clearly 
understood. 
Diabetics can experience a range of symptoms. For some there are 
extremely painful symptoms but others, usual ly  those with a more marked deficit, 
there may be no symptoms at a l l .  Some of the typical neuropathic symptoms 
include; painful symptoms including burning sensations,  kn ife- l ike pa in ,  electric 
sensations of shock, throbbing pain and a l lodyn ia .  The nonpainfu l symptoms 
i ncluding feel ing the part of the body is as leep or 'dead' ,  numbness, t ing l ing and 
prickl ing sensations (Bou lton ,  2005) .  
The biochemica l  imbalances that underl ie d iabetic neuropathy are simi lar to 
those of other compl icat ions.  A few have been mentioned previously and other 
mechanisms i nclude activation of mitogen-activated protein k inases and inducible 
n itric oxide synthase, elevated cytokines such as tumour necrosis factors, interleukin 
1 6 , 1 8 , hypoxia,  ischemia and deficiencies of g rowth factors such as nerve g rowth 
factor (Chan ,  Terash ima,  U rabe ,  L in ,  & Koj ima ,  201 1 ) .  
The progression of d iabetic neuropathy occurs i n  a 'stocking g love' pattern 
and has various stages (Table 2) (Thomas, 1 997) 
There are a lso various c l in ica l  types of peripheral d iabetic neuropathy (Table 
3)  (Boulton ,  2005a) 
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Stage of n e u ropathy Sym ptoms S ig n s  
No neuropathy None None 
Chronic painful Shooti ng ,  stabbing and burning Absent sensation to 
sensations several modal it ies 
Pin and needle sensations Reduced/absent 
reflexes 
Acute painful Above symptoms inc luding M inor or absent s igns 
hyperesthes ia 
Pain less with N umbness/deadness of feet; Reduced/absent 
complete/part ia l  pa in less inj u ry ,  sensation 
sensory loss Reduced sensit ivity 
to heat/cold 
Absent reflexes 
Late compl ications Foot les ions ;  neuropathic Various 
deformity; amputation 
Table 2: Stages of d iabetic peripheral neuropathy 
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Large f iber Sma l l  fi ber P rox i m a l  Acute mono P ress u re 
n e u ropathy n e u ropathy motor n e u ro pathies pa l s ies 
neu ro pathy 
Sensory loss Sensory loss Sensory loss Sensory loss Sensory loss 
o --7 +++ 0 --7 +  0 --7 +  o --7 +++ in  nerve 
(Touch,  (Thermal , Pain + --7 +++ Pain + --7 +++ d istribution 
vibration) a l lodynia) Tendon reflex Tendon reflex + --7 +++ 
Pain + --7 +++ Pain + --7 +++ N --7  H N Pain + --7 ++ 
Tendon reflex Tendon reflex Tendon reflex 
N --7  N --7  N 
Table 3 :  C l i n ical types of peripheral d iabetic neuropathy 
1 . 9 . 1  I m pact of D i a betic N e u ropathy 
The criteria requ ired to diagnose d iabetic peripheral neuropathy is based on 
the presence of neuropathic symptoms ,  signs and is reinforced by the presence of 
abnormal e lectrophysiolog ical resu lts - a lthough the latter is more important for 
d isease progression rather than d iagnosis (Eng land,  2005). I t  is apparent that 
periphera l  neuropathy is  h igh ly preva lent i n  d iabetics and appears to increase with 
the duration of the d isease and g lycaemic control . T ight g lycaemic control reduces 
the incidence and progression of neuropathy (M. J. Young,  1 993),  (Dyck, 1 993), (S. 
Tesfaye, 1 996). 
Diabetic autonomic neuropathy is poorly understood . Al l  organs receive 
innervation from the autonomic nervous system so every organ system can 
potentia l ly  be affected. Most organs have dua l  i nnervation with parasympathetic and 
sympathetic input .  M ost of the parasympathetic activity is med iated by the vagus 
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nerve which i s  the longest autonomic nerve a s  wel l  (Berthoud & Neuhuber, 2000) .  
S ince the longest nerve fibers are first affected i n  d iabetic neuropathy, early 
symptoms usual ly involve the parasympathetic system and are widespread (Ewing 
& Clarke, 1 9B2) .  Subcl in ical neuropathy is usual ly  present with in a short t ime of 
d iagnosing d iabetes The d iagnosis of d iabetic autonomic neuropathy depends on 
c l in ical and physiologica l  assessments. Although many systems are affected , the 
cardiovascu lar system is the most commonly tested for variations in  heart rate in  
re lation to deep breath ing ,  posit ion changing and breath ing out against pressure are 
measured by E KG (Pfeifer, 1 984). 
The risk of autonomic neuropathy increases with poor g lycaemic control and 
duration of d iabetes .  The presence of other factors that have been l inked to the 
development of ON include hypertension,  an a ltered l i pid profi le and compl ications 
such as ret inopathy (Cohen ,  Jeffers , Fa ldut, Marcoux,  & Schrier, 1 998; Gerritsen ,  
200 1 ; Z ieg ler, 1 993).  
The autonomic nervous system practical ly regu lates every bod i ly function 
and when it becomes derai led,  the consequences are wide and varied . From 
i rritating to deadly, d iabetic autonomic neuropathy has a s ign ificant impact on 
patients' l ives.  Cardiac manifestat ions are related to increased morta l ity. In the early 
stages there is  resti ng tachycard ia and loss of heart rate variation and as the 
sympathetic function is affected later cardiac adrenergic sensitivity increases that 
can lead to death. Other compl ications include exercise intolerance, orthostatic 
hypotension,  increased intraoperative death and s i lent myocardia l  ischaemia 
(Freeman,  2005) .  Gastro intest ina l  compl icat ions of d iabetic autonomic neuropathy 
can affect any part of the g ut .  From heartburn and dysphag ia in  esophageal 
involvement (Freeman,  2005) to gastroparesis (Kong , Horowitz, Jones, Wishart ,  & 
Hard ing ,  1 999) and d iarrhea (P .  A .  Low, 2004) - the symptoms are myriad.  
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The genitourinary involvement of  d iabetic autonomic neuropathy manifests 
as a ltered u rinary frequency (Clarke, Ewing ,  & Campbe l l ,  1 979) , bladder d isorders 
such as unne retention or overflow incontinence (Buck, Reed, Siddiq,  Chisholm, & 
Russel l  Fraser, 1 976) ,  erect i le dysfunction (Kolodny,  Kahn , Goldste in ,  & Barnett , 
1 974), vagina l  d ryness and decreased l ibido (Freeman,  2005) .  
Sudomotor dysfunction of  d iabetes often beg ins as a loss of  thermoregulatory 
sweating in  a g love and stock ing d istribution and progresses in  a length-dependant 
manner typica l of d iabetic neuropathy. I t  can predispose to heat stroke and 
hyperthermia and lead to a compensatory central hyperh idrosis (Fealey, Low, & 
Thomas, 1 989; Tentolouris,  2009) 
1 .9 . 2  Theories o n  the Pathogenesis of D i a betic N e u ropathy 
Several et iologies have been impl icated In d iabetic neuropathy .  
Hyperglycaemia is clearly an  important factor for the development and progression 
of d iabetic neuropathy. Severa l  pathways have been identified and stud ied; most of 
these are g lucose metabol ic pathways l inked to hyperg lycaemia that are re lated to 
the cel lu lar  metabol ic and/or redox status (Norman E Cameron & Cotter, 1 997) . 
These metabol ic pathways include g lucose flux through the polyol pathway, the 
hexosamine pathway, product ion of the prote in  k inase C isoforms and accumulat ion 
of advanced g lycation endproducts (R. S .  Clements, 1 979;  Toth . ,  2008) .  The 
addit ive imbalance of these pathways leads to an a ltered state of m itochondria l  
redox state of the cel l  and forms high levels of reactive oxygen species (Phi l l ip A 
Low, N ickander, & Tritsch ler, 1 997;  Andrea M .  Vincent, Brownlee, & Russel l ,  2002) ,  
(Norman E Cameron & Cotter, 1 997) . The increased level of reactive oxygen 
species with in  the cel ls a lso activates the Poly-ADP ribose polymerase (PARP) 
pathway ( I rina  G Obrosova , 2005; I rina  G.  Obrosova , 2004) .  This is i nvolved in 
expression of the genes that determ ine inflammatory reactions that are also involved 
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i n  neuronal  dysfunction ( I Inytska, 2006). Other etiologies invo lved include altered 
metabol ism of l ip ids,  amino acids, vascular  insufficiency, abnormal axon transport 
and reduced neurotrophism (Feldman, Stevens ,  & Greene, 1 997) .  Hyperg lycaemia 
has been impl jcated In  damaging nerve ce l ls  d i rect ly and via ischaemia.  
1 . 9 . 2 . 1  Polyo l  Pathway 
The polyol pathway was first identified in  the seminal vesicles (Hers, 1 956) 
and demonstrated to convert blood g lucose into fructose, an important source of 
energy for sperm cel ls .  Sorbitol was later identified to be present in  d iabetic rat lens 
(Hohman,  N ish imura ,  & Robison J r, 1 989) and the l ink between a ldose reductase, 
the polyol pathway and the development of d iabetic compl ications was postu lated 
(Ramana & S rivastava , 201 0; Van Heyningen ,  1 959) . Aldose reductase in rat is 
h igh ly expressed in the lens, the ret ina ,  and sciatic nerve (Hohman ,  1 989). These 
are all major targets for d iabetic compl icat ions.  
Aldose reductase is  an  enzyme that reduces g lucose to sorbitol ,  which is  
converted to fructose by the enzyme sorbitol dehydrogenase (SOH) (B lakley, 1 95 1 ) . 
These enzymes are abundant in  t issues more sensit ive to hyperg lycaemic damage. 
Aldose red uctase is present in  most cel ls (Yabe-Nish imura, 1 998) and in  the 
peripheral nerves it i s  local ized in  Schwann  cel ls .  This pathway is activated by mass 
action of excess g lucose and h igh levels of sorbitol are produced (D .  A .  Greene, 
Latt imer, & S ima ,  1 988) . This resu lt ing cel lu lar  hypertonicity causes osmolytes such 
as myo-inositol (F i negold ,  Latt imer, No l le , Bernstei n ,  & Greene, 1 983) and taurine 
(Nakamura ,  1 999) to leave the cel l  in an  effort to compensate the osmotic 
imba lance. NAOPH,  which is essential for regenerating reduced g lutathione, is 
consumed by the over activity of a ldose reductase and the format ion of excess 
fructose. Th is  contributes to oxidat ive stress in the cel l .  Activation of aldose 
reductase increases the formation of d iacylg lycerol which , i n  turn, activates the 
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protein  k inase C pathway The rise in  NADH/NAD+ ratio could a lso faci l itate the 
formation of diacylg lycerol by i ncreasing the avai lab i l ity of d ihydroxyacetone 
phosphate and favouring its reduction to g lycerol 3-phosphate, an intermediate of 
diacylg lycerol synthesis (Pugl iese, Ti lton, & Wi l l iamson, 1 99 1 ) . 
I n  normog lycemia ,  most ce l lu lar g l ucose is phosphorylated into g lucose 6-
phosphate by hexokinase as it shunts g lucose into the g lycolytic pathways (Yabe­
Nish imura ,  1 998). Overactiv ity of the polyol pathways is associated with a decrease 
in energy fl ux in  the d iabetic nerve. 
1 . 9 .2 .2  H exosa m i n e  Pathway 
The hexosamine pathway deals with excess fructose-5 phosphate, a 
metabol ic intermediate from the g lycolytic pathway, and converts it to g lucosamine-6 
phosphate by g lutamine fructose-6 phosphate amidotransferase. The result is the 
formation of ur idine diphosphate-N-acetyl g lucosamine - a molecule that attaches to 
the serine and threonine residues of transcription factors (Kornfe ld ,  1 967) .  
Hyperg lycaemia a l lows excess amounts of ur id ine diphosphate-N-acetyl 
g l ucosamine to be produced and in turn th is a lters gene expression (Chou ,  2004) .  
Transcription factors such as Sp1  assist the process .  Sp1 alters expression of 
genes involved in g lucose control such as transforming growth factor B 1  (TGF - B 1 )  
(Sysa ,  Potter, L iu ,  & Mezey,  2009) and plasmi nogen act ivator inh ibitor 1 (PAl - 1 )  
(X.-L .  Du ,  2000). The overexpression of TGF - B 1  leads to a n  increased production 
of col lagen matrix that cu lm inates in  endothel ia l  fibrosis and decreased mesang ia l  
ce l l  pro l iferat ion.  PAl  - 1 overexpression is  involved in  atherosclerosis because it 
encourages vascular smooth muscle cel l  pro l iferation (Y.-Q. Chen,  1 998). It is also 
overexpressed by the protein k inase C (PKC) pathway and hexosamine pathway. 
The presence of hyperg lycaemia produces excess NADP and overloads the 
m itochondria l  e lectron transport chain lead ing to oxidative stress , m itochondrial 
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damage a n d  activation of PARP. PARP acts with the hexosamine and PKC pathway 
to Induce Inf lammation and aberrant neuronal  funct ion. 
GlcNAc also impai rs beta cel l  function by adding to the oxidative stress of 
the cel l  (K .  L i IJ ,  Paterson,  Ch in ,  & Kud low, 2000) .  I ncreased g lutamine fructose-6 
phosphate amidotransferase or g l ucosamine levels has been l inked to insu l in  
resistance (Hebert Jr, 1 996) ,  increased hydrogen peroxide levels ,  reduced 
expression of insu l in ,  g l ucose transporter protein 2 and g lucokinase genes (Kaneto, 
200 1 ) . 
1 .9 . 2 . 3  P rote i n  K i nase C Pathway 
Hyperg lycaemia is intrins ical ly involved in  damaging tissues prone to 
compl icat ions. The prote in  k inase C pathway is no exception .  I ncreased levels of 
g l ucose stimulate d iacy lg lycerol which activates PKC . Excess levels of PKC � 
isoform has been l inked to increased levels of the ang iogenic protein vascular 
endothel ia l  g rowth factor (VEGF) ,  PAI- 1 , nuclear factor KB (N F-KB),  TGF� and other 
d iabetic compl ications such as reti nopathy , nephropathy and cardiovascular  
compl icat ions (Arikawa , 2007 ;  Das Evcimen & King,  2007 ; Geraldes & K ing ,  20 1 0 ; 
Veves & K ing ,  200 1 ) .  
The  activat ion of  the  PKC pathway a lso affects capi l lary permeabi l ity and 
vasoconstrict ion .  Th is  can lead to hypoxia ,  ang iogenesis,  endothel ia l  prol iferat ion 
and th icken ing of the basement membrane (Wi l l iams,  Gal lacher, Pate l ,  & Orme, 
1 997) .  These changes in the neurovascular blood flow are most l i kely how PKC is 
involved in  neuropathy (Way, Kata i ,  & King,  200 1 ) .  The sod ium potassium ATPase 
pump and other enzymes that are crit ical for nerve function are also targeted . PKC 
isoforms negatively affect sodium potassium ATPase pumps (D .  A. Greene, 
Lattimer, & Sima, 1 987;  I sh i i ,  Koya , & King, 1 998; Koya & K ing , 1 998) . I nh ibit ing 
PKC inh ibition improves both nerve blood flow and nerve conduction velocity ( I sh i i ,  
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1 996) ,  ( Das Evcimen & King , 2007) ,  0Nay ,  200 1 ) .  PKC isoforms a lso influence 
insu l in  resistance (Gnff ln ,  1 999; J .  K. Kim . ,  2004) .  
1 . 9 .2 .3  Advance G lycat ion E n d  P ro d u ct F o rmation 
These result from non-enzymatic reactions between reducing sugars and 
prote ins or l ipids (Goh & Cooper, 2008). The AGE precursors are also known as 
reactive dicarbonyls and are particu larly harmfu l .  Most common ly, the by-product of 
these i rrevers ible reactions form Sch iff bases that degrade into addit ional ly harmfu l 
Amadori products or fructosamine. Reactive dicarbonyls such as g lyoxal and 
methyloxal can a lso modify prote ins ,  l ip ids,  and nucleic acids and are more 
damag ing .  Thus reactive d icarbonyls are one of the main mechanisms to produce 
AGEs, add to carbonyl stress and lead to compl ications (Jack & Wright, 
201 2) , (Huebschmann ,  Regenste iner, Vlassara, & Reusch, 2006) . Methylg lyoxal ,  has 
been l i nked to increasing the suscept ib i l ity to vascular damage in endothel ia l  ce l ls 
(Yao, 2007) .  
AGEs go on to modify components of the cel l  and act via the receptor; 
RAGE (Schmidt , 1 996) wh ich is  expressed in  a multitude of t issues (Brett , 1 993) .  
The interact ion of AGE with i ts receptors has consequences such as the activation 
of the transcription factor nuclear factor KB (N F-KB) .  Upregulation of this factor can 
i ncrease expression of pro inflammatory genes and a lter neuronal function 
(Sugimoto, Yasuj ima ,  & Yag ihash i ,  2008). I ncreased levels  of AGE and RAGE are 
found in  d iabetic t issue (Tanj i ,  2000).  Diabetic mice with RAGE knockout showed an  
improvement in  the  neuropath ic state and had  decreased expression of  NF-KB and 
PKC (Toth,  2008). 
AGEs a lso resu lt in  decreased blood flow of nerves by a lteri ng vessel wa l l  
structu re and patency. AGEs are a lso impl icated in  affecting neurons by reducing 
neurotrophic support 0Nada & Yag ihash i ,  2005) . 
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1 . 9 . 2 . 5  PolyAD P-ri bose Polymerase Pathway 
The enzyme poly ADP-rl bose polymerase (PARP) is a nuclear membrane 
enzyme that synthesizes poly ADP-ribose . This represents a ce l lu lar  response 
mechanism to DNA damage (S. Smith, 200 1 ) .  PARP is activated by oxidative stress 
and a lso appears to contribute to oxidative stress ( I rina G Obrosova , 2005). The 
act ion of PARP involves transfer of ADPribose from nicot inamide adenine 
d inucleotide to nuclear proteins .  This results in  deplet ing NAD+ , changes gene 
transcription and expression , increases oxidative stress and shunts the 
I ntermediates of the g lycolytic pathways to pathological pathways PKC and 
advanced g lycation end product formation (Erdelyi ,  Bakondi ,  Gergely, Szabo, & 
Virag ,  2005; Soriano . ,  200 1 )  
The funct ional domains of PARP include a DNA binding domain at the amino 
terminus ,  a cata lyt ic domain at the carboxyl term inus and a central automodification 
domain which accepts polyADP-ribose. The DNA binding domain recognizes and 
b inds to DNA strand breaks and has two z inc-finger motifs which are s imi lar  to the 
motifs in  DNA l igase I I I  and DNA polymerase. When PARP binds to breaks in  DNA 
strands it tr iggers the polyADP ribosylat ion reaction (Jeggo,  1 998; Susse, Scholz, 
Burkle , & Wiesmul ler, 2004) 
Abnorma lit ies that have been l i nked to PARP man ifest cl i n ica l ly as decrease 
in nerve conduct ion velocity, neurovascular  abnorma l it ies, smal l  fiber neuropathy, 
thermal and mechanical hypera lgesia ,  and tacti le a l lodynia (F. Li , Dre l ,  Szab6, 
Stevens,  & Obrosova,  2005; I rina  G Obrosova , 2007; Pacher, 2002). 
1 . 9 . 2 . 6  Oxidative S tress and Apoptos i s  
Most of  the  pathological mechanisms d iscussed above contribute to 
oxidat ive stress in the ce l l .  AGE and the polyol pathways reduce the redox capacity 
of the cel l  by form ing ROS or reducing avai labi l ity of g lutath ione.  The hexosamine ,  
PKC and PARP pathways cause damage via increased expression of inflammatory 
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proteins .  Based on the observation that d iabetic neuropathy progresses in an axon 
length-dependent manner (Said ,  2007), the damage could orig in  in  the axon. These 
sites are more susceptible to damage by hyperg lycaemia because of the large 
number of mitochondria that they possess. Against the backdrop of ischaemia, 
hyperg lycaemla overloads the capacity of the mitochondria and sets the stage for 
OXidative stress. This fu rther enhances mitochondrial damage which in turn leads to 
axon degeneration and death (Leinn inger, Edwards,  L ipshaw, & Feldman, 2006) . 
M itochondria  are vu lnerable to damage by reactive oxygen and n itrogen 
species. Reactive oxygen species are produced by the mitochondria and usual ly 
removed by cel lu lar  agents such as g lutath ione, cata lase and superoxide d ismutase. 
Hyperg lycaemia accentuates ROS production in  the ce l l  v ia mitochondrial activity 
(Friederich, Hansel l ,  & Pa lm,  2009; Leinn inger ., 2006 ; Andrea M Vincent, Russel l ,  
Low, & Feldman,  2004) .  
The main reactive n itrogen species, peroxyn itrite is formed from the reaction 
of n itric oxide and superoxide ion. Peroxyn itrate is  i nherently unstable and results in 
the formation of n itrate through isomerisation . Reactive n itrogen species have 
several ce l l  damag ing effects; i nclud ing PARP activation and prote in  n itrosylation 
(Pate l, 1 999) .  
The presence of excess superoxide ion inh ibits GAPDH and upstream 
g lycolytic intermediates accumu late in the cel l .  These in turn enhance the Aldose 
red uctase, hexosamine,  PKC pathway and AGE product formation increase cel l  
i njury (N ish ikawa, 2000) , (X . -L .  Du,  2000). 
The vicious cycle of injury in  ce l ls prone to d iabetic compl ication continues. 
Hyperg lycaemia leads to ove r  activation of metabol ic pathways and produce cel lu lar  
oxidative stress. Aga inst the backdrop of  decreased nerve blood flow and 
ischaemia ,  the t issue suffers more i njury .  The production of reactive oxygen species 
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produces oxidative stress which leads to further injury and a lso impairs the 
protective antioxidative mechanisms of the cel l .  
M itochondria are a lso important in  determin ing cell v iabi l ity (Friederich 200 1 ) . 
The presence of oxidative stress in it iates s ignal l ing pathways that destroy local 
m itochondria . One of these uti l izes the dynamin-re lated protein 1 (Drp 1 ) . The usual 
process of mitochondrial fission and fusion,  a del icate ly balanced process essent ia l  
for m itochondrial v iabi l ity (Knott & Bossy-Wetzel ,  2008) is often disrupted by Drp1 
which translocates to the m itochondrial surface and t ips the balance towards fission. 
I rregu lar  fission is associated with m itochondrial death and apoptosis . Diabetic 
neuropathy is associated with increased levels of Drp1 (F igueroa-Romero, Sadid i ,  & 
Feldman ,  2008; Frank, 200 1 ; Knott & Bossy-Wetzel ,  2008). There is evidence of 
apoptosis in the ce l l  body of neurons and the presence of neuroaxonal  dystrophy 
(Russe l l ,  Su l l ivan,  Windebank,  Herrmann,  & Feldman, 1 999) . Recurrent i nju ry in  the 
face of hyperg lycaemia activates cel l  death pathways which are beyond the scope 
of g l ia l  support and repair. This in it iates mitochondrial damage and red istribution t i l l  
the axons die back towards the cel l  body (Srin ivasan,  Stevens, & Wi ley,  2000) ,  
(Le inn inger, 2006). 
1 .9 .2 .7  I nflammation 
I nflammation is l i nked to d iabetic neuropathy, substances such as C-reactive 
protein  and plasma levels of TN F-a are in h igher concentrations in d iabetics and 
appear  to correlate with the incidence of d iabetic neuropathy, amongst other 
neuropathies, and are also l i nked to other d iabetic compl ications.  HSP27 , an  
intermediate in  the  TNF-a induction of  the  inf lammatory mediators ;  cyclooxygenase-
2 (COX-2),  I nterleukin 6 ( I L-6), and I nterleukin 8 ( I L-8), is a lso increased in d iabetic 
neuropathy (Empl . ,  200 1 ; Gonzalez-Clemente, 2005; Gruden, 2008; Jager, 1 999; 
Makino,  2005; Schalkwijk ,  1 999). 
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Excess g lucose IS shunted to metabol ic pathways that increase expression 
of NF-KB and TGF-� (Esposito, 2002; G .  L. King & Loeken ,  2004) .  AGE 
mod ificat ions bring about their own contributions, one of which includes the 
formation of methylg lyoxal which decreases the binding of transcript ion factors such 
as Sp3 which is an  ang iotens in " repressor (Yao, 2007). Hyperg lycaemia increases 
tissue ang iotens in " and activates vascular  endothel ia l  ce l ls ,  which leads to 
Inflammatory cel l  recruitment, cytokine formation ,  ischaemia,  increased ROS 
formation etc (Lawrence J Coppey, 2006) . Other  AGE products util ize RAGE to 
increase intracel lu lar  inflammatory s igna l l ing to upregu late N F-KB (Toth,  2008) .  
N F-kB is a very important transcription factor and regulates the  expression of 
many genes that are involved in inf lammation such as COX-2 (L .  A. J .  O'Nei l l  & 
Kaltschmidt 1 997) .  COX-2 is upregu lated in  d iabetic neuropathy and is a potentia l  
target for treatment .  COX-2, in  turn , generates prostag landin E2 and reactive 
oxygen species that further activate N F-KB.  I nh ibit ion of COX-2 appears to prevent 
harmful changes to peripheral nerves such as nerve conduction deficits, reduction of 
blood flow, GSH depletion and increases in TNF-a production (Pop-Busu i ,  Kel logg, 
& Cheng,  2008) .  
N F-KB also regu lates another enzyme involved in  inflammation; inducible 
n itric oxide synthase (eNOS) which in turn induces NF-KB further and s imi lar  to 
COX-2 sets off a vicious cycle of inflammation (Y.  Kim . ,  2008) . The nitric oxide (NO) 
produced by iNOS increases nerve blood supply ,  modulates post inju ry changes in 
m icrovasculature and is l i nked to neuropathic pai n .  H igh levels of NO in  
inflammation could damage g rowth cones and axons ( N .  E .  Cameron ,  Eaton,  Cotter, 
& Tesfaye, 200 1 ; McDonald,  Cheng,  Martinez,  & Zochodne, 2007; Whitt le,  1 995;  
Zochodne & Levy, 2005) 
N F-KB is  important in  the inf lammatory pathways of d iabetic neuropathy. 
With chronic activation of NF-KB,  blood vessels and nerve cel ls  are more prone to 
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I nju ry In  ischaemia reperfusion . This i s  fo l lowed b y  infi ltration of monocytes, 
macrophages , and granu locytes into the periphera l nerves (Yanping Wang,  
Schmeichel ,  l ida,  Schmelzer, & Low, 2006). Th is  macrophage recru itment is  trigged 
by the cytoklf"le production induced by NF- KB in endothel ia l  ce l ls ,  Schwann cel ls  
and neurons. Macrophages in  turn contribute to d iabetic neuropathy by producing 
ROS, cytokines and proteases that degrade myel in  and increase oxidative stress. 
This a lso contributes to the impaired nerve regeneration in  d iabetic neuropathy 
(Conti ,  2002; Kennedy & Zochodne, 2005; Tesch ,  2007; Yamag ish i ,  2008) .  
1 . 9 . 2 . 8  G rowth Factors 
Growth factors promote the g rowth and survival of neurons and determine 
neurite outgrowth (Chiare l l i ,  Santi l l i ,  & Mohn, 2000; Leinn inger, Vincent, & Feldman, 
2004; Toml inson, Fernyhough ,  & Diemel , 1 997) . S ince d iabetic neuropathy exhibits 
evidence of neuronal degeneration and Schwann cel l  damage (Russel l ,  1 999), 
a lterat ions in  growth factors such as nerve g rowth factor, insu l in- l ike g rown factor 1 
( IGF- 1 ) and neurotrophin 2 could be involved i n  the pathogenesis.  These factors a l l  
b ind to tyrosine k inase receptors . The nerve g rowth factor (NGF) receptor is made 
up of p75NTR and a specific trk tyrosine k inase, which confers l igand specificity. 
Many g rowth factor levels  are a ltered in  d iabetic neuropathy. Nerve g rowth 
factor, the most widely stud ied factor, is produced by muscle ce l ls and 
keratinocytes. The nerve g rowth factor receptor; trkA receptor is expressed on 
sensory and sympathetic neurons (Anand,  1 996) .  Animal  models of d iabetic 
neuropathy have shown a ltered expression of several growth factors and both NGF 
leve ls  and retrograde transport of the g rowth factor are reduced (R Hel lweg & 
Hartung ,  1 990). 
The transport of NGF to the stoma is requ ired for its neurotrophic effects to 
occur (Rainer Hel lweg ,  Raivich, Hartung,  Hock, & Kreutzberg , 1 994) .  However, 
when  g lucose leve ls  were norma l ized,  NGF leve ls also return to normal suggest ing 
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a l ink  between hyperg lycaemia to g rowth factor levels (Rainer He l lweg , 1 99 1 ) .  
Admin istering insu l in  appears to bring  growth factor levels of several such as IGFI  
and I I  back towards normal  levels (M igdal is . ,  1 995) .  
1 .9 . 2 .9  L i p i d  Abnormal it ies 
The mechan isms by which plasma l ip ids influence neuronal inju ry have not 
been fu l ly elucidated but certa in  factors have been impl icated . Correlat ions between 
an altered l i pid profi le and the increased incidence of neuropathy have been 
identified in  both type 1 and type 2 d iabet ics. 
In an imal models,  a high fat d iet fed to mice results in  overexpression of 
1 2/1 5 l i poxygenase in periphera l  nerves even though these an imals are g lucose 
tolerant but not overly d iabetic ( I rina G. Obrosova , 2007) .  Along with 
hyperg lycaemia dysl ip idaemia in itiates neuronal inju ry (Rockenfel ler ,  201 0) .  These 
molecular a ltercations can also activate the endoplasmic reticu lum unfo lded protein 
response in  many types of ce l ls ,  which can a lso lead to cel l  death (McAlpine,  Bowes, 
& Werstuck, 201 0) . I t  i s  unclear if elevated l ipid levels have d i rect effects on the 
peripheral neurons.  Factors such as permeabi l ization of the lysosomal membrane 
by cathepsin L leading to damage of the mitochondria and oxidative stress could be 
important (Rockenfe l ler ,  201 0) .  
In  d iabetes, p lasma l i poproteins are exposed to an oxidizing environment. 
Periphera l  neurons express scavenger receptors for oxid ized LOLs including 
oxid ized LOL receptor 1 (LOX 1 )  ( I sh iyama,  201 0) and Tol l - l ike receptor 4 (Geng, 
20 1 0; Nowicki . ,  20 1 0 ; A .  M. Vincent, 2009) . These neurons a lso express RAGE,  
wh ich binds g lycated LOL and internal izes oxid ized LOL and glycated LOL ,  re leasing 
potentia l ly  i nju rious trig lycerides and fatty acids with in the cel l  that increase damage 
(Honjo ,  2008;  Stielow, 2006;  Andrea M.  Vincent, Cal laghan,  Smith, & Feldman,  
201 1 ;  A .  M .  Vincent, 2007) .  NAOPH oxidase is a lso activated and adds to the 
oxidative stress. Besides the other damaging effects ,  oxidative stress in d iabetes 
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enhances expression of oxLDL and RAGE via p38 mitogen-act ivated prote in  k inase 
MAPK s ignal l ing and adds to the damage (Toth,  2008) ,  ( I sh iyama, 201 0). 
Although treatments have been developed that target these pathogenetic 
mechanisms (F igure 1 )  there is no clear evidence to suggest remarkable benefits 
and thus early institution of opt imal  g lycemic control remains the only avai lable 
measure with proven efficacy in preventing or s lowing progression of d iabetic 
neuropathy (Soucek, 2006). 
Dia betes 
Hyperglycemia, hyper­
insul inemia, GF 
abnomalitles. dyslipidemia 
Nerve 
dysfunction 
(antigenic leakage) 
Organic/structural nerve damage 
- Axonopathy (atrophy, loss) 
- Demyelination (segmental, 
progressive) 
r ------------L------------, 
Nerve regeneration 
Restoration of nerve function 
Figure 1 :  Therapeutic i nterventions based on hypothetic pathogenetic mechanisms 
of d iabetic neuropathy 
I nterventions with inh ibitory effects are marked in  red, with mainly supportive 
effects in g reen. AGE :  advanced g lycation end products.  GF :  g rowth factor. DAG: 
d iacylg lycero l .  PKC: protein k inase C. PG: prostag land in .  NO: n itric oxide. ET: 
endothe l in  (Soucek, 2006) 
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1 . 1 0  Anatomy of the Autonomic Nervous System 
The autonom ic nervous system is a condu it between the central nervous 
system and the viscera . I t  is organized in  g roups of gang l ia , wh ich can be g rouped 
schematica l ly into paravertebral ,  prevertebral , paraviscera l ,  and intramural 
(Paxinos, 2004) .  Gangl ia are networks of bundled or connected somata and 
dendritic structures which serve as re lay points for the nervous system (Per, 201 0) .  
Dorsal root gangl ion (DRG),  a lso ca l led spinal  gangl ion,  is the gangl ion of 
the posterior root of each sp ina l  segmental nerve , conta in ing the cel l  bodies of the 
un ipolar primary sensory neurons. These a lso l ie on the side of the vertebra l co lumn 
i n  close association with the sp ina l  cord (Paxinos,  2004) .  These gang l ia reside at 
each segmental level of the sp ina l  column with i n ,  the intervertebral foramen.  The 
DRG is  interposed between the dorsal  root that resides with in the subarachnoid 
space and the spinal nerve that proceeds to periphera l receptive f ie lds. The sensory 
neuron somata for a l l  sensory moda l it ies and types of fibers reside i n  the DRG 
(Koopmeiners ,  M uel ler, Kramer, & Hogan,  20 1 3) .  The cel l  body of each sensory 
neuron in the dorsal root gangl ion has a long axon which extends from the dendrites 
such as the sk in ,  to the cel l  body in the dorsal root gang l ion and then continues to 
the spinal  cord . The section of the axon that runs from the gang l ion to the spinal  
cord is bundled with s imi lar axons.  These bundles are cal led dorsal roots (Hart ,  
201 0) .  
The axons of  posterior root gangl ion neurons are known as afferents 
because they re lay sensory information into the central nervous system ( i .e .  the 
bra in  and the sp ina l  cord) .  These neurons are of the pseudo-un ipolar type; the axon 
has two branches that act as a s ing le axon and are termed as a distal process and a 
proximal process. U nl ike the majority of neurons found in  the central nervous 
system ,  an act ion potential in  posterior  root gangl ion neuron may in it iate in  the distal 
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process I n  the periphery ,  bypass the cel l  body, and continue to propagate along the 
proximal process unt i l  reaching the synaptic term ina l  in the posterior horn of spinal  
cord(R ,  201 0) 
The d istal section of the axon may e ither be a bare nerve end ing or 
encapsulated by a structure such as a Meissner's corpuscle or Pacinian corpuscle 
to relay specific information to nerve . For example, corpuscle may encapsu late the 
nerve ending,  rendering the d ista l process sensit ive to mechanical st imu lat ion.  The 
dorsal root gang l ia  develops in  the embryo from neura l  crest ce l ls instead of the 
neura l  tube. This g ives rise to theories that regard the dorsal root gang l ia  as gray 
matter of the spina l  cord that became translocated to the periphery(R ,  20 1 0) .  
The  beg inn ing of  somatosensory information transmission occurs when 
peripheral receptors of the primary afferent neurons are activated . In cutaneous and 
visceral nerves of the rat, the Ai3 class of nerves is the fastest-conduct ing large 
myel inated sensory f ibers ;  the Ao g roup i s  the slower-conduct ing ,  thinly myel inated 
fibers and the s lowest-conduct ing u nmyel inated smal l  fi bers are C-fibers. C fibers 
respond to stronger and possible painfu l  stimu l i .  Several neurotransmitters are 
postulated to be released from the afferent neurons after a painfu l stimulus .  
Evidence points towards the excitatory amino ac ids (EMs), aspartate and 
g lutamate and substance P amongst others (Buda i ,  2000) .  The transm ission of 
impulses from nociceptive afferents to the centra l  nervous system,  essentia l  to 
perceive pain depends on the re lease of certa in neurotransmitters . These include 
g lutamate, substance P and calciton in gene-re lated peptide (Duggan ,  2002) .  
The autonomic gang l ia  house the cel l  bod ies of  sympathetic or 
parasympathetic motor neurons .  The paravertebral gangl ia are organ ized as the 
sympathetic chains that l ie  on  other s ide of the vertebral co lumn .  These neurons in 
these gang l ia  receive synapt ic i nput from pregangl ionic autonomic neurons whose 
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cel l  bodies are located in  the CNS.  The autonomic motor neurons in the gangl ia 
send efferent f ibers (postgang l ionic autonomic nerve fibers) to innervate cardiac 
muscle fibers of the heart and smooth muscle fi bers of body organs and g lands. 
Compared to the dorsal root gangl ia ,  the neuron cel l  bodies in  autonomic 
gang l ia  are more widely d ispersed, with a meshwork of nerve fibers lying between 
them, and the nerve fibers genera l ly are not as we l l  organ ized .  U nl ike the dorsal root 
gangl ia ,  which have no synapses and therefore no neuropi l ,  in sympathetic gang l ia  
many pregang l ion ic sympathetic fi bers from the sp ina l  cord synapse on the 
sympathetic neurons,  and others travel through the gangl ia  without synaps ing .  The 
cel l  bod ies of sympathetic neurons are smal ler  than those of sensory neurons in  the 
dorsal root gang l ion .  The cel ls  are mult ipolar  with eccentrical ly placed nucle i .  The 
sate l l ite cel ls (g l ia l  cel ls) are sparse and less a pparent .  
The pelvic gang l ia ,  in  the male rat, are usual ly located on the side of the 
prostate, closely apposed to its fascia .  The rat pe lvic gangl ia conta in neurons 
project ing to severa l urogen itary organs such as the bladder (Gu, 1 984) ,  penis (Y . ­
Q .  D ing ,  Takada ,  Kaneko, & M izuno,  1 995) , (Y .-q .  D ing ,  Wang, Q in ,  & L i ,  1 993) and 
prostate (Kepper & Keast) .  The gang l ion conta ins some cel ls  bodies with the 
characteristics of both adrenerg ic  and non-adrenerg ic  neurons. The latter conta in  
Vasoactive I ntestina l  Polypeptide and Ga lan in .  Another g roup of  neurons are the 
smal l  intensely fluorescent cel ls also termed as S I F  cel l s  (Paxinos, 2004) that 
conta in  transmitters such as  Substance P and Galan in (Dai l ,  Gal indo,  Leyba , & 
Barba,  1 997 ;  Keast, 1 99 1 ) . Substance P a long with CCK are present in presynapt ic 
term ina ls at d ifferent s ites i n  the gang l ion .  Two types of nerve endings, conta in ing 
SOM and/or CCK are preferentia l ly associated with the non-noradrenerg ic 
Neuropeptide Y neurons (Keast, 1 99 1 ) , and Substance P is present in  axon 
term ina ls  on other non-noradrenergic neurons as wel l  (Keast & Chiam,  1 994) . 
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1 . 1 0 . 1  The Pa i n  Pathway 
The endogenous somatosensory system transduces sensory information 
from the periphery to the centra l nervous system using a three neuron re lay system. 
The first order neurons are located in  the peri phera l nervous system with the ir  ce l l  
bodies In  the dorsa l  root gang l ia .  Peripheral sensory neuron cel l  bodies g ive rise to 
a pseudounipolar axon which is a s ing le axon that terminates in sites with in the 
central and peripheral nervous systems.  Pseudounipolar ce l ls have two axons rather 
than an  axon and dendrite . One axon extends centra l ly  toward the spinal  cord ; the 
other axon extends toward the sk in or muscle. Peripheral termina ls of primary 
afferent neurons innervate cutaneous and muscle t issues and transduce both 
innocuous and noxious sensory information .  Noxious (physica l/mechanical) ,  
therma l ,  or chemical stimu l i  preferent ial ly activate special ized types of primary 
afferent neurons which are termed nociceptors . Nociceptive primary afferent 
neurons s igna l  to the spinal  cord ,  term inat ing on second order neurons in the gray 
matter of the dorsal horn. The somatosensory system is a contra lateral system ,  and 
nociceptive signals cross the midl ine i n  the anterior white commissure at the level of 
the sp ina l  cord . The information that travels v ia axons in the latera l fun icu lus of the 
ventral horn and one of its major term ination sites is the tha lamic nucle i .  From the 
tha lamus,  neurons project to mu lt ip le sites with in the bra in  including the 
somatosensory cortex, prefrontal cortex and anterior c ingu late cortex which are 
reg ions important for integrat ing , interpret ing ,  and coord inating a relevant response 
to the nociceptive information .  In paral lel  to the ascending nociceptive system there 
is a descending system that provides inh ibitory and excitatory pain contro l .  The 
descending modulat ion of pain is when the integrated efferent message from the 
bra in  is  modulated by bra instem areas before reaching reaches the spinal  cord . This 
descending system provides communicat ion,  either d i rectly or ind i rectly, from the 
bra in  to the spinal  cord to modulate pain and can promote both endogenous 
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analgesia as wel l  as faci l itation of chronic pain states . The ascending and 
descending pain modulatory systems code for both sensory/d iscriminative and 
affective/emotional aspects of pain (Edelmayer, Brederson, Jarv is ,  & Bitner, 201 4) .  
The figure below del ineates the  pa in  pathway (Edelmayer, Brederson, Jarvis , & 
Bitner, 20 1 4) 
lo tOuS 
I I  Ull 
F ig u re 2: The pain pathway 
In the most basic sense, the ascending somatosensory pathway consists of 
a three neuron relay system .  The first order neuron resides in the DRG. DRG cel l  
bodies g ive rise to a s ing le  pseudounipolar  axon ,  which extends to  peripheral and 
centra l  termination sites .  I n  the periphery ,  nociceptors are a special ized type of 
pr imary afferent neuron that is preferent ial ly activated by noxious stimulation and 
transm its nociceptive s ignals to the central nervous system.  The afferent fibers 
synapse on second order neurons in the gray matter in the dorsal horn reg ion of the 
spinal  cord .  Second order neurons cross the mid l ine and nociceptive s ignals 
continue to be re layed to tha lamic neurons.  Th ird order neurons in the thalamus 
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have mu lt iple term ina l  projection sites. The descending system consists of 
bra lnstem nuclei that project to the spina l  cord, either d i rectly or Ind irectly ,  to 
inf luence endogenous analgesia .  
Several sensory abnormal it ies occur in  condit ions of chronic pa in ,  
hyperalgesia and a l lodyn ia .  These have been l inked to  the poss ible plasticity of 
dorsal horn circuits. Sensit ization of primary afferent fibers can be l i nked to primary 
hyperalgesia whi le a l lodynia could be due to sensitization of neurons in  the dorsal  
horn . Hypera lgesia,  a l lodynia and chron ic pa in sensation after peripheral t issue 
inju ry depends on the increase in  sensitivity of primary afferent nociceptors at the 
s ite of the inj ury ;  peripheral sensit izat ion,  and on an increase in  the efficiency of the 
synapses between primary afferent fibers and the dorsal horn neurons; central 
sensit ization (Yaksh ,  Hua ,  Kalcheva, Nozaki-Taguchi ,  & Marsa la ,  1 999) 
1 . 1 1  T h e  G l utamate S i g na l l i ng Pathway 
The main excitatory neurotransmitter of the nervous system is g lutamate that 
acts via its receptors . The released g lutamate from the presynaptic term ina l  is 
transduced to biochemical and e lectrical events in  the postsynaptic neuron for 
funct ions such as neuronal excitabi l i ty modu lation and synaptic transmission . 
The excitatory action of g lutamate in  the mammal ian bra in and spinal  cord 
has been known s ince the 1 950s (Curt is & Watkins ,  1 960) . S ince it is present in h igh 
concentration and is  re lat ively even ly d istributed throughout the d ifferent areas of 
the bra in ,  it was only recognized as a neurotransmitter by the 1 970s. It is one of the 
ma in excitatory neurotransmitters i n  the centra l nervous system of mammals 
(Meldrum, 2000) .  By the mid-1 980s, g l utamate was shown to have largely fi l led the 
four main criteria to be class ified as a neurotransmitter; presynaptic local ization ,  
re lease by physiologic stimu l i ,  identical i n  action to a natural ly occurring transmitter 
and mechan ism for qu ick term ination of its act ion .  Fu rther stud ies strengthened the 
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concept that g lutamate is a neurotransmitter. These included the demonstrat ion of 
ATP-dependent se lective transport of g lutamate into synaptic vesicles (Shigetaka 
Na ito & Tetsufumi  Ueda,  1 985) , the presence of h igh concentrations of g lutamate in 
synaptic vesicles Iso lated from the bra in (Orrego & Vi l lanueva, 1 993) and a ca lc ium 
dependent exocytot ic release of g lutamate from isolated nerve term inals (N ichol ls , 
1 995) .  
1 . 1 1 . 1 T h e  B i ochem istry of N e u rotra nsm itter G l utamate 
The metabol ism of g lutamate is compl icated as it involves neurons and g l ia l  
ce l ls .  The neurotransmitter g lutamate can be synthesized through d ifferent 
metabol ic pathways, and d ifferent populat ions of g l utamaterg ic neurons may d iffer in 
d ifferent aspects of g lutamate metabol ism.  
The formation and degradation of g lutamate is part of  the general energy 
metabol ism of the bra in because g lucose is the main substrate for the bra in .  
Glucose is one of  the most important precursors for transm itter g lutamate v ia  the 
tricarboxylic (TCA) cycle .  
The cerebra l TCA cycle activity is 1 5-20nmol min·' mg-1 protein (Mason , 
Rothman,  Behar, & Shu lman ,  1 992) and th is activity corresponds to the whole bra in  
activity of  a lpha ketog lutarate dehydrogenase, and it is  lower than a l l  other enzyme 
activit ies of the TCA cycle as measured in vitro. Alpha dehydrogenase which 
converts a lpha ketog lutarate into succinyl-CoA, is  a rate l im it ing step of the TCA 
cycle (Lai ,  Walsh ,  Dennis ,  & C lark, 1 977) .  This bott leneck a l lows alpha ketog luta rate 
to accumulate . Alpha ketog luta rate is transaminated to g lutamate by the h igh ly  
act ive transaminases such as aspartate aminotransferase and a lan ine 
aminotransferase (Mason , 1 992) .  These enzymes use aspartate or a lan ine as the 
amino g roup donor (Mason,  1 992) .  Alanine is exported from astrocytes, taken up by 
neurons and then metabol ized to g lutamate (Westergaard . , 1 993) .  Other amino 
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g roup donors such a s  leucine from the ci rcu lat ion are a lso used (Yudkoff, 1 997) .  
The large pool  of g lutamate present in  the g l utamaterg ic neurons is maintained by 
the bottleneck function of a lpha ketoglutarate dehydrogenase i n  the TCA cycle ,  the 
very h igh activities of transaminases compared to a lpha ketog luta rate 
dehydrogenase and the abundant supply of amino group donors in transamination 
actions 
Glutamate is  the precursor of GABA. However, g lutamate is  present in  low 
levels i n  the GABAergic  neurons and astrocytes and this could be because the 
a lpha ketog lutarate dehydrogenase bottleneck is bypassed in these cel ls .  I n  
GABAergic  neurons g lutamate enters the GABA shunt and is converted 
success ively into GABA, succin ic semialdehyde and succinyl-coA. I n  astrocytes, 
g l utamate is diverted from the bott leneck of a lpha ketoglutarate dehydrogenase by 
the formation of g lutamate which then exits the cel ls .  This leads to the levels of both 
g lutamate and aspartate to be low in astrocytes (Ottersen & Storm-Mathisen,  1 985) .  
Thus a l l  bra in  ce l ls  contain g l utamate as a byproduct of energy metabol ism . 
A neuron can be identified as g lutamaterg ic on an immunocytochemical basis only 
after detect ion of g lutamate in synaptic vesicles. 
G lutamate is pooled in  various parts of the bra in  and these pools 
communicate with each other, as and when req uired . The transmitter pool is located 
in the vesicles of g lutamaterg ic termina ls ,  the GABA precursor pool that is present in  
GABAerg ic neurons, the g lutam ine precursor pool that is located in  g l ia  and the 
lastly the metabol ic pool of g lutamate which is present in  al l cel ls .  These pools 
commun icate in  various instances; when g lutamate is  d iverted form the metabol ic 
pool to become transm itter or precursor of GABA and g lutamine,  or when the amino 
ac id transmitters return to the metabol ic pool and are processed to become carbon 
d ioxide and water. There is a lso extens ive transport of g lutamate and its 
derivatives, GABA and g lutamine,  between cel l  types(Fonnum, 1 993) . G lutamate is 
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synthesized d i rectly from g lutamine ,  1 -pyrro l ine-5-carboxylate (P5C) or a lpha 
ketoglutarate (2-oxogluta rate) in  the CNS.  The formation of g lutamate from 
g lutamine is an energy saving process that is catalyzed by phosphate-activated 
g lutaminase (PAG),  which could play a major role in the production of transm itter 
g lutamate. P5C is derived from ornith ine through g lutamic semialdehyde by the 
cata lysis of ornith ine delta-aminotransferase (OAT) or from prol ine by prol ine 
oxidase (PO),  then converted to g lutamate by P5C dehydrogenase (P5CDH) .  
Glutamine is an important precursor for transm itter g lutamate. The 
transmitter pool of g lutamate is preferent ia l ly suppl ied from g lutamine (Bradford , 
Ward , & Thomas, 1 978) . I n  the bra in ,  g lutamine synthetase is located in the 
astroyctes and ol igodendrocytes (Mart inez-Hernandez, Bel l ,  & Norenberg , 1 977 ;  
Tansey, Farooq , & Cammer, 1 99 1 ) .  Approximately 60% of a lpha ketog lutarate 
formed in astrocytes is converted to g lutamate and then to g lutamine (Akiyama, 
Kaneko, M izuno,  & McGeer, 1 990). G lutamine is formed from g lutamate by 
amidation .  
The enzyme g lutaminase is located on the  external aspect o f  the inner 
mitochondrial membrane and is an  amidohydrolase enzyme that generates 
g lutamate from g lutam ine .  S ince g lutamine is  an important energy substrate for 
neurons ,  most of the g lutamate that is formed from g l utamine enters the 
m itochondria (Bradford, 1 978) .  After g lutamine is converted to g lutamate, it is 
packed in  the secretory vesicles and awaits re lease. 
The astrocytic export of g lutamine impl ies a cont inuous loss of a lpha 
ketog lutarate from the astrocytic TCA cycle but th is is not the case.  The 
intermediates of the TCA cycle have restricted access across the blood-bra in barrier 
and so the anaplerotic process of pyruvate carboxylation cont inual ly  replen ishes the 
loss. Anaplerosis is the process of convert ing pyruvate , which is derived from 
g lucose via g lycolys is ,  to oxaloacetate or malate. Astrocytes express the enzymes 
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pyruvate carboxylase and cytosol ic and m itochondrial mal ic enzyme (A .  C .  Yu ,  
Drejer, Hertz , & Schousboe, 1 983) .  Observat ions that neurons and subpopulat ions 
of neurons have the abi l ity to replenish their TCA cycle by carboxylat ing pyruvate 
can explain w'rty some g lutamaterg ic pathways have a low level of g lutam inase, 
whereas others have h igh levels , and it explains how transmitter g lutamate can be 
formed from neuronal precursors (Hassel & Brathe, 2000a) .  Neurons can thus 
carboxylate pyruvate and not depend on  g l utamine as a precursor for transmitter 
g lutamate. 
The g lutamine cycle ,  the 1 : 1 exchange between astrocytes and neurons of 
g lutamine for g lutamate and GABA was conceptua l ized i n  the 1 970s (van den Berg 
& Garf inkel ,  1 97 1 ) . I n  th is cycle ,  astrocytes take up g l utamate re leased from 
neurons,  convert it to g lutam ine in an energy dependent process and then supply 
g l utamine to the extracel lu lar  flu id to mainta in a high concentration of g lutamine 
which is approximately 0 .3mM.  Neurons consume g lutamine and convert it to 
g lutamate by g lutaminase.  
1 . 1 1 . 2 Ves i c u l a r  U pta ke of Transm itter G l u ta mate 
The transmitter pool of g lutamate is  estimated to be about 20-30% of the 
total bra in  g lutamate content (Karlsen & Fonnum,  1 978) .  G lutamate formed in the 
nerve termina ls  is transported into the vesicles via the vesicular transporter. This 
transporter has a low affi n ity for g lutamate with a Km around 1 mM (S. Na ito & T. 
Ueda, 1 985) .  This is  approx imately 1 000 t imes h ig her than the Km of the plasma 
mem brane t ransporters, which corre lates with the concentration of g lutamate being 
1 000-fold h igher i n  the cytosol than extrace l lu lar  flu id .  G lutamate transport into 
vesicles is d riven by an e lectrochemical g radient.  This is generated by a proton 
pump that depends on A TP and magnesium and is  stimu lated by a chloride 
concentrat ion of 4-1 OmM,  s im i lar  to the cytosol ic re lease (S. Na ito & T.  Ueda ,  1 985) . 
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Glutamate in  the vesicles has a concentration of approx imately 1 00mM (Burger, 
1 989).  
1 . 1 1 . 2 M e c h a n i s m  of G l uta mate Release 
The depolarization of g lutamaterg ic neurons al lows calc ium to enter the 
termina l  and tr igger g lutamate exocytosis .  The vesicular re lease of g lutamate is a 
Ca2+ dependent mechanism that i nvolves N- and P/O-type voltage-dependent Ca2+ 
channels (B irnbaumer, 1 994) and these channels appear to be closely l i nked to 
vesicle docking sites. The vesicu lar  membrane fuses with the plasma membrane 
prote ins .  an ATP dependent process (Esser, 1 998) that is reg ulated by protein 
phosphorylat ion (Hanson, Heuser, & Jahn ,  1 997) .  Rapid appl ication of g lutamate to 
neuronal membrane patches at a concentrat ion that is estimated to be s imi lar  to a 
physiolog ic synapse, br ings about the postsynaptic response when excitatory 
synapses are activated (Berg les ,  Diamond, & Jahr, 1 999; J .  D .  C lements, Lester, 
Tong, Jahr, & Westbrook, 1 992) . 
Releasing a s ing le release ves icle produces an  excitatory postsynaptic 
potent ial  (EPSP) that is  re lated primari ly to g lutamate receptor activat ion.  The 
synaptic re lease of g lutamate is control led by a wide range of presynaptic receptors . 
After its release, g lutamate must be cleared from the synapt ic cleft. It is rapidly 
cleared from the cleft and internal ized into astrocytes .  I t  can now enter two major 
biochemica l  pathways. F i rst, g lutamate may become am idated to g lutamine by 
g lutamine synthetase in the cytosol .  Th is pathway is  important, which is ind icated by 
the presence of g lutamine synthetase in astrocytic processes that are near 
g lutamaterg ic  synapses (Derouiche & Frotscher, 1 99 1 ) .  Second, g l utamate may 
enter the m intochondria of astrocytes to become transaminated (by 
aminotransferases) or deaminated (by g l utamate dehydrogenase) to alpha 
ketog lutarate and may be oxid ized successively to succinate, fumarate and ma late . 
Ma late, after leaving the mitochondria, may then be decarboxylated to pyruvate by 
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cytosollc mal ic  enzyme (Kurz ,  Wiesinger, & Hamprecht, 1 993) . The magn itude of 
the fl ux of the transmitter g l utamate from neurons to astrocytes may be roughly 
estimated from the formation of g lutamine from transm itter g l utamate. GABA and 
a lpha ketog lutarate derived from the astrocytic TCA cycle a lso contribute to 
g lutamine formation .  
Astrocytes are metabol ica l ly  coupled with excitatory neurons a n d  serve them 
by supply ing precursor g lutamine and by de novo synthesis of g lutamate from alpha 
ketog lutarate and ammonia by using energy. I nh ib itory neurons appear to use 
g lutamate formed from alpha ketog luta rate as the immediate precursor of GABA. 
Glutam inase is mostly found in excitatory neurons, a lthough it is a lso found in a 
l im ited number  of GABAerg ic neurons in  certain areas of the bra in (Kaneko, 
Shigemoto, & M izuno,  1 988) .  
Forming and degrading transmitter g l utamate is  an ATP dependent process .  
The fusion of  the ves icu lar membrane with the plasma membrane needs prote in 
phosphorylat ion and needs ATP. The uptake of g lutamate by astrocytes is coupled 
to the inf lux of three molecules of sod ium which are cleared by the Na/K-ATPase, 
leading to the use of one molecular of ATP per molecule of interna lized g lutamate. 
Formation of g lutam ine from g lutamate requ i res one ATP per molecule (Levy, Warr, 
& Attwel l ,  1 998) .  The uptake of g lutamine across the neuronal plasma membrane 
goes against a concentration g radient and is  sod ium dependent. One molecule of 
g lutamine needs the entry of three sod ium or hydrogen ions,  which impl ies that one 
A TP is used up by the Na/K-ATPase. Therefore , one transmitter g lutamate cycle of 
vesicular uptake and re lease, astrocytic uptake and am idation ,  and neuronal  uptake 
of g lutamine,  could use at least fou r  molecules of ATP per molecule of g lutamate; 
two in  neurons and two in  astrocytes. This calculation does not include the ATP 
expenditure inherent i n  the depolarization of presynaptic membrane which triggers 
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the transmitter release and the depolarization of postsynaptic membra nes caused 
by g lutamate receptor activation .  
Assum ing a fl ux of  transm itter to  g lutamate to  astrocytes, which makes up 
approximately 30% of the cerebra l  TCA cycle rate , it means that less than 3% of the 
energy extracted form serum g lucose is  used in the handl ing of transmitter 
g lutamate. The uptake of g lutamate i nto cultured astrocytes i ncreases Na/K-ATPase 
activity and also an increase in g lucose uptake and lactate export (Magistrett i ,  
Pel leri n ,  Rothman,  & Shu lman,  1 999) .  
I n  summary, g lutamate is synthesized from g lutamine and a lso from 
neuronal precursors that are suppl ied by neuronal pyruvate carboxylation .  
Transm itter g lutamate is mostly taken up into astrocytes for conversion to  g lutamine, 
but some part of the g lutamate is metabol ized by the astrocytic TCA cycle either 
fu l ly  to CO2 and water or only part ia l ly  to form malate that is converted to pyruvate 
and lactate. The uptake of g lutamate into astrocytes stimu lates the astrocytic uptake 
of serum g lucose and exports lactate. G lutam ine is shunted to neurons where it is 
mostly converted to C02 and water and some of i t  is  converted to transmitter 
g lutamate. The uptake processes that are re lated to the handl ing of transm itter 
g lutamate and g lutamine ,  in addit ion to the formation of g lutamine uses up 
approx imately 3% of the total energy of the serum g lucose that is taken up by the 
bra in .  
The locat ion of  g l utaminase, on  the external s ide  of  the inner  mitochondrial 
membrane,  cou ld play a role in  events after cel l  damage occurs .  When trauma or 
hypoxia damages the cel l ,  the enzyme can leak out of neurons and into the 
extrace l lu lar  space where it can covert extrace l lu lar  g lutamine to g lutamate. This 
can contribute to a cont inuous and excitotoxic g lutamaterg ic stimu lation of neurons. 
This has been demonstrated i n  vitro and may occur in  vivo as wel l  (Driscol l ,  Deibler, 
Law, & Crane, 1 993) .  
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1 . 1 2  G l uta mate Recepto rs 
The g lutamate receptors transduce the g lutamate released from the 
presynaptic termina l  i nto biochemical and electrical events in  the postsynapt ic 
neuron Glutamate receptors are crit ical for transducing the vast amount of 
excitatory neurotransmission and reg ulat ing the strength of both excitatory and 
inh ibitory transmiss ion in  the nervous system (Vandenberg ,  1 998) .  
The g lutamate receptors are broadly classified into the l igand-gated 
ionotropic g lutamate receptors ( iGluRs) and G prote in-coupled metabotropic 
(Meld rum , 2000) g lutamate receptors (mGluRs) .  
The ionotropic g lutamate receptors were the first to be d iscovered and 
mediate the fast excitatory transmission i n  the postsynapt ic neuron .  These receptors 
comprise of a d iverse g roup of ion channels that are ma in ly gated by the binding of 
g lutamate. The metabotropic g lutamate receptors are composed of seven 
transmembrane-domain proteins that depend on heterotrimeric guanosine 
tr iphosphate (GTP)-b inding proteins to activate intrace l lu lar  s igna l l ing pathways 
(Greenamyre & Porter, 1 994) .  The g l utamaterg ic systems are dysfunct ional in most 
neuropathologies and receptor dysfunction appears to play a role in many 
neurologic d isorders. In  depth i nformation about these receptors in  terms of 
structure and function could play an important ro le . 
1 . 1 2 . 1  l onotro p i c  G l utamate Recepto rs 
I n  the early 1 990s, the c loning of cDNAs that encoded the g lutamate 
receptor subunits helped the fie ld immensely (Ho l lmann & Heinemann,  1 994) . 
l onotropic g lutamate receptors are class ified as; NMDA (N-methyl-D-aspartate), 
AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazoleproprion ic acid) and kainate 
receptor classes, named orig ina l ly  accord ing to their preferred , synthetic, agon ist. 
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Further stud ies showed that the receptors are encoded by at least s ix gene 
fami l ies based on sequence homology .  Further detai ls are in  Table 4. 
The s imi larity in  sequence ind icates a common evolut ionary or igin for these 
receptors. The gene fami l ies consist of a s ingle fami ly  fo r AMPA receptors , two for 
kainate, and three for NMDA. The genes are located over severa l ch romosomes but 
GRIA4 and G R I K4 genes are located on the long arm of chromosome 1 1  and 
G R I K5 and GRI N2D on chromosome 1 9 . The table below is for the g lutamate 
receptor subunits and corresponding genes (Dingledine, Borges, Bowie, & 
Traynel is ,  1 999) 
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G ro u p Receptor S u b u n it G e n e  C h romosome G e n E M B L  Accession No. 
Fami ly  h u m a n  Mouse Rat H u man 
1 AMPA GluA1 GRIA 1 5q33 X57497 X 1 7 1 84 1 57354 
1 AM PA GluA2 GRIA2 4q32-33 X57498 M85035 A46056 
1 AMPA G luA3 GRIA3 Xq25-26 M85036 X82068 
1 AMPA GluA4 GRIA4 1 1  q22-23 M 364 2 1  U 1 6 1 29 
2 Kainate G l u K 1  GRIK1 2 1 q 2 1 . 1 -2 2 1 X66 1 1 8  M83560 U 1 6 1 2 5 
2 Kainate G l u K2 GRIK2 6 q 1 6.3-q2 1 0 1 0054 Z 1 1 7 1 5  U 1 6 1 26 
2 Kamate GluK3 GRIK3 1 p34-p33 M835 52 U 1 6 1 27 
3 Kamate G l u K4 GRIK4 1 1 q2 2 . 3  X59996 867803 
3 Kamate G l u K5 GRIK5 1 9q 1 3. 2  0 1 00 1 1 Z 1 1 58 1  840369 
4 N M OA Glu N 1  GRIN1 9q34 . 3  0 1 0028 X63255 X58633 
5 N M OA Glu N2A GRIN2A 1 6p 1 3 . 2  0 1 02 1 7  0 1 32 1 1 U 09002 
5 N M OA G l u N 2 8  GRIN2B 1 2 p 1 2  0 1 06 5 1  M 9 1 562 U28861 
5 N M OA GluN2C GRIN2C 1 7q24-q25 0 1 0694 0 1 32 1 2  
5 N M OA G l u N 2 0  GRIN2D 1 9q 1 3 . 1 qter 0 1 2822 0 1 32 1 4  U77783 
6 N M OA Glu N3A GRIN3A 9q3 1 . 1  L34938 
7 N M OA G l u N 3 8  GRIN3B 1 9p 1 3. 3  
8 Delta 0 GRID 1 0 1 0 1 7 1  Z 1 7238 
9 Delta 0 GRID2 4q22 0 1 3266 Z 1 7239 
Table 4 :  G lutamate receptor subun its and their genes 
l onotropic g lutamate receptors are integral membrane prote ins that have four 
large subunits. These subunits that const itute the receptors have more than 900 
residues and together form a central ion channel pore .  Receptor heterogeneity 
with in each class ari ses from the homo-ol igomeric, or hetero-ol igomeric, assembly 
of distinct subun its into cation-selective tetramers. The subun its conta in  four 
domains ;  the extracel lu lar  amino-term ina l  domain (ATD) ,  the extrace l lu lar  l igand­
binding domain (LBO), the transmembrane domain (TMD), and an  intrace l lu lar 
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carboxyl- termina l  domain (CTD). The receptor has a 2-fo ld symmetry perpendicular 
to the plane of the membrane.  The g lutamate receptor TMD consists of three 
transmembrane hel ices which are M 1 , M3 and M4 and a cytoplasm-facing re-entrant 
membrane loor; M2 .  The M2 segment of the NMDA receptors is somewhat s imi lar  
to potassium channels and conta ins residues that influence the permeation 
propert ies of the ion channel .  M 1 ,  M2 and M3 form a structure that is s imi lar  to an 
inverted K+ channel pore and M4 main ly makes contacts with the TM D of an 
adjacent subunit (Dingledine,  1 999). 
The C terminus faces intracel l u larly whi le the N terminus extracel l u larly. The 
mechanism by which a receptor prote in  is threaded through the membrane during 
synthesis determines which segments wi l l  face the extra or intracel lu lar  areas and 
this In turn specifies the prote in  domains that wi l l  be ava i lable for l igand recognit ion, 
cytoplasmic mod ification , phosphory lat ion and interact ions between the receptor 
and cytoplasmic proteins (Ding ledine,  1 999). 
Receptors, ion channels and several other types of prote ins that are involved 
in  transmembrane signa l l ing a re usual ly composed of d ifferent subunits .  This varies 
based on the cel l  state, ava i lab i l ity of subun it types which depends in  turn on protein 
production and subcel lu lar  local izat ion.  Based on subun it ava i lab i l ity and interaction 
affinity, complexes may form in  one or more fixed stoich iometries or form with 
heterogeneous sto ich iometries.  Based on the subun it composit ion ,  it is clear that 
mu ltiple subtypes exist with in the ionotropic receptor fam i l ies .  Glutamate receptors 
are g rouped into four d ist inct classes based on pharmacology and on structural 
homology. These i nclude the AMPA receptors (GluA 1 -GluA4) ,  the ka inate receptors 
(GluK 1 -GluK5) ,  the N M DA receptors (GluN 1 ,  G luN2A-GluN2D,  G luN3A and 
GluN3B) ,  and the 0 receptors (GluD1  and G luD2) .  Please refer to Table 5 for 
previously uti l ized nomenclature .  
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N M OARs are composed of various combinations of Glu N 1  and GluN2 or 
G luN2A-GluN20 subunits and , In some cases , GluN3 or  GluN3A and GluN3B 
subunits. These subunits d iffer in  the length of the ir  C-term in i ,  with the longest ones 
found in G luN2A and G luN2B and the shortest in  G luN1  and GluN3B. G luN2 
subun its are the major determinants of  the functional properties of NMOARs, 
inc luding s ing le-channel  conductance, calcium permeabi l ity, magnesium sensitivity, 
agonist affinity and deactivation kinetics. The non-Glu N 1  subun its determ ine un ique 
physiological properties that lead to funct ional d iversity. G luN2 subun its b ind 
g l utamate and form Glu N 1 /GluN2 receptors that requ i re g lycine and g lutamate for 
activation .  G luN3 subun its bind g lycine and G lu N 1 /GluN3 receptors are gated by 
g lycine a lone;  however, excitatory g lycine receptors have not yet been observed i n  
neurons expressing the  G luN3 subunit .  The  genes encoding GluN 1 ,  G luN2 and 
GluN2A-GluN20 are GRI N 1 , GRI N2A GR I N2B, GR I N2C, G R I N20 and GRI N3A 
(g lutamate receptor, ionotropic, N M OA) (Stephen F Traynel is ,  201 0) .  
The AMPA receptor subunits GluA1 to GluA4 can form both homo- and 
heteromers. The subun its combine to form tetramers .  Most AMPA receptors are 
heterotetrameric, consist ing of symmetric 'd imer of d imers' of G luA2 and either 
G luA 1 ,  G luA3 or G luA4. AMPA receptor subun its d iffer most i n  their C-term ina l  
sequence, which determi nes their  interactions with scaffold ing proteins .  A l l  AMPA 
receptors conta in  post synapt ic density protein (POZ)-binding domains,  but which 
POZ domain they bind to d iffers . The AMPA receptors permeabi l ity to ca lcium and 
other cat ions, such as sodium and potass ium,  is governed by the G luR2 subunit .  If 
an AMPAR lacks a GluA2 subunit ,  then it wil l be permeable to sod ium,  potass ium,  
and calcium.  The presence of  a GluA2 subunit w i l l  a lmost a lways render the channel 
im permeable to calc ium. The receptor subun its of AMPARs are encoded for by 
separate but re lated genes that form a s ingle gene fami ly .  The receptor subunits are 
encoded by s im i larly  d ist inct fami l ies of genes.  The genes encoding GluA 1 -4 are 
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GRIA 1 -4 (g lutamate receptor, lonotropic, AMP A). The overa l l  s ize of these genes is 
l i ke ly to be >200 ki lo bases and the trans lated protein subunits contain approximately 
850-900 amino acids (Stephen F Traynel is ,  201 0) .  
Kalnate (KA) receptors are tetramers made up of homo or heteromeric 
association of the subunits ; G luK1 -5. G luK1 -3 homomers are functional kainate 
gated ion channels ,  G luK4 and G luK5 on ly form functional channel as heteromers .  
The Kainate recetors are formed from the products of  encoding genes denoted 
G R I K 1  - GRIK5 (g luatamate receptor, ionotropic, kainate) (Stephen F Traynel is , 
201 0) .  
The receptors class ified as Delta (0) ionotropic g lutamate receptors form a 
tetrameric stoichiometry .  G luD2 has been found to form heteromers with AMPA or 
kainate receptors and can modify the channel properties of these receptors . Genes 
encoding these receptors are G R I D 1  and G R I D2 (Glutamate receptor, ionotropic, 
Delta) .  The 01 and 02 subunits of G R I D 1  and GR ID2 have only 1 8-25% amino acid 
identity of the other g lutamate receptor subunits .  These subunits do not form 
funct ional channels themse lves or mod ify the function of other subunits. The 
importance of the 02 subun its was h igh l ighted i n  knockout mice that showed loss of 
activity-related depression of the paral lel  fiber-Purkinje cel l  synapse (Kashiwabuch i ,  
1 995) . The genetic mouse model of  excitotoxcity; Lurcher has been shown to be 
caused by a mutation of the 02 which makes the receptor into a constitut ive ly leaky 
cation channel (Vogel ,  Caston, Yuzak i ,  & Marian i ,  2007) .  Heteromeric assembly of 
ed ited and unedited subun its is a mechanism of funct ional  modu lation. 
There have been many d ifferent nomenclature schemes for the ionotropic 
g l utamate receptors . The fo l lowing table g ives the new nomenclature, agreed in 
Paris in 2008 by the I U H PAR ( I nternational Un ion of basic and cl in ical 
pharmacology) (S .  F .  Traynel is ,  201 0) .  
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N M DA A M P A  Kai nate Delta 
N R 1  - G l u N 1  GluRA - GluR 1 - GluR5 - GLUK5 - G l u K 1  01  = G l u D 1  
N R2A = G l u N 2A G l uA 1  GluR6 = GLUK6 = G l u K2 02 = G l u D 2  
NR2B = G l u N 2 B  GluRB = GluR2 = GluR7 = GLUK7 = G l uK3 
NR2C = G l u N 2C G l uA2 KA 1 = GLUK1  = G l u K4 
NR2D = G l u N 2 D  GluRC = GluR3 = KA2 = GLUK2 = G l u K S  
N R3A = G l u N 3 A  G l uA3 
N R3B = G l u N 3 B  GluRD = G luR4 = 
G l uA4 
Table 5 :  Nomenclature for lonotropic g lutamate receptors 
Studies have impl icated the NMDA receptors in many neurologic d isorders 
and neurodegenerative d iseases including the seizure spread in  epi lepsy (Ku l lmann ,  
Asztely, & Walker, 2000) ischemic bra in  damage,  Hunti ngton 's chorea ,  and 
amyotrophic lateral sclerosis (Heath & Shaw, 2002; Kawahara & Kwak, 2005; Kwak 
& Kawahara ,  2005),  Parkinson's (M .  J .  O'Nei l l ,  2005) and Alzheimer's diseases 
(Marenco & Weinberger, 2006) .  These receptors have a lso been l i nked to several 
neurodevelopmental d isorders such as Frag i le X mental retardation (Bear, Huber, & 
Warren ,  2004) schizophrenia (Marenco & Weinberger, 2006) ,  and the prol ife ration of 
g l ioblastoma tumours (Maas,  Patt , Schrey, & Rich,  200 1 ) depression,  and 
Rasmussen's syndrome (Granata, 2003) .  
G lutamate at elevated concentrations transit ions from being a 
neurotransmitter to a neurotoxin (Gi l l  & Pul ido,  200 1 ) .  The neurotoxicity of g lutamate 
depends on the cel l u lar  expression of the g lutamate receptors and their excessive 
activation (Choi ,  1 992; Gasic & Ho l lmann ,  1 992; Peng , Taylor, F inch,  Switzer, & 
Ramsdel l , 1 994) .  A neurotoxic phenomenon ensues, termed as excitotoxicity. 
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DIabetes IS  l inked to a ltered activity and regulation of neurotransmitter 
receptors and cel lu lar  enzymes Certa in gene expression studies in  d iabetic rats 
have shown interest ing outcomes such as the down-regulation of the enzyme 
g lutamate decarboxylase (GAD) mRNA and g lutamate aspartate transporter 
(GLAST) . GAD is the rate l imit ing enzyme that catalyses the decarboxylation of 
g lutamate. There are studies that report g lutamate mediated excitoxicity l inked to 
neuronal damage and to d iabetic compl ications such as retinopathy (Delyfer, 2005). 
G LAST conta ins cysteine residues that develop cysteine bridges in the 
presence of oxidative stress and leads to g lutamate flux inh ibit ion through the 
transporters (Trott i ,  Danbolt , & Volterra , 1 998) . The presence of hydrogen peroxide, 
superoxide anion and peroxyn itrite anion can inh ibit g l utamate uptake through 
G LAST (Zeng,  201 0) .  
Hyperg lycaemia has a lso been l i nked to d im in ished blood flow to nerves and 
neural ischaemia is an important factor contributing to d iabetic neuropathy (L .  J .  
Coppey, Davidson,  Dunlap, Lund,  & Yorek,  2000) .  This is due to the deranged 
mitochondrial funct ion,  which is further damaged by the presence of excitotoxic 
g lutamate (Srin ivasan,  2000) . Over activity of g lutamate induced by ischaemia is 
l inked to neuronal damage in  neurological condit ions such as stroke, amytorph ic 
lateral scleros is and neuropathic pa in .  L im itation of toxic g lutamate receptor 
activation is expected to be neuroprotective (Zhang ,  2002) .  
The g lutamate receptors , v ia a common injury pathway, are i nvolved in  
inflammation and cel lu lar  inju ry .  I n  the CNS ,  receptor overst imulat ion a l lows excess 
ca lci um influx into the neuron and subsequent neuronal  inj u ry (Choi , 1 992; Erda, 
1 992; L ipton, 1 993; L ipton & Rosenberg , 1 994; Meldrum,  1 994) . The iGluRs perm it 
entry of ions such as Na+ ,  K+ and Ca2+ and sustained stimu lation al lows excessive 
ion and water entry leading to osmotic i nju ry .  The increased intracel lu lar  calcium 
activates several enzyme pathways and s igna l l ing cascades including 
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phosphol lpases, prote in  k inase C,  proteases, protein phosphatases, n itric acid 
synthases and generates free radicals (Aszte ly & Gustafsson ,  1 996; Barb, 
Campbel l ,  Armstrong , & Cox, 1 996 ; G .  Bertrand , Gross, Puech, Loubatieres­
Marian i ,  & Bockaert, 1 992; H . -O.  Bertrand,  Bessis, Pin,  & Acher, 2002; Brun i ,  Bose , 
Pinsky, & Glavin ,  1 99 1 ; Burns,  Stephens, & Benson ,  1 994; Butcher, Sandberg , 
Hagberg , & Hamberger, 1 987;  Carlton, Hargett, & Coggesha l l ,  1 995;  Caste l l i ,  
I ng lann i , Stefan in i ,  & Gessa, 1 999; Chaudhari , 1 996 ; Dierkes, Hochstrate , & Schlue, 
1 996; L ipton, 1 993; L ipton & Rosenberg ,  1 994; Meldrum,  1 994) .  Protein kinase C 
translocates from the cytoplasm to the membrane and this leads to phosphorylation 
of membrane prote ins via PKC. This further destabi l izes the regu latory mechanisms 
for calci um homeostasis and toxicity (Choi ,  1 992).  Arach idonic ac id is  generated 
when phosphol ipase A2 is activated . P late let-activati ng factors increase the calci um 
levels in  neurons by st imu lating g lutamate release. Arachidonic acid potentiates 
N M DA evoked currents and inh ibits g l utamate reabsorption into astrocytes and 
neurons. This feeds forward when free radicals are formed during arachidonic acid 
metabol ism and further phospho l ipase A2 activation occurs. This increases the 
concentration of extrace l lu lar  g lutamate which activates the GluRs (Choi ,  1 992; 
Conn & Pin ,  1 997). 
As a consequence, cyste ine transport is then inh ibited and this decreases 
intracel lu lar  reducing su lphydry ls ,  more free rad icals are produced and cel l  death 
ensues.  N uclear enzymes such as endonucleases are a lso activated and lead to 
nuclear chromatin condensation ,  DNA fragmentation and nuclear breakdown . Th is 
leads to apoptosis .  The presence of free radicals adds to DNA fragmentation .  The 
raised calc ium concentration activates n itric oxide synthetases and produces more 
nitr ic oxide and free radica ls .  N itric oxide has been observed i n  peripheral t issue, 
gang l ion cel ls ,  nerve fibers and so on. These are a lso s ites where g lutamate 
receptors are present (Gi l l  & Pul ido,  200 1 ) .  
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Pain IS  one of the most common symptoms of diabetic neuropathy and IS  
experienced in vary ing types and degrees of intensity. Glutamate has been 
Impl icated in  the generation and ma intenance of neuropathic pa in .  Certa in  d rugs 
that modulate g lutamate neurotransmission have been l i nked to neuropathic pain 
rel ief in  an imal  models of periphera l  neuropathy (Bord i  & Quartarol i ,  2000; Bruno . ,  
1 995) . I n  an imal  models chronic d iabetic pain i s  postu lated by increased 
spontaneous firi ng of afferent neurons (Burchie l ,  Russe l l ,  Lee , & S ima,  1 985) .  This 
is  associated with the presence of increased voltage-dependent calcium currents in  
dorsal root gang l ion cel ls  and leads to  increased calcium concentrations in the 
neurons. This is added to by the open ing of g lutamate-regu lated calcium channels 
(Kawamata & Omote, 1 996; Thayer & Wang,  1 995; White , 2000).  
However, depend ing on the type of mGluR subtype activated the 
consequence can be neuroprotective or neurotoxic (Glaum & M i l ler ,  1 994 ; L in ,  
Chong,  & Maiese, 2002; Trombley & Westbrook,  1 992) .  I n  an imal  models, activation 
of certain mGluR subtypes such as Group I I  and I I I ,  protects cel ls  against neuronal  
insu lts such as N M DA excitotoxicity, bra in  inj u ry due to trauma,  stroke, g l ucose 
deprivat ion , oxygen deprivation and oxidative stress (Aarts & Tymianski ,  2003; 
Baskys & Blaabjerg , 2005; Berent-Spi l lson ,  2004 ; Blaabjerg ,  Fang , Z immer, & 
Baskys, 2003; Cai ,  Xiao, Fratkin ,  & Rhodes, 1 999; Chong,  L i ,  & Ma iese, 2005; 
Kalda, Kaasik ,  Vassi ljev , Pokk, & Zharkovsky, 2000; Leker & Shohami ,  2002 ; L in ,  
Vincent, Shaw, Maynard ,  & Maiese, 2000; Sagara & Schubert, 1 998; A.  M .  Vincent, 
Mohammad,  Ahmad,  Greenberg ,  & M aiese, 1 997 ;  Zhu, DeCoster, & Bazan ,  2004) . 
A role of these receptors in  prevent ing hyperg lycaemia induced neuronal inj u ry has 
been observed (Berent-Spi l lson,  2004; Berent-Spi l lson & Russel l ,  2007) .  
Group I I  and I I I  i nh ibit voltage gated calcium entry and regu late g lutamate 
release. These receptors act as  neuroprotective presynaptic autoreceptors that 
control g l utamate release from presynaptic term ina ls .  Group I I  mGluRs regulate 
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g lutathione (GSH), an important component of cel lu lar  antioxidant defence . The 
g lutathione homeostasis is maintained by oxidation reduction pathways that recycle 
GSH from oXid ized g lutath ione d isu lfide and synthesis by the gamma g lutamyl cycle.  
Cyste ine u ptake and the formation of cyste ine is important in  the GSH cycle .  This is 
l inked to g lutamate transporters (Baker, Xi ,  Shen, Swanson, & Kal ivas, 2002; 
Bender, Reichelt ,  & Norenberg ,  2000; Moran ,  Melendez, Baker, Kal ivas, & 
Seamans, 2003; Shanker & Aschner, 200 1 ;  Tang & Kal ivas, 2003) .  Gl ia synthesize 
GSH and support nearby neurons. The released GSH is degraded to precursors that 
are taken up by neurons and synthesized. Activati ng mGluR3 on Schwann  cel ls and 
g i la ,  where these receptors are prevalent ,  increases neuronal  GSH.  The GSH 
synthesis inh ibitor; buth ionine su lfox imine b locks the protective act ion of mGluR3 
(Berent-Spi l lson & Russe l l ,  2007) . 
The enzyme g lutamate carboxypeptidase I I ,  formerly NAALADase is a 
neuropeptidase primari ly expressed in  g l ia l  ce l ls .  The enzyme converts N-acetyl­
aspartyl-g lutamate (NAAG) to NAA. NAAG protects neurons by act ing as an 
mGluR3 agon ist . D i rect and ind irect activation of mGluR3 receptor by inh ibit ing 
g lutamate carboxypeptidase I I  (GC P I I )  protects from g lucose induced neuronal  
injury .  The GCP I I  inh ibitor; 2- phosphonomethyl pentanedioic acid (2-PMPA) 
protects the dorsal root gangl ia  neurons against g l ucose-induced cel l  i nju ry and 
neurite degeneration (Berent-Spi l lson . ,  2004) ,  (Spi l lson & Russel l ,  2003) .  Another 
agonist APDC has activ ity at mGluR2 as wel l  as mGluR3,  suggesting mGluR2 could 
a lso be neuroprotective. In animal models of d iabetic neuropathy, evidence of 
neuroprotect ion is  observed . GCP I I  i nh ibitors have shown to be benefic ia l  aga inst 
the hyperalgesia and neurophysiolog ical and structural degenerative d iabetic 
neuropathy changes in inbred type 1 d iabetic BB/Wor rats (Zhang,  2002). 
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1 . 1 3  G l utamate T ra n s po rte r  P rote i n s  
Glutamate is cont inuously being released from cel ls  and is cont inuously 
bei ng removed from the extrace l lu lar  fl u id .  I t  is of critical importance that the 
extracel lu lar  g lutamate concentration is  kept low. Its receptors are found on most of 
the cel lu lar  e lements such as dendrites, nerve termina ls ,  neuron cel l  bodies and g l ia l  
cel l s .  The importance of keeping g l utamate at a low concentration is  not just l im ited 
to the synaptic clefts.  
Ma intain ing a low extrace l lu lar  g lutamate concentration is essential to 
preventing g lutamate neurotoxicity that may occur under many pathological 
condit ions such as d iabetic neuropathy.  A low extracel lu lar  g lutamate concentration 
is req uired for a h igh signa l-to-no ise (background) rat io in synaptic as wel l  as in  
extrasynaptic transmission.  The clearance of  extracel lu lar  g l utamate v ia  g lutamate 
metabol ism or d iffus ion is not s ign ificant (Oanbolt , 200 1 ) ,  the regulation of 
extrace l lu lar  g lutamate depends on a h igh ly  efficient g lutamate transporter system 
consist ing of h ig h-affin ity membrane-bound g lutamate transporters. The transporter 
proteins represent the on ly  s ign ificant mechan ism to remove g lutamate from the 
extrace l lu lar  fluid and their importance for the long-term maintenance of low and 
non-toxic concentrat ions of g lutamate is now wel l  documented . 
1 . 1 4  G e n e  E x p ress i o n  
Gene expression is a process involving fundamental ce l l  processes such as ;  
transcript ion,  m RNA degradat ion, translation and prote in  deg radat ion .  Each step is 
controlled by gene regu latory events (Schwanhausser, 201 3) .  Gene expression 
profi l ing is the measurement of the activity or the expression of thousands of genes 
at once, to create a g lobal picture .  Changes in  gene expression in d iabetes presents 
a d ifferent pathway involved in  d iabetic pathogenesis.  The resu lts of a lterations in 
gene expression lead to molecular and consequently funct ional  changes that 
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malfunction as t ime goes on. Studying gene expression might ind icate how 
therapies can be developed that can prevent or at the least slow down the 
compl ications of chronic d iabetes (Kle in & Waxman , 2003).  
For experimental work, s ingle stranded DNA; complementary DNA or cDNA 
is often used because it is  more stable than RNA. I t  is generated by reverse 
transcript ion which uses s ing le stranded RNA as a template and the abi l ity of the 
enzyme reverse transcriptase to synthesis the DNA from the 3' end of the primer 
using the RNA sequence as template . Primers are integral to th is process and there 
are several types ava i lable ,  the choice depends on the end result requ ired. An 
o l igo(dT) primer wi l l  a l low the synthesis of cDNA from most mRNAs because it can 
bind to the poly(A) ta i l .  Random primers can be used for non-polyadenylated RNA 
because they anneal throug hout the target RNA. Gene specific primers are used to 
reverse transcribe specific m RNA (L ife science technolog ies , 2 0 1 3) .  
1 . 1 5  Hypothesis and Aim of the Study 
Based on the pre l im inary data, the hypothesis was that g lutamate pathways 
are l ike ly to be involved in d iabetic neuropathy part icu larly neuropathic pa in .  
Pathways were investigated to  look for changes that m ight reflect neuropathic pain 
and f i t  with previously establ ished pharmacological evidence. The a im of this project 
was to identify changes in expression of genes and their prote in  products that are 
involved in  g lutamate s igna l l ing in  d iabetes.  This wi l l  he lp to further the 
understanding of the mechan isms of d iabetic neuropathy. 
1 . 1 6  A n i m a l  M o d e l s  
Animal  models a l low control in  v ivo the genetic and environmental factors 
that infl uence the development of d iabetes and its compl ications.  Rodents are 
preferable due to advantages such as short generation intervals ,  economic viabi l ity, 
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ease of care and housing compared to larger models. Animal  models develop 
d iabetes e ither spontaneously or by using chemica l ,  surg ical ,  genetic or other 
techniques (Chatzigeorgiou,  Halapas, Kalafatakis, & Kamper, 2009). For type 1 
d iabetes, the 8n imal  models range from spontaneously developing autoimmune 
d iabetes to chemical ablat ion of pancreat ic beta cel ls .  Type 2 d iabetes is modeled in 
both obese and non-obese an imal  models with varying degrees of insu l in  res istance 
and beta ce l l  fa i lure (A. J .  King , 201 2) .  For the importance of re levance to the study, 
the characteristics of the an imal  model should reflect the pathophysiology and 
natural h istory of d iabetes or the model should develop d iabetic compl ications with 
an etiology s imi lar  to humans (Cefa lu ,  2006). However, no one an imal  model fits a l l  
these criteria. Us ing severa l d ifferent models to check for changes that affect a 
broad range of d iabetic models can be considered a su itable approach. 
In type 2 d iabetes, a popu lar model i s  the Goto-Katazaki  (GK) rat wh ich is a 
nonobese and has a decrease beta ce l l  mass. It is characterized,  s imi lar  to humans,  
by the presence of l iver and skeletal muscle insu l in  resistance. The fast ing blood 
g lucose shows only a moderate increase (Cefa lu ,  2006). The streptozotocin (STZ) 
model is created by inject ing the rats with d rugs such as streptozotocin to destroy 
the Langerhans is lets beta ce l ls .  I t  represents a model ,  with l im itat ions,  for type 1 
d iabetes and its subsequent compl icat ions (Akbarzadeh ,  2007) (Rossin i ,  1 977) .  
Although d iabetic compl ications such as neuropathy are typica l ly  associated 
with a chronic durat ion of the d iabetes itself, studies have a lso ind icated the early 
presence of abnormal it ies which could represent a premature development of these 
compl icat ions in autonomic and peripheral nerves (Pfeifer, 1 984) ,  (R .  J. Young, 
Ewing ,  & Clarke, 1 983), (Schaan,  2004). 
In the STZ model, early neuropathic changes are detected as early as 2 
weeks of developing d iabetes ,  as can be l inked to mechan ical hypera lgesia and 
7 1  
thermal hypoalgesia, tested b y  observing a s  paw withdrawa l thresholds to 
mechanical stimu l i  or tail f l ick latencies to thermal stimu l i  (Sugimoto, Rashid , Shoj i ,  
Suda,  & Yasuj ima,  2008). 
The GK model showcases a more chronic scenario of neuropathy. This is  
s imi lar  to humans as there is a strong correlat ion between duration of the d iabetes 
and development of neuropathy (Dyck, 1 999), (Dyck, 201 1 ) . Early stages of this 
model show l ittle change in  nerve conduction velocity and few morphometric 
abnormal it ies such as atrophy or axonal loss.  However, at later stages abnormal it ies 
in  these areas beg in  to man ifest and are indicators of neuropathic changes. 
Decreased expression of nerve g rowth factor, its receptor, susbstance P and 
calciton in gene-related prote in  can be observed in  the dorsal  root gangl ia 
(Murakawa , 2002) .  
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Chapter 2:  Material and Methods 
2 . 1  Eth ica l  A p p roval  
The protOcol of the experiment was a pproved by the Faculty of Medic ine and 
Health SCiences Animal  Ethics Committee, which uses protocols based on those of 
the Nat ional I nstitutes of Health i n  the USA. 
2.2 G ro u ps of A n i m a l s  and C o n d it ions of A n i m a l  C a re 
Proper housing and management of the an imals are essential to the wel l­
be ing of the an imals ,  t�e qua l ity of research data and testing .  Good management of 
the an imals also helps to min im ize the variat ions that affect research results 
(Research,  1 996) . 
B lood g lucose levels were measured in  a l l  groups of rats by Accu-check 
performa blood g lucose Mon itori ng System (Roche Diagnostics) us ing �2 IJI of 
whole blood col lected from the tail tip after a 25-G needle puncture of unrestra ined 
rat. 
Al l  an imals were maintained under specific pathogen free cond it ions at 22-
25°C ambient temperature and re lative humid ity at 50% with a 1 2  h l ight-dark cycle 
( 1 800-0600 h). The cages were polycarbonate cages with wood chip bedd ing . There 
was free access to water and Harlan-Teklad rat chow was provided. 
The rats belonged to d ifferent rat models; streptozotocin treated and Goto­
Kakizak i .  
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2 . 2 . 1  Stre ptozotocin  Treated Rats 
Expenments were performed on t issues of adult male Wistar rats (200-250 
g bred Inhouse) which had been g iven intraperitoneal injection of STZ (Sigma,  St 
Louis,  MO, USA) at the dose 60 mglkg at 8 weeks of age. The STZ was d issolved in 
a cit rate buffer solut ion (0. 1 molll citric acid ,  0 . 1 molll sodium citrate; pH 4.5) .  Age­
matched controls received an eq u ivalent volume of the citrate buffer solution alone. 
Both g roups of an imals were ma intained on the same d iet and water ad l ib itum unt i l  
they were used. 
Blood g lucose (mg/dl )  for the control rats were (78 .3±2. 5 ,  n=9) and STZ rats 
(366.7±23 .8 ,  n=9) .  The body weights of the d iabetics were s ign ificantly less than the 
contro ls ,  by approximately 35% at 1 2  weeks and 24% at 20 weeks of age. 
2 . 2 . 2  Goto-Ka kiza k i  Rats 
Young adult male (5 weeks) G K  rats and age-matched Wista r contro ls with 
in it ial  body weights of 1 50-1 80 g were obtained from a commercia l  colony (Taconic 
City ,  Germantown, NY,  U SA) . 
B lood g lucose concentrations 1 20 m in  fol lowing a g lucose chal lenge in  GK 
rats (236.27 ± 1 5 . 1 2 , n = 1 5 , mg/d l )  was s ign ificantly (p<0.0 1 ) h ig her than blood 
g lucose in  sedentary contro ls (93.93 ± 2 . 32 ,  n = 1 5 , mg/d l ) .  Body we ight and non­
fasti ng blood g lucose, measured immediate ly before experiments, were s ign ificantly 
(p<0.0 1 ) increased in  GK compared to control rats 
The control blood g lucose concentrations were in the range 53-70 mg/dL 
(mean 62 mg/dL) and the d iabetic levels were 1 25-375 mg/d L (mean 225 mg/dL) .  
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The body weights of the d iabetics were more than the contro ls , by 
approximately 1 2% at 1 0months. This was also the point when the an imals were 
sacrificed . 
2 . 2 . 3  Goto-Kakiza k i  Rats - S u c rose Fed 
Five week GK rats were obta ined (Taconic City, Germantown , NY, USA). 
The seven-week-old GK rats were fed with 1 00 m M  for 4 weeks, 200 and 300 mM 
sucrose for 4 weeks each and 400 mM sucrose solut ions thereafter t i l l  term ination. 
The objective was to induce more severe hyperg lycemia .  Their cond ition was 
compared with that of age-matched GK rats that were not g iven sucrose were used 
for comparison All rats received normal rat chow and drink ing water ad libitum. 
Body weight ,  non-fast ing blood g lucose, food and water consumption were 
measured period ica l ly .  
At the beg inn ing of the study,  the G K  Sucrose rats had a non-fast ing b lood 
g lucose value of 1 42 mg d l - 1  compared with 1 1 5 mg d l- 1  in  GK Control rats .  By the 
end of the study, the blood g lucose had risen to 254 mg d l- 1  in  GK Sucrose rats , 
compared with 1 43 mg d l- 1  in  G K  control rats. 
The non-fast ing blood g lucose i n  GK Sucrose rats (254 .25 ± 20 . 5 1  mg d l- 1 ,  
n = 5) was s ign ificantly (P < 0. 05) h igher than that in  G K  ( 1 43 .06 ± 6 .67 mg d l- 1 , n = 
5) .  The an imals were sacrificed at 1 0months of age.  Gene expression experiments 
began after 8 months of dietary intervention. 
The body weights were; GK Sucrose (445.08 ± 8.98 g, n = 5) and GK rats 
(442 . 38 ± 6 .08 g ,  n = 5) .  L iqu id consumption in GK Sucrose rats was ( 1 64.65 ± 5 .76 
m l  per rat day- 1 ,  n = 5)  compared to G K  (50.06 ± 0 .97 ml  per rat day- 1 , n = 5) .  
A g lucose tolerance test (GTT) was performed at the end of the experiment 
(after 1 2  weeks of treatment) for each rat. Al l the rats were made to fast overnight 
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(at least 1 8hr) prior to the test Glucose 1 0ml/kg/wt, was g iven intraperitoneal ly to 
the animals on the day of the GTT. B lood samples were col lected from the tai l  veins 
of the rat at t ime 0 (pr ior to the g lucose load) ,  30, 60, 1 20 and 1 80min after g lucose 
load All an imals are weighed before terminat ion. Tissues were removed with the 
utmost rapidity possible after d issect ion to ensure RNA qua lity and samples placed 
in  RNALater RNAlater (AM702 1 ;  Appl ied Biosystems, Carlsbad, CA, USA) and kept 
overnight at 4°C to a l low thorough penetration of the t issue. The samples were then 
stored in  -20°C t i l l  fu rther processing . 
N e u ra l  t issu e  
Spina l  cord ; Cervica l ,  Upper thoracic, Lower thoracic, Lumbar, Sacral 
Thoracic dorsal root gangl ia  (TDRG); 1 -3 , 4-6, 9- 1 2  
Thoracic sympathetic gang l ia  (TSG);  1 -6 ,  7- 1 2  
Pelvic gangl ia  
Lumbar dorsal root gang l ia  (LDRG) 
Sacra l dorsal root gang l ia  (SDRG) 
Non n e u ra l  tis s u e  
Retina and Lens 
Penis 
Bladder 
Kidney 
Tai l  sk in and foot skin 
Table 6 :  The l i st of t issue samples harvested from an imals 
2 . 3  D i ssection Tec h n i q u e  
Anima ls  are sacrificed us ing  the g u i l lot ine method (Suckow A M ) .  
Decapitation yields t issues uncontaminated b y  chemical agents. A special ized 
rodent gu i l lotine was used after ensuring it is in  good, clean condit ion with sharp 
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blades. If  correctly handled , rats do not show evidence of hypothalam ic-pitu itary­
adrena l  aXIs activation from this method or from being present when other rats are 
s imi larly terminated (A V. M . Associat ion) .  
Many autonomic gangl ia can be recogn ized without a microscope as 
swel l ing or protrusions a long nerve trunks or as knots with in a mesh of nerves. 
Certa in  gangl ia  are connected in a sequence or gangl ionated chain such as the 
paravertebral sympathetic cha in ,  whi le other gang l ia are connected by a mesh of 
nerve trunks with which they form a plexus .  Many m icroscopic gangl ia are buried 
with in a nerve or embedded in the wal l  of the viscera . In contrast the sensory 
com ponent cons ists main ly of neurons located i n  dorsal root gangl ia (and in  the 
nodose gangl ion of the vagus nerve) ;  in  addition ,  afferent neurons are present with in 
enteric gangl ia .  
2 . 3 . 1  Thoracic Sym pathetic G a n g l i a  
I n  the  thorax, the  sympathetic cha ins l ie  ventral to  the head of  the ribs and 
dorsal to the parieta l p leura. Each cha in  i s  made up of some 1 0- 1 2  gang l ia .  The 
lowermost gang l ion l ies opposite the 1 0th intercostal space. In the a bdomen the 
sympathetic chain is retroperitoneal and is  embedded in  the psoas muscle. Once 
identified under the dissecting scope, the sympathetic chain was isolated from its 
adherent t issue. The use of m icro d issect ing forceps was of the utmost importance. 
The chain was divided based by count ing the ribs. 
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Figure 3 :  Removal of thoracic sympathetic gangl ia .  
This is  beg inn ing from the sta rt of  the r ib cage .  The black rectangle represents the 
location of the sympathetic gangl ia  before removal .  
Figu re 4 :  Removal of thoracic sympathetic gangl ia from its adherent t issue 
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2 . 3 . 2  Pelvic G a n g l i a  
I n  the ma le  rat, the ma in  component of  the pelvic plexus is a s ingle,  large,  
b i latera l ly  symmetric gangl ion ,  the r ight and left pe lvic gangl ia .  The gangl ion is 
d iamond-shaped, measuring about 2x4 mm, and l ies on the side of the prostate, 
closely apposed to its fascia,  ventral to the rectum, and caudal to the ureter and vas 
deferens.  It shows lobulat ions that protrude in the d i rection of the surround ing 
organs .  The gangl ion is accompan ied by a few, smal l ,  accessory gangl ia ,  main ly 
related to the seminal  vesicles and the vas deferens.  Once identified , the gangl ia 
was separated as much as poss ible from its adherent t issue and isolated . The 
encircled area represents the location in  the picture below. 
F ig u re 5: Location of pelvic gangl ia .  
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2 . 3 . 3  D o rsa l Root G a n g l i a  
Paral le l  cuts us ing  micra-d issect ing scissors were made through the 
verterbrae adjacent to the spinal  cord and any overly ing muscle and bone were 
removed The entry point for the scissors was between the vertebral co lumn and 
spinal  canal at rostra l end and this a l lowed easier access to cut the vertebra l 
column The right and left ha lves of the vertebral column were separated to expose 
the spinal  cord and DRGs. The spinal  cord was l ifted from the dorsal structures by 
g rasping the spina l  cord at the rostral end while carefu l ly  cutt ing beh ind and around 
the dorsal root gang l ia  to sever the adherent t issues. The dorsal root gang l ia  were 
present along either s ide of the spinal  column ,  in smal l  "pockets" in the bone. Each 
dorsal root gang l ion was identified under the d issecting scope as being a round 
structure with smal l  pieces of nerve root on either s ide.  The dorsal  roots are very 
short at cervical and upper thoracic leve ls ,  and the gang l ia  l ie closely opposed to the 
spinal  cord . The last thoracic gangl ion (T 1 3) and the L4 gang l ion which is  the largest 
gangl ion were identified for orientation with respect to the whole rat. The 
thoracolumbar transit ion i s  easi ly identified because T 1 3 is just caudal to the last rib. 
L4 is general ly the largest lumbar gang l ion .  The dorsal  root gang l ia  were g rasped 
with micro forceps, then cut root on either s ide with micro scissors. All v is ib le nerve 
roots were sn ipped away before removing dorsal  root gang l ia from cords.  Us ing 
establ ished anatomical landmarks and visual identificat ion,  the dorsal root gang l ia  
were d ivided into thoracic, l umbar  and sacral gang l ia .  
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Figure 6 :  Removal of dorsal  root gang l ia  from its location .  
2 . 4  R N A  E xtra ction 
Extract ing RNA a l lows the study of genes of interest amongst the myriad of 
coding and non-coding seq uences is by fol lowing the m RNAs that correspond to the 
genes of interest. At the moment of extraction ,  being able to identify a particu lar  
mRNA means i ts correspond ing gene is being expressed (Peirson & Butler, 2007) . 
Tissue homogenization was using the Polytron mechanical homogenizer 
(POL YTRON® PT 2 1 00 Homogenizers ,  K inematica, Switzerland) .  Total RNA was 
extracted by us ing the Trizol method ( 1 5596-026, TRlzo l® Reagent, Life 
Technolog ies ,  Thermo Fisher Scientific ,  U SA) which a l lows the s imultaneous 
isolation of R NA,  DNA, and protein  from the same sample. This is an  important 
consideration because most of the samples of gangl ia  weigh 1 mg and less. 
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Sample homogenizations were done a t  intermittent intervals with samples 
kept In  Ice In between to avoid RNA and prote in  degradation .  I nterm ittent 
homogenization is one of the best methods avai lable to assist complete retrieval of 
RNA and prote in  from such smal l  sample (Ha imov-Kochman,  F isher, & Winn ,  2006) . 
Homogenizat ion was done unti l  t i l l  no clear vis ib le homogenate particles were 
observed . The generator was cleaned in between samples in the fol lowing 
sequence;  DNase/RNase free d isti l led water, 70% ethanol  in  DNase/RNase free 
dist i l led water, fo l lowed by DNase/RNase free dist i l led water. This was to prevent 
cross-contamination .  
The total R N A  was then precipitated us ing ethanol  a n d  processing of RNA 
isolat ion was completed using the SV Total R NA I solat ion System (Promega, 
Madison, USA) accord ing to manufacturer instruct ions.  
2.4.1  RNA P u rity 
The concentration and purity of RNA samples was measured by checking 
absorbance at 260 nm A260 and the ratio of the absorbance at 260 and 280 nm 
us ing N D-1 000; NanoDrop (ND-1 000 NanoDrop, Thermo Scientific, Wi lm ington, DE,  
USA) .  Only ratios � 1 . 8 were accepted . RNA samples were kept on ice dur ing 
processing and qua l ity check and then stored at -800 C pending further processing . 
Purity of the extracted RNA was also checked by running RNA samples on a 
1 % agarose gel  and observing the 1 8S and 28S bands . These r ibosomal RNA 
bands are 5 . 0  kb and 1 .9 kb in  size respective ly .  The RNA was a lso treated with the 
DNase protocol by I nvitrogen wh ich should improvement i n  the purity of the RNA. 
Post DNase treated RNA was a lso run on a gel  for qual ity check (Wieczorek 0,  
201 2 ) .  
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2.5 Reverse Tra n s c r i pt ion 
Using a High Capact lY cDNA Reverse Transcription Kit by Appl ied 
Biosystems (H igh Capacity cDNA Reverse Transcript ion Kit; 4374966; Appl ied 
Biosystems,  Carlsbad, CA, USA) , using the manufacturer's instruct ions.  The tota l 
RNA was converted into cDNA. Samples were d i luted to make a fina l  concentration 
of 4ng in  a 30 iJl PCR react ion .  
Reverse T ra n s c r i pt ion M aster M i x  Vo l u m e  
Com ponents 
1 x 
1 0  x RT Buffer 3 .0  iJ l  
25 x dNTP M ix  1 . 2 iJ l  
10  x RT Random Primers 3 .0  iJ l  
M u ltiscribe ™ Reverse Transcriptase 1 .0 iJl 
RNASE I n h ibitor 1 .0 iJ l  
RNase Free H2O = 30 - 9 .2 - vol of RNA template used iJ l  
Total Volume Reaction 30.0 iJl 
Table 7 :  Reverse Transcript ion Master Mix Components 
The above reaction g ives a fina l  cDNA concentration of = 1 ug/30iJ l  = 1 6ng/iJ l .  Each 
cDNA sample were then d i l uted to 4ng/iJl and stored in  -200 C. 
Reverse transcript ion react ion was carried out i n  a Verit i  thermal  cycler (life 
Technologies,  Appl ied Biosystems ,  USA) us ing the fol lowing parameter values:  
Ste p 1 Step 2 Ste p 3 Ste p 4 
Tem p  °C 25 °C 37 °C 85 °C 4 °C 
Time 1 0  minutes 1 20 minutes 5 minutes 00 
I 
Table 8: Reverse Transcription Reaction paramater values 
2.6  P rote i n  E xtraction 
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The organic phase that was obtained during trizol extraction of RNA was 
processed using the manufacturer's recommended method. Samples were then 
quantified us ing BCA method (Pierce) and stored in  -80 t i l l  fu rther processing.  
2.7  Low Dens ity Arrays 
These al lowed screening to identify genes that showed a ltered expression.  
Gene expression a rrays were performed by first load ing 1 00ng of cDNA (RNA 
equ ivalent) with an equal  amount of TaqMan© Gene Expression Master M ix  for a 
total of 1 00 iJ llport .  The cDNA and master mix were mixed by inversion and spun 
briefly in  an Eppendorf m icrocentrifuge. After the cards reached room temperature ,  
1 00 iJL  of  the  pooled control and pooled d iabetic samples was loaded i nto each of 
the 8 ports on the TaqMan Low-Density Array.  The cards were placed in  Sorva l l® 
Custom Buckets and centrifuged for 1 m in  at 1 580g . This was repeated after 
checking the flu id level i n  the cards .  I mmediate ly after centrifugation ,  the cards were 
sealed us ing an array sealer to prevent cross-contaminat ion and run on the ABI 
7900HT Fast Rea l-Time PCR system with thermal cycl ing condit ions :  
P u rpose Act ivate u ra c i l - Activation Denatu ration An n ea l i ng 
of ste p  D N A  Exte n sion 
g lycosy lase 
Temp °C 50 0e 94 . 5 °e 59.7 °e 59 .7 °e 
Time 02 minutes 1 0  minutes 30 sec cycles 1 m inute 
Table 9: Fast Real-Time peR system thermal cycl ing condit ions 
Analyses were restricted to genes that were expressed at detectable levels .  
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a n d  
2 . 8  Rea l T i m e  Polymerase C h a i n  React ion ( RT -PC R )  Gene E x pression Assay 
Gene expression is a process involving fundamental ce l l  processes such as; 
transcription ,  mRNA degradation ,  translat ion and protein  degradation . Each step is  
control led by gene regulatory events (Schwanhausser . ,  201 3) .  Gene expression 
profi l ing is the measurement of the activity or the expression of thousands of genes 
at once, to create a g lobal picture .  Changes in gene expression in  d iabetes presents 
a d ifferent pathway i nvolved in d iabetic pathogenesis .  The resu lts of a lterat ions in  
gene expression lead to  molecular and consequently funct ional changes that 
ma lfunction as t ime goes on .  Studying gene expression might indicate how 
therapies can be developed that can prevent or at the least s low down the 
compl ications of chronic d iabetes (Kle in & Waxman ,  2003) . 
For experimental work , s ing le stranded DNA; complementary DNA or cDNA 
is  often used because it is more stable than RNA. I t  is generated by reverse 
transcript ion which uses s ing le stranded RNA as a template and the abi l ity of the 
enzyme reverse transcriptase to synthesis the DNA from the 3' end of the primer 
using the RNA sequence as template . Primers are integral to th is process and there 
are several types avai lab le ,  the choice depends on the end result requ i red.  An 
o l igo(dT) primer wi l l  a l low the synthesis of cDNA from most mRNAs because it can 
bind to the poly(A) tai l .  Random primers can be used for non-polyadenylated RNA 
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because they anneal throughout the target RNA. Gene specific primers are used to 
reverse transcribe specific mRNA (technolog ies, 201 3) .  
Low dens ity arrays are effective approaches to  gene expression profi l ing . 
These are more sensitive and focused than gene ch ips and offer higher throughput 
than more establ ished approaches (Goulter, Harmer, & Clark , 2006) . 
The TaqMan© Low Density Array is an easy-to-use m icro flu id ic card for 
real-t ime PCR .  The micro flu id ic technology uti l izes e ight sample-loading ports,  each 
connected to 48 reaction chambers . These function as an array of reaction vessels 
for the PCR step. The wel ls conta in  custom TaqMan© Gene Expression Assays and 
are used to detect the real-t ime ampl ification of user-specified targets . Relative 
levels of gene expression wi l l  be determined from the f luorescence data generated 
during PCR (Biosystems, 20 1 0) .  
The express ion levels of mRNA were analyzed us ing target specific 
TaqMan® gene expression assays and performed in a 7900HT Fast ABI  Prism 
7900HT Sequence Detect ion System .  
O n  a 9 6  wel l  optical react ion plate (4306737 , Appl ied Biosystems, USA), 2ng 
of cDNA is used in  a 1 0u l  react ion and the fo l lowing components were added; 20x 
Taq Man© Gene Expression Assay, 2x TaqMan© Gene Expression Master M ix,  and 
the endogenous control or  gene of interest. This was then run in  the 7900HT Fast 
Real-Time PCR system (Appl ied Biosystems,  U SA) .  
Analyz ing the data from Taq Man© Gene Expression Assays requ i red 
viewing the ampl ification plots for the entire plate, sett ing the basel ine and threshold 
values and then using the relative standard curve or the comparative CT method to 
ana lyze the data. 
The TaqMan® primers and probes kits were from Applied Biosystems: 
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Assay ID Gene symbo l  Gene name 
1 R n00689046 
-
m 1  Gclc, rCG26075 g lutamate-cysteine l igase, catalytic 
subunit 
2 R n 00583547 _m 1 G ria3,  rCG532 1 0  g l utamate receptor, ionotropic, AMPA 3 
3 R n 00709588_m 1 Gna 1 ,  rCG34336 glutamate receptor, ionotroplc, AMPA 1 
4 R n0056 1 34 1 _m 1  Grin2a,  rCG49797 g lutamate receptor, ionotropic, N -methyl 
D-aspa rtate 2A 
5 R n 00583 322_m 1 Grip 1 , rCG49 1 64 g l utamate receptor interacti ng protein 1 
7 R n00570 1 30_m 1 SIc1  a3 ,  rCG50959 solute carrier fa mi ly 1 (gl ial h ig h  affin ity 
g l utamate tra n sporte r), member 3 
8 R n 00 583283_m 1 SIc1 a6, rCG294 1 9  solute carrier fami ly  1 (h ig h  affi n ity 
aspartate/g luta mate tra n sporter), 
member 6 
9 R n00564705_m 1 SIc1 a 1 ,  rCG48035 solute carrier family 1 ( n e u rona l/epithel ial  
h igh affi n ity g l utamate transporter, 
syste m Xag), member 1 
1 0  R n 0056 1 285_m 1 Gis ,  rCG22604 Gl utami nase 
1 1  R n 0056662 5_m 1 G rm 1 , rCG57330 g lutamate receptor, metabotropic 1 
1 2  R n 0 1 436038_m 1 G n n 1 ,  rCG4 5539 g l utamate receptor, ionotropic, N -methyl 
D-aspa rtate 1 
1 3  Rn007 1 0532_m 1 Grik3,  rCG30794 g luta mate receptor, ionotropic, kainate 3 
1 4  Rn0056 1 33 1 _m 1  G rik4, rCG57905 g l utamate receptor, ionotropic, kai nate 4 
1 5  R n00568 5 1 4_m 1 G ria2 , rCG62437 g l utamate receptor, ionotropic, A M PA 2 
1 6  R n00568 544_m 1 G ria4, rCG24522 g l utamate receptor, ionotrophic,  AM PA 4 
1 7  R n005 1 5053_m 1 Grid 2 ,  rCG55329 g lutamate receptor, ionotropic, delta 2 
1 8  R n 00691 548_m 1 SIc1 a2,  rCG26600 sol ute ca rrier fa mi ly 1 (g l ia l  high affi n ity 
g l utamate tra n sporter), member 2 
1 9  Rn00561 244_m 1 Gad2 , rCG40828 g l utamate decarboxylase 2 
Table 1 0 : TaqMan® primers and probes k its 
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The react ion mix of 1 O�I conta in ing a total cDNA of 4ng/reaction was prepared using 
TaqMan® H Fast U niversal  PCR Master Mix, No AmpErase H UNG (L ife 
Technologies #4352042, Applied Siosystems, USA) as fo l lows : 
Real  Time P C R  Maste r M ix Reactio n  Volume 
1 x 
DNase/R Nase free H2O 3 .5  � I  
cDNA (stock concentrat ion 2ng/� I)  1 � I  
2 X TaqMan H Fast U n iversal PCR Master 5 � I  
M ix  
20 X Gene of  I nterest (GOI )  0 .5  � I  
Table 1 1 :  Rea l  T ime PCR Master Mix Reaction Components 
Quantitative real-t ime PCR assay for the gene of interest was performed in 
dupl icates and in a sing leplex PCR react ion.  
The PCR thermal cycl ing parameters were run in  fast mode as fo l low: 
Step 1 Ste p  2 Step 3 Step 4 
Tem p °c 500 C 95 0 C 40 cycles of 95 0 C 60 0 C 
T i m e  2 minutes 20 seconds 1 second 20 seconds 
Table 1 2 : Real Time PCR Master M ix Reaction Components 
Results were in it ia l ly  ana lyzed with the ASI Prism 7900HT SDS program 
v2 .4 ,  al l remain ing calculat ions and stati stical ana lysis were performed by the SDS 
RQ Manager 1 . 1 ,4 software us ing the 2 -",:.et method with a relat ive quantification 
RQmin/RQmax confidence set at 95%. 
88 
The endogenous control used was rat f3-acti n .  Other expression related 
g U idel ines were fol lowed from the M I QE gu idel ines (Bustin . ,  2009) . 
2.9 Statistics 
Resu lts are expressed as the means ± S . E . M .  of 'n '  observat ions.  Statistical 
comparisons wi l l  use either Student's unpaired t test or ANOVA fol lowed by 
Bonferron i  corrected t tests for mu lt ip le comparisons,  as appropriate. A value of P < 
0 05 wi l l  be considered to ind icate a s ign ificant d ifference. Statistical ana lyses were 
done uS ing the GraphPad Prism Software and SPSS (v2 1 ) . 
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Chapter 3 :  Results 
3. 1 . Gene ra l  C h a racteristics of A n i m a l  G ro u ps Stud ied 
3 . 1 . 1 Gene ra l  C h a racteristics of C o ntro l a n d  Goto-Kakizaki  Rats ; G K  Group 
The general characteristics of the an imals are shown in  Table 1 3 . 
The bodywelghts of G K  (443.64 ± 7 .94 g ,  n= 1 8) were s ign ificantly (p<0.05) 
h igher than Control (37 1 73 ± 1 1  80 g ,  n= 1 8) rats. 
The non-fast ing blood g lucose in  GK rats ( 1 6 1 .29 ± 1 2 77 ,  n=1 8) was 
sign ificantly (p<0. 05) h igher than Control (89.67 ± 1 . 58 mg/d l ,  n = 1 8). 
C o ntrol G K  
Bodywe i g h t  ( g )  37 1 . 73 ± 1 1 . 80 443.64 ± 7 . 94 
N o n -fasti n g  b l ood 89.67 ± 1 . 58 1 6 1 .29 ± 1 2 .77 
g l ucose ( m g/d l )  
Table 1 3  Body weight measurements and fasting blood g lucose values of G K  group 
Data are mean±SE M .  Number  of an imals in  each group = 1 8 . Sign ificance 
values refer to numbers in parenthesis .  
3. 1 .2 Gene ra l  C ha ra cteristics of C ontro l and Goto -Ka kiza ki  Rats ; G K  S u c rose 
G ro u p  
The  genera l  characteristics o f  t he  an imals are shown in  Table 1 4 . 
C o ntro l S u c rose G K  S u c rose 
Bodywe i g ht ( g )  362 33± 1 7 .9 1  444 33 ± 1 8 37 
N o n -fasti ng b l ood 1 06.67± 1 5 8 1 223.00 ± 30.04 
I g l u cose (mg/d l �  
Table 14  Body weight measurements and fasti ng blood g lucose values of  GK 
Sucrose group 
Data are mean±SEM.  N umber  of an ima ls in  each group = 5 .  S ign ificance 
values refer to numbers In parenthesis.  
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The bodyweights of GK Sucrose (445 .08±8.98 g, n=5) were s ignificantly 
(p<O 05) h igher  than Control Sucrose (42 1 .28± 1 3 .36 g, n=5) rats. 
The non-fast ing blood g lucose in  GK Sucrose (254 .25±20. 5 1 , n=5) was 
s ign if icantly (p<0 .05) h igher than Control Sucrose ( 1 1 0 .93± 1 .76 mg/d l ,  n=5) .  
3 . 1 . 3 Gene ra l  C h a racteristics of C o ntrol and Streptozotocin  Rats;  
Streptozotoc i n  20w k  G ro u p  
The genera l  characteristics of the an ima ls  are shown i n  Table 1 5 . 
Body we ights were sig n ificantly (P<0.05) lower in  STZ 20wks rats 
(259.05±8.67 g, n=9 rats) compared to Controls (351 .05±8 .47 g, n= 1 0  rats) .  
Non-fast ing blood g lucose was sign ificantly (P< 0 .05) e levated in  STZ rats 
(440. 38±24. 56 mg/d l ,  n =9 rats) compared to Controls (98.00±2 .47 mg/d l ,  n = 1 0  
rats) 
C ontrol STZ 20wk 
Bodywe i g ht ( g )  351 .05±8 .47 g 259.05±8 67 g 
N o n -fasti ng blood g l ucose 98.00±2 .47 mg/dl 440.38±24 .56 mg/d l 
( m g/d l )  
Table 1 5 : Body weight measurements a n d  fasting blood g lucose values of 
STZ20wks 
Data are mean±SEM.  Number  of an imals in  each group = 9. Sign ificance values 
refer to numbers in  parenthesis .  
3. 1 .4 Gene ra l  C h a racteristics of C ontro l  and Stre ptozotocin  Rats ; 
Stre ptozoto c i n  30wk G ro u p  
The general characteristics of t h e  an ima ls are shown in  Table 1 6 . 
9 1  
Body weight was sign ificantly (P<O .00 1 )  lower i n  STZ 30wk rats (266± 1 0  g ,  
n=5) as com pared t o  control (426± 1 3  g ,  n=5) rats .  
C o ntrol  STZ 30wk 
Bodywe ight  ( g )  426± 1 3 g 266± 1 0  g 
N on-fasti ng b l ood g l ucose 1 1 0±4 mg/dl 554±25 mg/d l 
( m g/d l )  
Table 1 6: Body weight measurements a n d  fasting blood g lucose values of 
STZ30wks 
Data are mean±SE M .  Number  of an imals  in each group = 5. S ign ificance 
values refer to numbers in parenthesis.  
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3 . 2  Low Density Array Resu lts 
G E N E  G E N E  TDRG LDRG S D RG 
N A M E  9-1 2 
N e u ro pe ptides a n d  e nzymes reg u lat ing n e u rotra ns m i tters p rod uction,  
m eta bo l i sm or tra ns p o rt 
Calcb calcitonin-related polypeptide ,  beta 0.62 3 .73 2 .76 
CCK Cholecystok in in 0.6 1 3 .73 2.79 
Vip vasoactive intest ina l  polypeptide 0.22 0 .24 6.39 
Tac2 tachykin in  2 0 .57 4.27 1 .93 
N py neuropeptide Y 0 .79 1 .56 3.05 
Nos 1 n itric oxide synthase 1 ,  neuronal 0 .92 1 .69 3.08 
Nos3 nitr ic ox ide synthase 3 ,  endothel ia l  ce l l  0.41 0.93 1 . 48 
Maob monoamine oxidase B 0.49 0.97 1 .64 
S Ic6a2 solute carrier  fami ly 6 (neurotransmitter 0 . 3 1  1 . 37 3 . 90 
transporter), member 2 
SIc6a4 so lute carrier fami ly 6 (neurotransm itter NA 0 .8 1  4.03 
transporter), member 4 
SIc1 8a3 solute carrier fami ly  1 8  (vesicu lar  0.40 1 .82 8 . 54 
acetylchol ine transporter), member 3 
Rece ptors for neu ropeptides a n d  n e u rotra n s m i tters 
Chrna3 chol inerg ic receptor, n icotin ic ,  alpha 3 0.45 0 .72 0 .86 
(neuronal) 
CCKar cholecystok in in  A receptor 0.59 1 . 3 1  1 . 58 
Npyr1 neuropeptide Y receptor Y1 0.45 0 .70 2.74 
Sstr2 somatostatin receptor 2 0. 1 8  1 .66 3.99 
Tacr2 tachykin in  receptor 2 0.25 0.92 5 . 3 1  
Vipr2 vasoact ive intest ina l  peptide receptor 2 6.42 1 . 32 2 .53  
P2rx4 purinerg ic receptor P2X, l igand-gated ion 0.45 1 . 3 1  1 . 78 
channel  4 
P2rx7 purinerg ic  receptor P2X, l igand-gated ion 0.44 0.93 1 . 57 
channel , 7 
I o n  c ha n n e l s  
Accn2 acid-sensing (proton-gated) ion channel 1 0.42 1 .73 2.26 
Scn3a sod ium channel ,  voltage-gated ,  type I I I ,  0.39 0.79 2.33 
a lpha subunit 
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G E N E  G E N E  TDRG LDRG S D RG 
N A M E  9-1 2 
I o n  c ha n ne l s  
Trpv1 transient receptor potential cation channel , 0.45 2 . 1 6 1 .65 
subfam i ly V, member 1 
S Ic 1 2a5 solute carner fami ly  12 (potasslum-chlonde NA 4.74 4.48 
transporter), member 5 
G rowth factors a n d  their  rece ptors 
Ntrk 1 neurotrophic tyrosine kinase, receptor, type NA 1 78 2.06 
1 
Ntrk2 neurotrophic tyros ine kinase, receptor, type 0.37 1 . 34 2.40 
2 
Ntrk3 neurotrophic tyrosine k inase, receptor, type 0.41 1 .47 2 . 34 
3 
M i c rotu b u l e  associated p rote i n s  
Map1 a microtubu le-associated prote in  1 A 0.43 1 .65 2.02 
Map2 microtubule-associated protein 2 0.32 1 .24 1 .67 
Mapt m icrotubule-associated prote in  tau 0.32 0.94 2.35 
Nrtn  Neurtunn NA 6.39 3.04 
Pdyn Prodynorph in  NA 2.95 1 .09 
Table 1 7 : STZ 20wks low density array resu lts 
G E N E  T D RG 9 - LDRG S D R G  Pelv G 
1 2  
Gad2 Glutamate decarboxylase 2 . 1 7  6 . 2 8  8 .95 NE 
Gnp2 g lutamate receptor interact ing protein  1 .04 1 .26 1 . 1 4  0.45 
1 
Grip 1  g lutamate receptor interacting prote in  1 . 24 1 .45 2.65 3 .93 
2 
Grm5 Glutamate receptor 5 1 .48 3 . 8 8  1 .95 NE 
Gri n 1  g lutamate receptor, ionotropic 1 . 1 2  1 . 77 1 .22 0 . 36 
Gnn2a g lutamate receptor, ionotropic 1 .62 0 .61  1 . 58 N E  
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I G E N E  TDRG 9 - LDRG SDRG Pelv G 
1 2  
Gnn2b g lutamate receptor, lonotroplc 1 03 1 36 1 .22 NE 
Gna1  g lutamate receptor, lonotroplc, 0 89 1 23 1 .4 1  N E  
AMPA1  
I I Gna2 g lutamate receptor, lonotroplc, 0 98 0 59 0 .77 0.67 
AMPA2 
Gnk3 g lutamate receptor, lonotroplc, 0 99 1 .43 1 .09 0 .47 
I kalnate 3 
Table 1 8  STZ 20wks results of genes involved in g lutamate s igna l l ing pathways. 
ThoracIc dorsal root gangl ia  9 - 1 2  TDRG 9 - 1 2, Lumbar dorsal  root gangl ia 
LDRG, Sacra l dorsal root gangl ia SDRG, Pelvic gangl ia PelvG with fold changes 
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3 . 3  I n d i v i d u a l  Gene E x p ress ion Res u l ts 
C LA S S I F ICATION G E N E  
G LUTAMATE RECEPTORS 
Gria 1  
Gria2 
l onotroplc g lutamate receptors AMPA 
Gria3 
Gria4 
Grik3 
lonotroplc g lutamate receptors Kalnate 
Grik4 
Gri n 1  
lontroplc g lutamate receptors NMDA 
Grin2A 
l onotroplc g lutamate receptors Delta 2 Grid 2 
GLUTAMATE TRANSPORTERS 
S Ic 1 a 1  
SIc1 a2 
Solute carrier fami ly  
S Ic1  a3 
SIc1 a6 
ENZYMES I NVOLVED I N  THE GLUTAMATE CYCLE & GLUTAMATE RECEPTOR 
I NTERACTING PROT E I N  
Glutamate decarboxylase Gad 2 
Glutamate-cysteine l igase Gclc 
Glutaminase Gis 
Glutamate receptor interacti ng prote in  Grip 1  
Table 1 9  Classification of genes that were studied for levels of specific mRNA 
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3 . 3 . 1  Genes e x p ressing G l utamate Receptors - lonotro pic A M P A  
Genes encoding for the lonotroplc g lutamate receptors AMPA are Gria 1 , 
Gna2 Gna3 and Gna4 These are shown In Figures 7 - 1 2  F igure 7 and 8 shows 
gene expression of Ind iv idual  genes; Gna1  and Gria3 In GK rats (diabetic vs 
control) F igures 9 - 1 2  show gene expression of indiv idual genes, Gria2 and Gna4 
In GK rats (d iabetic vs control) In comparison to GK Sucrose rats (diabetic vs 
control) 
Gna 1 showed a s ign ificant decrease in express ion (p<O.05) in  TDRG 1 -4 and 
TDRG5-8 There was a s ign ificant increase in  expression (p<O.05) in the LDRG of 
GK 1 0months compared to control rats.  Gria 1 showed no sign ificant change in  
expression In  G K  Sucrose rats compared to  control rats. 
Gna2 showed a s ign ificant decrease i n  expression (p<O.05) in  TSG 1 -6 of GK 
compared to control rats. 
Gna3 showed a s ign ificant increase in expression (p<O.05) in LDRG of G K  
compared t o  control rats. 
Gria4 showed a s ign ificant increase in  expression (p<O.05) in  both TDRG5-8 
of GK compared to control rats and in  TDRG9-1 2 in  GK Sucrose compared to 
control rats.  
0 
"-
.., 
e: 
0 
0 
0 
.., 
Q) 
> . -
.., 
CO -
Q) 
"-
e: 
0 . -
C/) 
C/) 
Q) 
"-
e. 
>< 
W 
2.5 
2.0 
1.5 
T D RG 1 -4  
T DRG 5-8 
T D RG 9-1 2 
CONT OIAS 
LDRG 
P 0 4072 
CONT OIAS 
Figure 8: Expression of Gria 1 in  
dorsal root gang l ia  in G K  rats 
and controls 
T D RG 1 -4  
0 
"- CONT OIAS 
.., 
e: T DRG 5-8 
0 
0 
0 
.., 
Q) 
> . -
.., 
CO CONT OIAS 
Q) T DRG 9-1 2 
"-
e: 
0 
C/) 
C/) 
Q) 
"-
e. 
LDRG >< 
W 
Figure 7 :  Expression of Gria3 in  
dorsal root gang l ia  in  G K  rats and 
controls 
97 
0 ... 
+J 
C 
0 
0 
0 
+J 
Q) 
> . -
+J 
� -
Q) ... 
C 
0 
en 
en 
Q) ... 
c.. 
>< 
W 
T D RG1 -4 
CONT OIAB 
T D R G  5-8 
CONT OIAS 
T D R G  9-1 2 
L D R G  
CONT 
S D R G  
Reliable dam 
not available 
T S G  1 -6 
P 0.0307 
DIAS 
T S G  7-1 2 
Figure 9 :  Expression of Gria2 in  
dorsal root gang l ia  and thoracic 
sympathetic gangl ia  in GK rats 
and controls 
0 ... 
+J 
C 
0 , 0 
0 
+J 
Q) 
> 
+J 
� -
Q) ... 
C 
0 
en 
en 
Q) ... 
c.. 
>< 
W 
TDRG 1 -4  
P 0 1 057 
CONT OIAS 
T DRG 5-8 
T D R G  9-1 2 
P 0 3459 
LDRG 
S DRG 
CONT OtAB 
T S G  1 -6 
CONT OIAS 
T S G  7-1 2 
F igure 1 0 : Expression of Gria2 in  
dorsal root gang l ia  and thoracic 
sympathetic gangl ia in  G K  
sucrose fed rats a n d  controls 
98 
0 � 
... 
c: 
0 
0 
0 
... 
(1) 
> 
... 
n:s -
(1) � 
c: 
0 
(/) 
(/) 
(1) � 
0. 
>< 
W 
T D RG 1 -4  
P 0 1 1 54  
T DRG 5-8 
T DRG 9-1 2 
L D RG 
CONT DIAB 
S D RG 
CONT DIAB 
0 � 
... 
c: 
0 
0 
0 
... 
(1) 
> 
... 
n:s -
(1) � 
c: 
0 
(/) 
(/) 
(1) � 
0. 
>< 
W 
1. 
0 
T D RG 1 -4  
P 0 50 1 3  
CONT OIAB 
TDRG 5-8 
T DRG 9-1 2 
LDRG 
TSG 1 -6 T S G  1 -6 
P 0 2856 P 0 9354 
T S G  7-1 2 
Figure 1 2 : Expression of Gria4 in  
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Figure 1 1 :  Expression of Gria4 in  
dorsal  root gang l ia  and thoracic 
sympathetic gangl ia in  GK 
sucrose fed rats and controls 
99 
100 
3 . 3 . 2  Gene E x p ressing G l utamate Recepto rs - I onotropic  KAI N AT E  
Genes encod ing for the  ionotropic g lutamate receptors kainate are Grik3 and 
Grik4 These are shown in  F igures 1 3  - 1 6 . The figures show gene expression of 
Ind iv idual  genes; Grik3 and Grik4 in GK rats (diabetic vs control) in  comparison to 
GK Sucrose rats (d iabetic vs contro l ) .  
Grik3 showed a s ign ificant decrease in  expression (p<O.05) in  TDRG 1 -4, 
TDRG5-8, TDRG9- 1 2 ,  LDRG, SDRG, TSG 1 -6 and TSG7- 1 2  of both GK 1 0months 
rats and GK Sucrose rats in  comparison to control rats.  
Grik4 showed a s ign ificant decrease i n  expression (p<O.05) in  TDRG1 -4, 
TDRG5-8, TDRG9-1 2 ,  LDRG and SDRG of both GK rats and G K  Sucrose rats in  
comparison to control rats.  Grik4 did not show a s ign ificant change in  expression i n  
TSG 1 -6 and TSG7 - 1 2 of  both G K  and GK Sucrose rats compared to  control rats. 
2 T DRG 1 4 
T DRG 5-8 
lORG." OIAB 
0 � T D R G  9-1 2 
..., 
t: 
0 
0 
0 
..., 
Cl> 
> 
..., LDRG 
CO 
-
Cl> � 
t: 
0 
en 
en DIAB 
Cl> S DRG � 
Co 
>< 
W 
OIAB 
T S G  1 -6 
P 0.0376 
T S G  7-1 2 
Figure 1 4 : Expression of Grik3 
in  dorsal root gangl ia and 
thoracic sympathetic gang l ia  in 
GK rats and controls 
T D RG 1 4  
OIAS 
T D R G  5-8 
OIAS 
0 T DRG 9-1 2 � 
..., P 0.0007 
t: 
0 
0 
0 
..., 
Cl> 
> 
..., LDRG 
CO 
Cl> � 
t: 
0 
en 
en 
Cl> S D RG � 
Co 
>< 
W 
DIAS 
T S G  1 -6 
P 0.0002 
T S G  7-1 2 
Figure 1 3 : Expression of Grik3 in  
dorsal root gang l ia  and thoracic 
sympathetic gangl ia in  GK 
sucrose fed rats and controls 
101 
-
0 � .... 
c: 
0 
0 
0 .... 
Q) 
> .-.... 
C'Q -
Q) � 
c: 
0 
tJ) 
tJ) 
Q) � 
a. 
>< 
W 
TDRG 1 -4  
TDRG 5-8 
T DRG 9-1 2 
LDRG 
S DRG 
TSG 1 -6 
P 0 3480 
CONT OIAB 
TSG 7-1 2 
CONT DIAB 
Figure 1 5 : Expression of Grik4 
in  dorsal  root gangl ia and 
thoracic sympathetic gangl ia  in  
G K  fed rats and controls 
TDRG 1 -4  
TDRG 5-8 
0 T DRG 9-1 2 � .... 
c: 
0 
0 
0 .... " 
Q) 
> .- LDRG .... 
C'Q -
Q) � 
c: 
0 
tJ) 
tJ) 
Q) S D RG � 2.5 a. P < 0.0001 
)( 2." 
W 1.5 
TSG 1 -6 
TSG 7-1 2 
Figure 1 6 : Expression of Grik4 in  
dorsal root gang l ia  and thoracic 
sympathetic gangl ia in  G K  
sucrose fed rats a n d  controls 
102 
103 
3 . 3 . 3  Gene E x p re s s i n g  G l uta mate Receptors - I onotropic  N M DA and D E LTA 2 
Genes encoding for the ionotropic g lutamate receptors NMDA are Grin 1 and 
Grin2A. The gene encoding for the ionotropic g lutamate receptor Delta 2 is Grid2. 
These are shown in  F igures 1 7  - 20. F igure 1 7  shows gene expression of 
ind iv idual  genes; Gri n 1  i n  G K  (diabetic vs control) in  comparison to control rats. 
F igure 1 8  shows Grid2 in  GK (diabetic vs control) in  comparison to control rats. 
F igure 1 9  shows Grin2A in  GK rats (d iabetic vs control) in  comparison to F igure 20 
which shows Grin2A in GK Sucrose rats (d iabet ic vs contro l ) .  
Gri n 1  showed a sign ificant decrease in  expression (p<0.05) in  TDRG 1 -4, 
LDRG and SDRG of GK rats in comparison to control rats. 
Grid2 showed a sign ificant increase in  expression (p<0.05) in  TDRG5-8 in 
GK rats in  comparison to control rats.  
Grin2A showed a s ign ificant decrease in  expression (p<0 .05) in  TDRG 1 -4 ,  
TDRG5-8, TDRG9- 1 2, LDRG and  SDRG of  both G K  rats and G K  Sucrose rats i n  
com pa rison to  control rats.  
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Figure 1 8 : Expression of Grid2 in 
dorsal root gangl ia and thoracic 
sympathetic gangl ia in  G K  
sucrose fed rats a n d  controls 
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Figure 1 9 : Expression of Gri n2A 
in dorsal  root gang l ia and 
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Figure 20:  Expression of Grin2A 
in  dorsal  root gangl ia and 
thoracic sympathetic gangl ia in  
G K  sucrose fed rats and controls 
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3 . 3.4 Genes E x p ress i n g  G l uta mate Tra n sporte rs 
Genes encoding for g lutamate transporters are SIc1  a 1 , S Ic1  a2 , S Ic1  a3 and 
S Ic1  a6. These are shown in  F igures 21 - 27.  F igure 21 shows gene expression of 
Indiv idual  genes; S Ic1  a 1  i n  G K  (d iabetic vs control)  and Figure 22 shows GK 
Sucrose in  com panson to  control rats. F igure 23 shows the expression of  SIc1 a2 in 
GK (d iabetic vs control) in  compari son to control rats . F igure 24 and 25 show the 
expression of SIc1 a3 in  both GK rats (d iabetic vs control) and GK Sucrose rats 
(d iabetic vs contro l ) .  F igure 26 and 27 show the expression of S Ic1  a6 in both GK 
rats (d iabetic vs  contro l )  and G K  Sucrose rats (diabetic vs  contro l ) .  
S Ic1  a1  showed a sign ificant increase in  expression (p<O.05) in  TDRG 1 -4 of 
G K  rats in  comparison to control rats.  S Ic1  a 1  showed a s ign ificant increase in  
expression (p<O. 05) in  TDRG5-8 and TDRG9- 1 2  i n  both G K  and GK Sucrose rats 
in comparison to control rats . S Ic1  a1 showed a signif icant increase in expression 
(p<O.05) i n  LDRG, SDRG and TSG 1 -6 in  GK Sucrose rats compared to contro l .  
S Ic 1  a2 showed no s ign ificant change in  expression i n  G K  rats compared to 
control rats.  
SIc1 a3 showed a s ign ificant increase i n  express ion (p<O.05) i n  TDRG1 -4 
and TSG 1 -6 i n  G K  rats compared to contro l .  S Ic1  a3 showed a sign ificant i ncrease 
(p<O.05) in expression in TDRG5-8 in both GK and GK Sucrose rats com pared to 
control rats.  S Ic1 a3 showed a sign ificant increase in expression (p<O.05) in 
TDRG9- 1 2  and SDRG in GK Sucrose rats com pared to control rats. 
SIc1 a6 showed a s ign ificant decrease i n  expression (p<O.05) in  TDRG1 -4 
and LDRG in G K  and G K  Sucrose rats com pared to control rats. S Ic1 a6 showed a 
s ign if icant decrease in  expression (p<O.05) in  TDRG5-8 and TDRG9- 1 2  in G K  rats 
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compared to control rats . S Ic1 a6 showed a s ign ificant decrease in expression 
(p<O 05) In  TSG 1 -6 in the GK Sucrose rats compared to contro l .  
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Figure 22: Expression of SIc1 a 1  
in  dorsal  root gangl ia and 
thoracic sympathetic gangl ia in  
G K  sucrose fed rats and controls 
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Figure 24:  Expression of S Ic1  a3 
in  dorsal root gangl ia  and 
thoracic sympathetic gang l ia in  
G K  rats and controls 
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Figure 25 :  Expression of S Ic1  a3 
in  dorsal  root gangl ia and 
thoracic sympathetic gangl ia in  
GK sucrose fed rats and controls 
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Figure 26: Expression of S Ic1  a3 
in  dorsal  root gang l ia  and 
thoracic sympathetic gang l ia  in 
GK rats and controls 
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Figure 27:  Expression of SIc1 a3 
in  dorsal  root gangl ia and 
thoracic sympathetic gangl ia in  
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3 . 3 . 5  G e n e  Ex pres s i n g  E nzymes i nvolved i n  t h e  G l u tamate C y c l e  a n d  
G l uta mate Receptor I nteract ing P rote i n s  
Genes encod ing for enzymes that are involved in  the  synthesis g lutamate 
and metabol ism of g lutamate include; Gad2, Gclc and Gis .  These are shown in  
F igures 26 - 33. Figure 26 and 27 shows gene expression of  ind ividual  genes; 
Gad2 in  GK (diabetic vs control) and GK Sucrose in comparison to control rats. 
F igure 28 and 29 shows the expression of Gclc in  GK (diabetic vs control)  and GK 
Sucrose in  comparison to control rats. F igure 30 shows the expression of Gis in  G K  
rats (d iabetic v s  contro l )  in  comparison t o  figure 3 1  that shows GK Sucrose rats 
(d iabetic vs contro l ) .  F igure 32 shows the expression of Gri p 1  in GK rats (diabetic 
vs contro l )  in comparison figure 33 that shows GK Sucrose rats (d iabetic vs 
contro l ) .  
Gad2 showed a s ign ificant decrease in  expression (p<0 .05) in  TDRG1 -4 and 
TDRG9- 1 2  of G K  rats compared to control rats. Gad2 showed a sign ificant 
decrease in  expression (p<0.05) in  TDRG5-8 and a sign ificant increase in 
expression (p<0.05) in  TSG7 - 1 2 in GK Sucrose rats compared to control rats.  
Gclc showed a sign ificant increase in  expression (p<0.05) in  TDRG1 -4 , 
TDRG5-8, LDRG and SDRG in  G K  rats and GK Sucrose rats compared to control 
rats. 
Gis showed a sign ificant decrease in expression (p<0.05) in TDRG9- 1 2  in  
G K  rats compared to  contro l rats. Gis showed a s ign ificant decrease i n  expression 
(p<0.05) in  LDRG and TSG 1 -6 in  G K  Sucrose rats com pared to control rats . Gis 
showed a sign ificant increase in expression (p<0.05) in  TSG7- 1 2  i n  G K  rats 
compared to control rats.  
1 1 3  
Gnp1  showed a s ign ificant decrease in  expression (p<O.05) in  TDRG 1 -4 of 
GK rats compared to control rats. Grip 1  a lso showed a s ign ificant decrease in 
expression (p<O.05) in  LDRG and TSG 1 -6 in  both G K  and G K  Sucrose rats 
compared to control rats. 
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sympathetic gangl ia in  G K  
sucrose fed rats a n d  controls 
H T DRG1 -4 
P 0 0005 
:l0 
1 S 
1 0  
O S  
0 0  
CONT DIAS 
TDRG 5·8 
0 � TDRG 9-1 2 ... 
c: 
0 
(.) 
0 ... 
Q) CONT DIAS > 
. - LDRG ... 
ra 
-
Q) � 
c: 
0 
tJ) 
tJ) CONT DIAB 
Q) S DRG � 
a. 
>< 
W 
0 � ... 
c: 
0 
(.) 
0 ... 
Q) 0 
> 
. -... 
ra 
-
Q) � 
c: 1 
0 
tJ) 
tJ) 
Q) � 
a. 
>< 
W 1 
TDRG 1 -4  
CONT DlAS 
T D RG 5-8 
T DRG 9-1 2 
P 0.4895 
LDRG 
P 0.0577 
S DRG 
P 0.00 1 1  
CONT OIAB 
1 1 5  
T S G  1 -6 TSG 1 -6 
P 0 3480 
TSG 7-1 2 
Figu re 30 :  Expression of Gclc in  
dorsal root gang l ia and thoracic 
sympathetic gangl ia in  GK rats 
and controls 
TSG 7-1 2 
F igure 3 1 : Expression of Gclc in  
dorsal root gang l ia  and thoracic 
sympathetic gangl ia in  G K  
sucrose fed rats and controls 
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Figure 33: Expression of Gis in  
dorsal root gang l ia  and thoracic 
sympathetic gangl ia  in GK rats 
and controls 
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Figure 32: Express ion of Gis  in  
dorsal root gang l ia  and thoracic 
sympathetic gangl ia in  G K  
sucrose fed rats a n d  controls 
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Figure 34: Expression of G rip 1  
i n  dorsal root gangl ia  and  
thoracic sympathetic gang l ia in  
G K  rats and controls 
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Figure 35: Expression of Gr ip1 in  
dorsal root gang l ia and thoracic 
sympathetic gangl ia in  GK 
sucrose fed rats and controls 
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3.4 Analysis  of Varia nce 
Using ANOVA fol lowed by Bonferron i  post hoc test for mu lt ip le comparisons, the 
fol lowing results were obta ined . P <0 .05 was considered to indicate a s ignificant 
difference ( I B M  SPSS statistics, v2 1 ) . 
G e n e  F v a l u e  P va l u e  
Gria2 1 07 . 1 59 (4, 1 60) 0.000 
Gria4 44.603 (4, 200) 0 .001 
S Ic 1 a 1  24.684 (4 , 200) 0 .000 
SIc1 a3 5 .44 5  (4 ,200) 0 .831  
S Ic1  a6 5 . 350 (4,200) 0.000 
Grik3 2805. 8  (4,200) 0 .000 
Grik4 50.002 (4,200) 0 .000 
Grin2A 2 .675 (4, 200) 0 . 1 1 5  
Gclc 64.227 (4, 200) 0 .000 
Gis 43 .895 (4, 200) 0 .000 
Grip 1  1 2 .779 (4 ,  200) 0 .000 
Gad2 3 . 303 (4,  1 20)  0 .888 
Table 20: Analysis of variance for the effect of dorsal root gangl ia on gene 
expression 
In the case of Gria2, concentration in  SDRG were d ifferent from a l l  levels of 
the dorsal root gang l ia .  
For Gr ia3 and Gr ia4 ,  concentration i n  LDRG were different from a l l  leve ls  of 
the dorsal root gang l ia .  
1 19 
For S Ic1  a 1 , concentration In  LDRG and SDRG were d ifferent from a l l  levels 
of the dorsal root gang l ia . 
For SIc1 a3 and SIc1  a6, Grik3, Grip 1  and Grin2A there was no sign ificant 
d ifference In the any of the dorsal root gangl ia  across the levels .  
For Grik4 and Gclc and Gis ,  concentration in  TDRG 5-8 were d ifferent from 
a l l  leve ls of the dorsal  root gangl ia .  
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C h a pte r 4: Discussion 
While d iabetic peripheral neuropathy affects at  least 50% of older type 2 
d iabetic patients , its pathogenesis is not clearly understood. Considering the large 
number  of ind iv iduals afflicted with d iabetes , th is is an issue of epic proportions. 
D iabetic patients suffer ing from neuropathic compl ications can experience a range 
of symptoms. For some there are extremely painful symptoms but others, usual ly 
those with a more marked deficit, there may be no symptoms at a l l .  Typical 
neuropathic symptoms can include burn ing sensations, kn ife- l ike pa in ,  e lectric 
sensations of shock, throbbing pain and al lodynia .  On the other end of the spectrum,  
pat ients can experience sensations such as feel ing the part of  the body is asleep or 
'dead' ,  numbness, t ing l ing and prick l ing sensat ions. 
The d iabetic patients that experience pain frequently exhibit one or more 
kinds of stimu lus-evoked pa in ,  inc luding increased responsiveness to noxious 
stimu l i  (hypera lgesia) as wel l  as a hyper-responsiveness to normal ly innocuous 
stimu l i  (a l lodynia) that are often concurrent with a paradoxical loss of stimu lus­
evoked sensation .  
C l in ical examinat ion of patients with chron ic d iabetic periphera l  neuropathy 
usual ly  reveals a symmetrical sensory loss to al l modal it ies in  a stocking d istri bution .  
This may wel l  extend into the mid-calf level and may also affect the upper l imbs in  
more severe cases. 
Changes in  the expression of mRNA, caused by d iabetes and/or changes in  
d iet , i f  trans lated into changes in  proteins may cause a lterations to  the arch itecture 
of g lutamate receptors wh ich may i n  turn have implications for d iabetic neuropathy. 
Studies involving gene expression suggest that chronic neuropathic pa in is 
associated with strong activation of certa in  neuronal genes and defin ing these gene 
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expression profi le can further the understanding of  neuropathic pain 
etlology(Rodriguez Parkitna, 2006). 
The pathogenesis of d iabetic neuropathy has severa l theories that endeavor 
to expla in  It .  When several theories orbit a condit ion,  it suggests that there is  no 
un ifying hypothesis.  The pathological s igna l l ing pathways associated with d iabetic 
neuropathy are complex and th is influences the deve lopment of targeted therapies. 
Despite extensive investigat ions and deve lopment of mu lt iple theories the 
mechanism involved in  the deve lopment of d iabetic neuropathy are st i l l  not 
complete ly understood . I n  order to shed l ight on th is process we decided to 
i nvestigate changes in  gene expression i n  the gangl ia  that is  crucial for the 
neuropathic process. Pre l im inary investigations us ing low density arrays comprised 
of genes invo lved in neurotransmitter production and degradat ion,  neuropeptides, 
receptors, post receptor signa l l i ng and transport showed several prom is ing resu lts. 
The most i nteresting resu lts involved the genes that are involved in  the g lutamate 
pathway. Genes for g lutamate receptor expression,  g lutamate processing enzymes 
and g lutamate transporter prote ins  showed sign ificant changes in  expression .  
Furthermore, existing studies have focused predominantly on the spinal  cord 
and peripheral t issue, the dorsal root gangl ia have not received such in-depth 
attention and scrut iny .  This could be due to the inherent d ifficulty i n  harvesti ng the 
t issue intact from an ima l  models because of the extremely smal l  s ize of the gangl ia .  
The results i n  th is  study are un ique in  addressing the ro le of genes involved in  the 
g lutamate signa l l i ng pathway in  d iabetic neuropathy. The changes observed wil l be 
d iscussed in relation to symptoms of d iabetic neuropathy, particu larly in  l ight of the 
substantial  evidence that g lutamate is involved in  neuropathic pa in .  The cel lu lar and 
molecu lar  s igna l l ing pathways revealed in  th is study could provide strateg ies for the 
development of analgesics and management of d iabetic neuropathy. This study 
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Identifies that the genes involved in the expression of  g lutamate receptors, genes 
that are Involved in  the expression of enzymes regu lating g lutamate concentrations 
and transporter of the neurotransmitter g lutamate could play a role in  the 
development of d iabetic neuropathy and its phys ica l manifestations.  
4 . 1  A n i m a l  M od e l  
This study investigated the expression of  genes involved in  g lutamate 
signa l l ing and their possib le ro le in the deve lopment of d iabetic neuropathy. The 
experiments ut i l ized an an imal  model that represents type 2 d iabetes;  the most 
common type of d iabetes in  humans .  
Two of  the an ima l  g roups studied were Goto-Kakizaki d iabetic an imals who 
exhib it modestly elevated g lucose levels and their l itter mate contro ls .  In order to 
investigate the effect of increased hyperg lycaemia ,  we a lso studied the same two 
groups of an imals fo l lowing a sucrose enriched d iet . Thus there are four study 
groups overa l l :  Control an ima ls  (Cont), GK diabetic an ima ls  (GK), Control Sucrose 
fed (Cont-Suc), GK Sucrose fed (GK-Suc).  The longer the duration of exposure to 
risk factors, the worse are the effects of T20M on the nervous system as we l l  as the 
whole body. The combination of subtle and pronounced changes in  expression of 
genes encoding the receptors, enzymes and transport prote ins involved in the 
g lutamate s ignal l ing pathway suggests an important role that these play in  the 
development of d iabetic neuropathy. 
4.2 G l utamate Rece ptors and N e u ropathic P a i n  
The metabotropic g lutamate receptors (mGluRs) have received more 
attention that the fast act ing ionotropic g lutamate receptors ( iG luRs) in  terms of their 
role in  neuropathic pa in .  The fast acti ng iGluRs have not been as explored in  their 
potential  roles in  causing the symptoms of d iabetic neuropathy. Furthermore the 
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IG luRs are a lso Involved In  g lutamate toxicity whi le  certain subtypes of mGluRs are 
actual ly neuroprotectlve. Since most fast excitatory synaptic neurotransm ission in  
the mammal ian  nervous system i s  mediated by g lutamate, i t  is plausible that many 
neurological d isorders may be associated with abnormal it ies in  the g lutamaterg ic 
signa l l ing system,  and that therapeutic benefits might be atta inable through the 
manipu lation of this system .  We therefore conducted a study to characterize the 
expression of messenger RNAs (mRNAs) cod ing for subun its of a-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid (AM PA) receptors, N-methyl-d-aspartate 
(NMDA) receptors, Kainate receptors, g lutamate transporters and enzymes involved 
in  g lutamate regu lation such as g lutaminase and g lutamate cysteine l igase in the 
dorsa l  root gangl ia in  two rat models of d iabetic neuropathy. 
I t  is general ly assumed that neuropathic pain is  caused by changes in 
expression and function of receptors , enzymes ,  and voltage-dependent ion channels 
in  peripheral nerves and DRG neurons. The changes at synapses in  the nociceptive 
pathway in the centra l  nervous system a lso contribute(W. Wang, Gu ,  L i ,  & Tao, 
201 1 )  
There are possibly a variety of modified a lterations in  pain-re lated gene 
expression in  DRG neurons that underl ie the neura l  plast icity in  neuropath ic pa in .  
What role does the  g lutamaterg ic system play in  d iabetic periphera l  neuropathy? 
This is akin to asking how large a hole can be made in  a sh ip without s ink ing it . 
What the sh ip  tolerates depends on the capacity of its pumps to remove water, the 
energy for the pumps,  the weather,  the mass and propert ies of the cargo, the ski l ls 
of the crew as wel l  as a number  of other factors. As long as one var iable is not 
extreme,  it wi l l  be the combinat ion of several factors that wi l l  determ ine whether the 
sh ip  wil l s ink .  
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Col lective ly.  the different responses of g lutamate and its receptors in DRG 
neurons to neuropathic pain could be promoting or conquering the overexcited 
neuronal  transmission that may be substantia l ly  associated with corresponding gene 
expression mod ifications.  Alterations in gene express ion may function as 
pathological contributor to the deve lopment and maintenance of neuropath ic 
symptoms In  d iabetic neuropathy. 
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Figure 36: MAP-kinase signa l l i ng a long pain pathways in experimental rodent 
models.  
Patholog ica l pain s ignal l ing can be a dual  process of activat ion and 
sensitization which has the potential to become self-perpetuating and ult imately 
b id irect iona l .  Activation beg ins  with an increase in  the presynaptic re lease of 
nociceptive transmitter-mediators from presynaptic neuron termina ls or g l ia .  These 
include neuropeptides (substance P or calciton in  gene re lated product) chemokines 
(fracta lk ine) .  amino acids (g lutamate), neurotrophins (nerve growth factor or bra in-
derived neurotrophic factor) . Further activation occurs due to the postsynaptic 
stimu lation of nociceptors located on neurons or gl ia that include:  GPCRs (G-prote in  
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coupled receptors) that b ind  neuropeptldes and chemokines, LGICs ( l igand-gated 
Ion channels) that bind amino acids (such as g lutamate; NTR (neurotrophin 
receptor) tyrosine kmases that bind the neurotrophins (e .g .  NGF and BDNF) and 
cytokine receptors . Nociceptor stimu lation activates of various second-messenger 
s ignal  transduction cascades that converge to "turn-on" MAPKs via 
phosphorylat ion , regarded as a key component in  nociceptive sensitization .  
Activation (phosphorylat ion) of MAPKs leads to transcriptiona l  regu lation on DNA 
producing gene products, as wel l  as non-transcript ional regulation that enhances the 
excitatory propert ies of nociceptive activation and sensitizat ion.  The combination of 
these factors underl ie the generation and maintenance of chronic pa in (Edelmayer, 
201 4) .  
4 . 3  M e c h a n i sm s  of N e u ropat h i c  Pain 
Neuropathic pain can be caused by changes i n  the expression and function 
of receptors , enzymes, and ion channels in  peripheral nerves and DRG neurons ,  as 
wel l  as at the synapses in  the nociceptive pathway of the centra l nervous system.  
There dynamic interactions between periphera l  and central mechanisms are 
impl icated in  neuropathic pain(Gracely, Lynch , & Bennett, 1 992) 
The dorsal root gangl ia express many d ifferent k inds of ion channels and 
receptors . Broadly their  functions are; transduct ion (sod ium channels and ATP­
sensit ive receptors expressed in  the periphera l  term inals of DRG neurons that 
transduce noxious stimu l i  into e lectric impulses) ,  conduction (e .g . ,  sod ium and 
potass ium channels are invo lved action potent ia l  propagation) and synaptic 
transmission modulation (e .g .  g lutamate receptors expressed on presynaptic 
termina ls  of the primary afferents in  dorsal  horn to regu late neurotransmitter 
re lease). The a bnormal activity of neurons in  condit ions of neuropathic pain could be 
126 
re lated to changes i n  the dens ity, d istri bution,  and functional activit ies of g lutamate 
receptors in the dorsal root gangl ia neurons.  
The most important changes responsible for the induction of neuropath ic 
pain are found in  the a ltered gene/prote in expression in  primary sensory neurons. 
After damage to periphera l  sensory fibers, upregulated expression of certa in 
receptors can contribute to hyperalgesia;  whi le the downregulation of other 
receptors in  unmyel inated neurons is responsible for the phenotypic switch in pain 
transmission (Sapunar,  Kostic, Banozic, & Pu ljak,  201 2) .  
The major cel lu lar  mechanisms that have been studied in  d iabetic 
neuropathy include ectopic or spontaneous nerve activity, peripheral and central 
hyperexcitabi l ity, phenotypic changes in  the pathways that conduct pain and 
morphological reorgan izat ion .  Understanding the re lat ionship between symptoms 
and key cel lu lar and molecu lar  mechan isms is  vital to deve lop strategies to d i rect 
rat ional  d rug therapy rather than fo l lowing c l in ical serend ipity. Antinociceptive gene 
therapies that involve the g lutamate s igna l l ing pathway to treat d iabetic peripheral 
neuropathies have been met with some success i n  reducing neuropathic pain in  
an ima l  models of  d iabetes after gene transfer to  the dorsal root gang l ion(Y.  Wang , 
20 1 3) 
Mechan ist ic and molecular-based u nderstand ing of chronic neuropath ic pa in 
has re l ied heavi ly  on an ima l  studies us ing a d isease or mechanism-related models 
that emphasize key symptomatic characteristics such hyperalgesia and mechanical 
a l lodyn ia .  Most of these models have involved periphera l  nerve lesions such as 
sciatic nerve l igat ion or L4 and L5 spina l  nerve l igation .  However, there are relatively 
fewer studies from other d isease-re lated models such as d iabetic neuropathy to 
provide a balanced view a bout the ubiqu ity of key mechanisms.  
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The pathogenesis of periphera l  and central neurological complications of 
d iabetes IS l i kely to share many features. The pathogenesis of periphera l  
neuropathy I S  multifactoria l  and involving metabolic alterations,  such as increased 
polyol pathway flux, oXidative stress and non-enzymatic prote in g lycat ion. There is 
a lso evidence for vascular  dysfunct ion,  leading to decreases in  nerve blood flow and 
hypoxia and a lterations in neuronal  funct ions. I ncreases in  polyol pathway flux, 
leading to accumulation of sorbitol and fructose, accumu lat ion of advanced g lycation 
end products and increased concentrations of the by-products of l i pid peroxidation 
have al l been demonstrated in  the neural t issue of d iabetic rats. 
Neuropathic pain most often originates from a lesion in the nervous system 
and d iabetic neuropathy is one type. A characteristic of neuropathic pain is that the 
aberrance lead ing to pain m ust d i rect ly involve the nociceptive pathways. Painful 
d iabetic neuropathy is  length dependent which means the longest axons in  the 
peripheral nerve are most vulnerable. Patients a lso compla in of bi lateral burning 
pain in  the toes and feet. Quantitative sensory test ing reveals decreased pa in 
sensib i l ity (with or  without decreased touch sensibi l ity) . 
Although physiolog ica l  pain has a protective effect , pathological pa in is pain 
that has lost i ts orig ina l  biological s ignal l ing funct ion and does not serve the surviva l .  
Pathological pa in  is  characterized by  exaggerated responses to  a l l  suprathreshold 
and eventua l ly  subthreshold stimu l i .  The pain is  e l icited by stimu l i  which is otherwise 
innocuous and the pain spreads from the site of inju ry to the surrounding unaffected 
area. This type of pain a lso persists even in the absence of any apparent stimu l i .  
4 . 4  Hypera lgesia a n d  A l lodynia 
I n  physiolog ica l terms hyperalgesia and al lodynia refer to a dramatic 
decrease in the threshold of pain e l icited by unmyel i nated C-fibre afferents 
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(hypera lgesia) and that of  A� myel inated fibres that are activated normally on ly  by 
mechanical stimu l i  and carry non-nociceptive i nformat ion.  
However, hypera lgesia and a l lodynia are two major forms of sensitized 
behavioural responses assessed in an imal  models of neuropathic pa in .  Diabetic 
patients often experience hypera lgesia wh ich is abnormal ly heightened sensit ivity to 
pain and can be class ified into primary and secondary .  Primary hypera lgesia occurs 
at t issue i njury s ite and is mediated by primary afferent nociceptor sensit ization 
wh ich shows as increased response to stimu l i such as heat. Secondary 
hyperalgesia occurs in  un injured t issue surrounding site of inj u ry and is l i nked to 
central sensitization and shows an increased response to mechanica l st imu l i .  
Mechan ical hyperalgesia can man ifest as pa in  to  l ight-stroking st imu l i  ( i . e .  a l lodynia) 
and enhanced pain to punctate stimu l i .  In summary hyperalgesia is when 
nocicept ive responses to noxious stimu l i  are sig n ificantly enhanced whi le in 
al lodyn ia ,  previously non-noxious stimu l i  such as cold st imu l i  or mechanical touch 
leads to nociceptive responses. Hyperalgesia and a l lodyn ia are often concurrent 
with a paradoxical loss of stimu lus-evoked sensation .  
The pain in  d iabetic neuropathy is complex and involves numerous cel lu lar  
receptors ,  channe ls  and chemica ls .  Hyperexcitabi l ity of  primary afferent neurons 
after inj u ry could be due to a change i n  the expression of ion channels(Passmore ,  
2005) . Th is makes ion channe l  subun its, part icularly those predominant ly expressed 
in  nociceptive neurons,  novel targets to better understand the mechanisms behind 
d iabetic neuropathy and for future therapeutic target ing .  Most studies of ion 
channels have been carried out in  d issociated DRG neurons in  cu lture because of 
the ease with which neurons in  cu lture can be experi mental ly man ipu lated . Studies 
done on DRG harvested from various d iabetic models such as the Goto-Kakizaki 
and Streptozotocin rat model are relative ly uncommon.  
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4.5 T h e  Role of Dorsal  Root Gangl ia  i n  the Pain  P athway 
The cel l  body of sensory neurons is an interest ing model to study the 
properties of afferent termina ls .  Experimental ly ,  the soma of neurons is more 
accessible that the termina ls and may serve as a model of mechanisms that are at 
play in the term ina ls .  Studying the dorsal root gangl ia cel ls  are un ique because the 
responses of the somas of these cel ls  to neurotransm itters may reflect those of the 
synaptic termina ls of the primary afferent neurons.  The dorsal root gangl ia have a lso 
been subject to being used as targets for cel l  therapy treati ng neuropathic pain (H .  
Yu ,  201 5) .  Many  mediators l ike neurotransm itters, ionic channels and  cytokines 
have been identified being involved i n  the reg ulation of pain through funct ion ing on 
the DRG neurons.  As the entrance s ite of pain transm itted i nto the CNS, DRG 
possesses a pivota l role in  the funct ional regu lation of context of chronic pain .  
Alterations in  the expression of neurotransm itters and corresponding 
receptors play a sign ificant role in  sensit izing or desensit izing DRG neurons.  The 
imbalanced levels of excitatory and inh ibitory transmitters including their receptors 
make the whole DRG be easier to sensit ize to stimulat ion due to a reduced 
threshold or spontaneous activity. 
In a reg ional approach to understanding the role of pain s igna l l ing though the 
g lutamate pathways, the dorsal root gangl ia present un ique targets . The DRG is 
located between the dorsal root and the spinal  nerve and conta ins pseudounipolar 
neurons that convey sensory information from the periphery to the CNS.  Fol lowing 
nerve i nj u ry or inflammation ,  these neurons may become an important source of 
increased nociceptive s igna l l ing through increased neuronal excitabi l ity and the 
product ion of ectopic d ischarges. The DRG also lacks a protective surrounding 
capsular  membrane and has a permeable connective t issue capsule which can 
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make It a good choice for drug appl ication . Its permeabi l ity is due to a very h igh 
density of blood capi l laries in  the gang l ion t lssue(Sapunar, 201 2) .  
When nociceptive signals are produced at d istal nerve fibers, the signals 
travel through DRG neurons to the CNS. When the nerves are inju red, the DRG 
neurons become hyperexcitable, generating spontaneous action potentials or 
abnormal high-frequency activity that contributes significantly to neuropathic pa in .  
The development of  chronic pa in  was considered as a mixed result of  mu lt iple 
factors that involve the neurons and neurons and g l ia .  Support ing g l ia l  cel ls of the 
peripheral nervous system include sate l l ite cel ls of dorsal root gangl ia and Schwann 
cel is  of peripheral nerves. Pathological a lterat ions in  the p lasticity and homeostasis 
of the neural m icro-environment g ive way to hypersensit ivity. 
Theories such as the phenotypic switch predict neurons repeatedly 
stimu lated by noxious stimu l i  activate genes result ing in transcript ion factors that 
enhance the expression of various neurotransmitters and receptors which 
perpetuate the dysfunction(Neumann,  Doubel l ,  Les l ie ,  & Woolf, 1 996) . 
The neurons i n  DRG are typica l ly divided accord ing to the s ize of their cel l  
soma ;  sma l l ,  medium and large.  The  neurons with a cel l  body d iameter less than  30 
IJ m  are putative nociceptors and large d iameter neurones (>30 IJ m) are regarded as 
non-nociceptive . Non-myel inated C-fibres, that transmit nox ious information,  arise 
from neurons with small ce l l  bodies, whi le myel inated Aa- and A�-fibres, which 
convey low-threshold non-noxious information ,  are from large cel l  body neurons. Ao­
fibres, which can also be nociceptive , a re from neurons with cel l  bodies that are 
med ium i n  size(Passmore, 2005) .  
G lutamate has been shown to play a role a lso i n  the transduction of sensory 
i nput at the periphery and its involvement i n  peripheral neuropathies has been 
suggested on the basis of experimental studies in  an imals . 
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At spinal  level the most intense g lutamate Immunoreactivities can be found 
in the superficia l  laminae ( I ,  I I )  of the dorsal  horn, in the dorsal root gangl ion ce l ls 
and their efferent axons(Szekely, Torok, & Mate, 2002) 
In neuropathic pa in ,  neurons are important but so are the g l ia ce l l  responses 
that a lter neuronal  function in  the peripheral and centra l nervous system.  Neurons in 
the DRG are surrounded by sate l l ite g l ia l  ce l ls (SGCs), which carry receptors for 
numerous neuroactive agents and can therefore receive s ignals from other ce l ls  and 
respond to changes i n  their  environment .  Activating these cel ls  can influence nearby 
neurons,  and thus SGCs may participate in s ignal  processing and transmission in  
sensory gang l ia .  Damage to  the axons of  sensory gang l ia  contributes to  neuropath ic 
pa in .  Such damage also affects SGCs so these cel ls have a role in  the pathological 
changes in  the gangl ia(Hanani ,  2005) 
4.6 The Role of l onotro p i c  G l utamate Receptors i n  N e u ropath ic P a i n  
Glutamate receptors (GluRs) are widely expressed i n  the  membrane of 
sp ina l  neurons postsynapt ic to nociceptive afferents. AMPA,  KA and NMDA 
receptors are expressed in  the rat DRG neurons(Sato, Kiyama,  Park, & Tohyama,  
1 993) .  In  addit ion to th is ,  subun its of  both ionotropic and metabotropic g lutamate 
receptors that are trans lated a nd synthesized in dorsal root gangl ion (DRG) neurons 
are transported to periphera l  and central 10cat ions(Carlton, 1 995; Coggeshal l & 
Carlton ,  1 998; Lu ,  Hwang ,  Phend,  Rustion i ,  & Valtschanoff, 2003) . The peripheral 
transport of GluRs is suggested by immunoreactivity for NMDA, ka inate, or AMPA 
receptors detected on nerve fibers and end ings in  the rodent and human 
sk in(Carlton . , 1 995;  Coggeshal l  & Carlton ,  1 998; K inkel i n ,  Brocker, Koltzenburg ,  & 
Carlton ,  2000). Periphera l  G luRs can be activated by us ing agon ists and these 
receptors function as sensors of g lutamate re leased by peri phera l  termina ls ,  
contributing to sensitization after inj u ry .  The central termina ls of DRG neurons 
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release g lutamate, so presynaptic iG luRs expressed by these terminals may act as 
autoreceptors. Activation of  presynaptic autoreceptors in  centra l endings of  DRG 
neurons decreases the release of g lutamate from these termina ls (8ardon i ,  Torsney, 
Tong, Prand in l ,  & MacDermott, 2004; Kerchner, Wi lding , H uettner, & Zhuo, 2002; C. 
J Lee . ,  2002) .  
AMPA-receptor antagonists, N MDA-receptor antagon ists , and mGluR 
antagonists have a l l  been shown to amel iorate correlates of hypera lgesia and 
a l lodynia in  other an imal  models of d iabetes such as the streptozotocin model 
(Calcutt & Chaplan,  1 997;  Gupta, S ingh ,  Sood , & Arora , 2003; Ma lcangio & 
Toml inson,  1 998). 
l onotropic g lutamate receptors are essential to the appropriate function of 
the mammal ian CNS.  They mediate chemica l  synaptic transmission at the vast 
majority of excitatory synapses, underl ie ce l lu lar  models of learning and memory ,  
modu late neurona l  network excitabi l ity, and are requ i red for maturation of synaptic 
connect ions during early development. 
4 . 6 . 1  A M P A  l onotro p i c  G l utamate Rece ptors and N e u ropath i c  P a i n  
I n  the  dorsal root gangl ia  there were no s ign ificant changes in  expression of 
G ria 1 , Gria2 and Gria3. With regard to Gria4, statist ical ly s ign if icant but modest 
increase in expression was seen in TDRG 5-8 and LDRG of the GK group and i n  
TDRG 9- 1 2  of  the G K  Sucrose g roup. The  other levels o f  DRG showed a trend for 
i ncreased expression but did not reach statist ical sign ificance. Therefore, the 
biological im portance of the s ign ificant changes might be min ima l .  
The modest increase in  mRNA expression of  Gria4 i n  the lumbar dorsal root 
gangl ia ,  considering its role of presynaptic inh ibit ion ,  could be an adaptive response. 
This suggests the possibi l ity of a compensatory mechanism to reduce the increased 
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activity of  these receptors . Th is  would serve the purpose of  reducing the synaptic 
sensit ivity to g lutamate and tempering the information flow from the periphera l  
nervous system to  the  centra l nervous system .  I ncreasing Gria 1  conta in ing AMPA 
receptors at progressively more distal synapses can help to normal ize synaptic 
strength by compensating for increased dendrit ic fi ltering of synapses more distal to 
the ce l l  body. This down-regu lation mig ht be related to epigenetic gene si lencing.  
This information suggests that the development of sensitization could requ i re 
g lutamate transmission and it a lso suggests mechanistic s imi larit ies to other forms 
of neuronal  p lasticity. 
Antagonists that target AMPA receptors are more effective in  abol it ion of 
hyperalgesia seen during experi mental inflammation a lthough N M DA antagonists 
are more potent in experimental models of neuropath ic pain (Szekely, Torok, & 
Mate, 2002) .  
I n  low doses g lutamate receptor antagonists have been observed to elevate 
the threshold of the physiological pain sensat ion .  This leads to suppression of 
pathological sensit isation i . e .  lowering of the pain threshold seen upon excessive or 
lasting stimulation of C-fiber afferents . Both N M DA and AMPAlkainate receptors 
inh ibit wind up i . e .  last ing activation of the polymoda l ,  second-order sensory 
neurones i n  the deeper layers of the dorsal  horn. During sensit isation the rest ing 
Mg++ blockade of transmembrane Ca2+ channels is abol ished, certa in  second 
messenger pathways are activated , the transcript ion of many genes is enhanced 
leading to overproduction of g lutamate and other excitatory neurotransmitters and 
expression of Na+ channels in  the primary sensory neurons activated at lower level 
of depolarisation .  This cascade of events can lead to increased excitab i l ity of the 
pain pathways (Szekely,  2002).  
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AMPA receptors are transported to the centra l terminals of DRGs and are 
present in  d ifferent DH lam i nae. The AMPA receptors are most prom inently located 
near central term ina ls  of primary afferent fi bers . This is unusual  for ionotropic 
receptors on DRG neurons s i nce most other fami l ies of ionotropic receptor are 
found both at the termina ls and on the cel l  bodies (C .  J .  Lee . ,  2002). The AMPA 
receptors are expressed by smal l  d iameter dorsal root gangl ion neurons (C . J .  Lee . ,  
2002) and these neurons are i nvolved i n  nociception .  These receptors are detected 
at the level of the soma and are strongly expressed near the primary afferent central 
termina ls .  G lutamate is released from the term inals of these central primary 
afferents, upon nociceptor stimu lat ion,  onto the dorsal horn neurons. Prolonged 
stimu lation of nociceptors, such as after nerve damage, can lead to the cont inuous 
re lease of g lutamate. 
Activat ion of presynapt ic AMPA receptors inh ib its the release of g lutamate 
from the termina ls which suggests that primary afferent depolarization is a lso 
med iated by g lutamate acting on presynaptical ly local ized AMPA receptors (C.  J .  
Lee, 2002) .  Thus AMPA receptors on primary afferent central termina ls mediate 
primary afferent depolarizat ion and modulate g lutamate re lease. 
G lutamate released from centra l  termina ls  of primary afferents into the spinal  
cord in  response to nociceptor stimu lation primari ly activates the AMPA receptors on 
dorsal horn neurons. Prolonged stimulat ion of nocice ptors that often occurs after 
nerve damage can lead to a cont inuous release of g lutamate that can cause long­
last ing depolarization of the nerve membrane and consequently activation of NMDA 
receptors by g lutamate (Chizh , 2002).  
The AMPA receptors play a very important role in  presynaptic inh ib it ion.  The 
mechanism that d rives AMPA receptor-mediated presynaptic inh ibit ion at the 
primary afferent to dorsal  horn neuron synapse is probably primary afferent 
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depola rization (PAD) (Rudomin & Schmidt , 1 999) and is accompanied by an 
enhanced excitabi l ity of afferent fiber terminals This is a s low negative potential and 
when I t  reaches firing threshold i t  produces dorsal root reflexes (DRRs) and is also 
Impl icated in  generating neurogenic inflammation (C.  J .  Lee . ,  2002 ; Lobanov & 
Peng, 201 1 ;  Wi l l is .  1 999). It tempers the flow of information from the peripheral 
nervous system to the central nervous system.  
Besides, GABAA receptors, evidence now suggests that ionotropic g lutamate 
receptors at the presynaptic termina ls of afferent fibers a lso contribute to PAD 
(Rudomin & Schmidt, 1 999) .  The expression of AMPA and kainate receptors by 
noclceptors makes it p lausible to predict that these receptors participate in activity­
dependent generation of PAD in Ao and C fibers. The mechanism can be blocked 
by GABAA and non-NMDA g lutamate receptor antagonists (Evans & Long , 1 989; 
Wi l l is ,  1 999). Di rectly activati ng these presynaptic AMPA receptors resu lts in  a 
strong Inh ibit ion action on the amount of g lutamate released from some primary 
afferent termina ls in  the superfic ia l  dorsal horn of the spina l  cord .  
The pain system in  the spina l  cord i s  phylogenetica l ly  prim itive and exhibits 
behavioral changes such as hypera lgesia in  response to inflammation .  The use of 
AMPA receptor antagonists has been l i nked to suppressing inflammation- induced 
structura l  changes in the dendrites in  the spina l  dorsal horn (Matsumura,  Taniguchi ,  
N ish ida,  Nakatsuka ,  & Ito, 201 5) .  
G lutamate s igna l l ing through the AMPA receptors plays important roles in  
central pa in  circu its.  The subun its of  AMPA receptors are dynamic at  synapt ic sites 
and trafficking to the p lasma membrane has been impl icated in pathological 
condit ions.  The prote in  product of Gri a 1  and its accumu lat ion has been h inted at 
playing a role in sensory modulation at the level of the spinal  cord . 
Pharmacological ly induced down regu lation of the Gria 1 receptor in  the spinal  dorsal 
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horn can help amel iorate hyperag lesla (Y .  Z . Li . ,  20 1 4) .  Pharmacological 
compounds such as AMPAkines have been l i nked to help al leviate pain 
hypersensitivity In  rat models of persistent neuropathic pain and inflammatory 
associated pain (Le, Lee, Su ,  Zou, & Wang, 201 4) .  
Several studies suggest that receptor encoded for by Gri a 1  may p lay d isti nct 
roles In the regu lat ion of AMPA receptor trafficking and synaptic plasticity (Toyoda, 
2009). The Gri a 1  receptor is requ i red for NMDA receptor-dependent synaptic 
del ivery of AMPA receptors i n  L TP (Yang, Wang, Frerk ing , & Zhou, 2008) .  Long­
term potentiation (L TP) in  nociceptive sp ina l  pathways also shares severa l features 
with hypera lgesia and has been proposed to be one of the ce l lu lar  mechanisms of 
pain ampl ification in chronic pain states .  
Previous studies have suggested that periphera l Gri a 1  receptors located at  
sensory nerve endings in  the skin are involved in nociceptor activation and 
sens itizat ion.  Us ing an  ant ibody that recogn izes the three low-affin ity ka in ite 
receptor subunits Gri a 1 /2/3 that one or more of these receptor subun its is  l i ke ly 
expressed on 28% of unmyel inated fibers i n  the d ig ita l  nerve from normal  rats,  and 
that th is increases to roughly 40% acutely fol lowing Freund's adjuvant-induced 
inflammat ion .  I n  addit ion to th is ,  injection of ka inate in the h indpaw induced acute 
mechanical hypersensitivity , and that an AMPAIKainate receptor antagon ist (CNQX) 
injected in  the paw cou ld  reduce inflammation- induced mechanical hypersensitivity 
(J. Du ,  Zhou , & Carlton, 2006). 
Gri a 1  contain ing AMPA receptors are thought to be involved in the regu lation 
of synaptic strength. The Gr ia1  conta in ing receptors are a lso the predominant type 
of ionotropic g lutamate receptor expressed by the smal l-diameter sensory neurons 
in  dorsal  root gangl ia (Qiu . ,  201 1 ) . 
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There is  a pool  of AMPA receptors that recycle rapid ly between the plasma 
membrane and intracel lu lar  vesicles, the processes of exocytosis and endocytosis 
have Important roles In  transporting these receptors to and from synapses. Studies 
on subunit specific AMPA receptor transportation routes suggest Gria2/3 subunit 
conta in ing receptors are del ivered by d i rect insert ion and are cont inuously recycled 
with in  the synapse. Th is is  important to determine basal synapt ic strength . Gria 1 /2 
subun it conta in ing receptors , on the other hand,  are thought to in it ia l ly i nsert i nto the 
extrasynaptlc membrane and then move latera l ly into the postsynaptic density 
depending on the activity pattern of the synapse (Andrasfalvy, Smith ,  Borchardt, 
Sprengel, & Magee, 2003). AMPA receptor trafficking in  complex and i nvolves 
vesicu lar traffick ing,  lateral d iffusion and prote in-prote in  i nteractions to determi ne the 
distr ibution of AMPA receptors on the neuronal surface. 
The pain  pathway also i nvolves the h igher centers in the bra in and includes 
one of the most s ign ificant parts ;  the acute c ingulate cortex. Certa in patholog ical 
condit ions such as periphera l  chronic inflammation or nerve i njury is l inked to a long 
term potentiation of excitatory synaptic transmiss ion in  the acute c ingu late cortex. 
AMPA subun its are dynamic at synaptic s ites and their  trafficking onto the plasma 
membrane has shown to be important in  synaptic potentiation such as long term 
potentiation (T. Chen,  201 4) .  Long term potentiation (LTP) is a major form of 
synaptic plast icity and is l i nked to chronic pa in (Sandkuh ler, 2007) .  It resu lts in a 
long term i ncrease in synaptic strength and has two stages that depend on the 
duration and involvement of signal transduction ;  early and l ate.  Whi le the early 
phase lasts only for a few hours ,  the late phase involves protein synthesis and 
involves structura l  changes at synapses that can l ast the l ife span of the an ima l .  
L TP can be expressed pre- and/or postsynaptical ly .  This means the synaptic 
strength can i ncrease if the neurotransmitter release is  enhanced or  if the 
postsynaptic effects of the neurotransmitter are enhanced. Recent studies have 
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shown that L TP can a lso be induced I n  pain pathways and may contribute to 
hyperalgesia caused by Inflammation, trauma or neuropathy . I nduction of L TP at C 
fiber synapses also requ i res the activation of ionotropic g lutamate receptors and the 
Influx of ca lc ium via the AMPA receptors (Hartmann . ,  2004) .  When g lutamate binds 
to the AMPA receptors , it a l lows sodium to flow i nto the postsynaptic ce l l  and bring 
about depolarizat ion .  NMDA receptors which also play a role in  L TP cannot open 
d irect ly because at resting membrane potentia l  these receptors are blocked by Mg2+ 
ions and only open when a depolarization from the AMPA receptor activation leads 
to repel l ing of the Mg2+ cation out into the extracel lu lar  space and the pore can then 
pass current. The NMDA receptors are permeable to both Na+ and Ca2+ and when 
Ca2+ that enters the cel l  it triggers the upregu lat ion of AMPA receptors to the 
membrane, which resu lts in  a long- last ing increase in  excitatory postsynaptic 
potential size underlying L TP. The calcium entry also phosphorylates 
Ca2+/ca lmodul in-dependent prote in  k inase I I  (CaM K I I ) , which phosphory lates AMPA 
receptors and increases their s ing le-channel conductance. AMPA receptors 
i ncrease in ratio to N M DA receptors after h igh-frequency stimu lat ion. A nonsynaptic 
pool of AMPA receptors is present adjacent to the postsynaptic membrane and 
without the need for protein synthesis i n  early L TP, these receptors are rapidly 
trafficked into the postsynaptic membrane when the appropriate L TP- inducing 
stimu lus arrives (Ma l inow, 2003). Gria 1 has been impl icated in playing a role in 
cortical p last ic ity and persist pain us ing the ERK-dependent s igna l l ing pathway.  
During long term LTP, transcribed mRNA of AMPA receptors must reach the 
intended dendrit ic spine and can be transported even to synapses that did not 
receive the L TP-inducing stimu l i .  The neuronal  soma can synthesize receptor 
m RNA in  the nucleus, package it with in  a transport r ibonucleoprote in complex (a 
subtype of an  RNA complex) , in itiate transport, prevent trans lation during transport ,  
and del iver the com plex to the appropriate dendrit ic spine ( Bramham & Wel ls ,  
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2007) The synaptic tagg ing hypothesis partly expla ins how mRNA IS  trafficked to 
the appropriate dendritic spine and s ignal l ing the mRNA-RNP complex to dissociate 
and enter the dendrit ic spine (Martin & Kosik ,  2002). 
At the synaptic level ,  hyperalgesia and a l lodynia may be mim icked by 
changes in  synaptic transmiss ion in  spinal cord dorsal horn or cortical synapses. For 
hypera lgesia,  enhanced synaptic responses, main ly by postsynaptic mod ification of 
AMPA receptors, may d i rectly contribute to enhanced sensory responses to stimU l i .  
A synaptic amplif ier of  nociception has been identified at  the synapses between 
primary afferent C-fibres, many of which are nociceptive , and neurons in the 
superficial dorsa l  horn of the spinal  cord i n  rodents(R .  Ruscheweyh , Wi lder-Smith, 
Drd la ,  Liu, & Sandkuh ler, 201 1 ) . In the case of a l lodyn ia ,  the recru itment of 's i lent' 
synapses, or increases in synaptic AMPA receptors may expla in  why subthreshold 
sensory st imu lation can activate nociceptive neurons .  
Central sensitization is an  enhanced responsiveness of  nociceptive neurons 
in  the CNS to their  normal afferent input. Some forms of central sensitizat ion could 
contribute to hyperalgesia and/or a l lodynia (Sandkuh ler, 2007) .  I n it iat ion and 
ma intenance of central sensit izat ion is a consequence of evoked or spontaneous 
and this is suggested by the a bi l ity of transient local anesthesia to end hyperalgesia 
in  an ima l  models of central sensitizat ion (Re ich l ing & Levine,  2009) Sensitization 
and its role in neuropathic pain can be understood at some fundamental mechanism 
such as i ncreased re lease of excitatory neurotransmitter (e .g . ,  g lutamate) and/or 
enhanced synaptic efficacy. These mechan isms may relate to several cel lu lar  
events that are divided into changes that are at  the presynaptic, postsynaptic 
changes and interneuron leve l .  There is a lso evidence of sensitization being subject 
to changes in  descending modulat ion of pain (Campbel l  & Meyer, 2006) 
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Summation determ ines whether or not an action potentia l  wi l l  be triggered by 
the combined effects of postsynaptic potentia ls . Spatial summation requ i res the 
Input from mult iple presynaptic cel ls while temporal summation is when a h igh 
frequency of action potentials in  the presynaptic neuron el icits postsynaptic 
potent ia ls that overlap and summate with each other. In terms of nociceptive 
stimu lat ion, spat ia l  summation integrates painful input from large areas whi le 
tempora l summation integrates repetitive nocicept ive stimu l i .  Widespread and long 
lasting pain are characteristics of many chronic pain syndromes such as d iabetic 
neuropathy and this suggests that both types of summation could play a role .  
Through pressure stimu lat ion experiments, it has been shown that spatial 
summation faci l itates temporal summation of nociceptive inputs , specifical ly 
pressure pain .  The AMPA receptor-mediated excitatory postsynaptic potent ia ls 
(EPS Ps) have a ha lf-t ime of less than 1 0  ms (Swanson & Sakai ,  2009) .  This a l lows 
the receptors to be avai lab le for re-activation during periods of re lative ly h igh 
frequency i nput. The ionotropic g lutamate receptors respond to both spatial and 
temporal summat ion .  
Along with the presynaptic ka inate receptors, AM PA receptors should prove 
to be an important regulator of synaptic transmission in the pa in  pathway as wel l  as 
an  important modulator of non-noxious sensory transm ission.  
Activation of presynaptic ionotropic g lutamate receptors may reduce 
neurotransmitter re lease. As autoreceptors in  termina ls  of Ao and C afferent fi bers i n  
the  spina l  cord laminae I-I I I ,  presynaptic ionotropic g lutamate receptors may  play a 
role in  inh ibit ing nociception .  As heteroreceptors in GABAergic term ina ls in the same 
laminae, on the other hand,  presynaptic ionotropic g lutamate receptors may have an 
opposite role and contribute to central sensit ization and hyperalgesia (Lu . ,  2005) .  
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4.6 .2  N M DA l o notropic  G l uta mate Receptors a n d  N e u ropathic P a i n  
I n  the  present study, a marked and h igh ly  s ignificant reduction in  Grin2A 
expression was seen at al l levels of the ORG . In addit ion there was a smal l  
reduction i n  expression of Grin  1 throughout the ORG which reached statistical 
s ign ificance In  TORG 1 -4 ,  LORG and SORGo These reductions in  expression may 
reflect adapt ive changes that protect the neurons from excitotoxicity and 
overst lmu lation .  
I n  neurons, a lterations i n  the level of i ntrace l lu lar  calcium regu lates electrical 
actiVity, neuropeptide secretion ,  synaptic transmiss ion,  and gene expression.  The 
sensory neurons located in the dorsal root gangl ia express numerous voltage-gated 
and l igand-gated calcium channels important in transducing nociceptive s ignals from 
the periphery to the spina l  cord .  Studies point towards a prolonged, smal l  i ncrease 
in basal [Ca2+]1 that exists in the ORG neurons of d iabetic an imal and a reduction in  
the Ca2+ dynamics of  d iabetic an imals ( Biessels, ter  Laak ,  Hamers, & Gispen, 2002). 
G lutamate is  released s imu ltaneously with substance P (SP) and calciton in 
gene related peptide (CGRP) s ince they are stored in  the same termina ls .  The wind 
up in  sens it ization cou ld  be because of the concerted actions of g lutamate with 
neurope ptides such as substance P and CGRP. The short- last ing excitation induced 
by g lutamate cou ld  be extended and ampl ified by the co-released peptides. The 
EPSPs induced by them lead to enough depolarisation to abol ish the voltage 
dependent Mg++ blockade of N M OA receptor contro l led channels .  These channels 
upon opening a l low Ca2+ i nflux into the cel l ,  activat ing i ntracel lu lar  biochemical 
cascades that lead to long lasting depolari sation of the postsynaptic cel l  membrane 
i . e .  hyperexcitabi l ity (Szekely, 2002). 
The N M OA receptors deserve part icu lar attention in the study of neuropathic 
pain due to their crucia l  roles in  excitatory synapt ic transmiss ion , p lasticity, and 
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neurodegeneratlon In  the nervous system N M DA receptors have certa in unique 
propert ies that d istingu ish them from other l igand-gated ion chan nels These 
receptors controls a cation channel that IS h igh ly permeable to monovalent Ions and 
calcium Second,  S imu ltaneous binding of g lutamate and g lYCine, the coagonlst, IS 
requ i red for effiCient activation of NMDA receptors. Th ird ,  at rest ing membrane 
potential the NMDA receptor channels are blocked by extracel lu lar  magnesium and 
open on ly  on S imultaneous depolarization and agonist b inding.  
The NMDA receptors are regulated by prote in  ki nases as wel l  and protein 
k inase C mediated channel phosphorylat ion can either enhance or suppress the 
activity of NMDA receptors depending on the Grin2 subun its and the Grin 1 spl ice 
variants involved. Phosphorylat ion can alter the ion channel  k inetics or  alter the 
number of funct ional receptors on the cel l  surface by trafficking of channels in  and 
out of the plasma membrane. The N M DA receptors are a lso able to couple to other 
s ignal  transduct ion pathways such as PKC, calmodu l in  k inase I I ,  n itric oxide 
synthase, and mitogen-activated protein  k inases (MAP k inases) (Chaban ,  2004). 
Experimental pa in  models have shown sustained MAPK activation in  nociceptive 
primary sensory neurons located in  dorsal root gangl ia (DRG) (Reichl ing & Levine, 
2009) and I n it ia l  MAPK activation has been postu lated to be involved in  the in it iation 
and mai ntenance of patholog ica l pa in .  As the d iabetic neuropathy progresses the 
decrease In MAPK phosphory lat ion observed in  re levant t issues such as DRG from 
experimental neuropathic models can be viewed as a biochemical 
marker/phenotype of adaptive nociceptive s igna l l ing .  
In  the peripheral nervous system receptors N M DA receptors are expressed 
on the central and periphera l  termina ls  of primary afferent neurons wh ich are 
Invo lved In  nocicept ion.  Nerve i nj u ry can resu lt i n  a ltered peptide expression in  the 
dorsal  root gangl ia and i n  the dorsal horn of the sp ina l  cord . The m RNA of d ifferent 
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ion channels can be downregulated at the nerve membrane and the dorsal root 
gangl ion 
The situation that arises in pain experienced by d iabetics is even more 
complex by the phenomenon of central sensitization if it is i nduced. Excitation of 
unmyel inated C fibers produces s low excitatory postsynaptic potent ia ls that re lease 
g lutamate which then acts on its receptors such as N M DA receptors . The NMDA 
receptor is an  Important receptor in  the mechanisms of chron ic neuropathic pa in .  
The  receptor consists of  a Grin 1 /Grin2 heterodimer and  physiologica l ly the  receptor 
and its associated ion channel  is blocked my magnes ium.  When the membrane is 
depolarized and sensit ized, magnesium is removed and different ions pass through 
that induce an  intrace l lu lar  second messenger and resu lt i n  pa i n .  The variabi l ity in  
the modulat ion of these neura l  processes has made i t  d ifficult for thera peutic 
interventions to be effective (Devulder & De Laat, 2000) .  
Studies show that  nociceptor sensitization depends on g lutamate release at 
the DRG and subsequent N M DA receptor activation in sate l l ite g l ia l  cel ls  (Ferrari ,  
201 4) which supports the idea that periphera l  hypera lgesia is an event that is 
modulated by the DRG g lutamaterg ic system.  
N M DA receptors conta in ing Grin2A or Grin28 subunits contribute to  most of 
the NMDA receptor currents (Zhuo,  201 4) .  Physiologica l ly ,  the express ion of Grin2A 
expression increases with age (Shipton & Paulsen,  20 1 4) .  
Evidence suggests that Grin 1 -conta in ing N M DARs are local ized synapt ica l ly  
whi le Grin2A-conta i n ing receptors are usual ly local ized perisynaptica l ly  or 
extrasynaptica l iy  (Townsend, Yoshi i ,  M ish ina ,  & Constant ine-Paton ,  2003).  Studies 
have shown that during over activity, calpain cleaves the Grin2 subun its of NMDA 
receptors that are on the cel l  surface. This serves to down regu late the function of 
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NMDA receptors wh ich provides a neuroprotective mechanism against NMDA 
receptor overstlmulation (Andrasfa lvy , 2003). 
Wind-up is a frequency-dependent increase in the excitabi l ity of spinal cord 
neurons that occurs due to electrical stimu lation of C-fiber primary afferent nerves. 
The low-frequency st imulat ion of C fiber afferents leads to an increased response i n  
the  dorsal horn cel l .  This increase is excitabi l ity is due  to  temporal summation of 
s low postsynaptic potentials and spatial summation because of the convergence of 
the afferent fi bers of d ifferent moda l it ies on the same population of postsynaptic 
neurons. Windup lasts tens of seconds and represents a short-term form of 
sensitization .  I t  ampl ifies the nociceptive message that arrives from peripheral 
nociceptors The receiving neurons become consequently responsive to otherwise 
subthreshold stimulation induced by afferents that carry even non-nociceptive 
information.  The fact that these second order multireceptive cel ls demonstrate wind 
up shows that the basis of th is phenomenon is s imultaneous activation of afferents 
of d ifferent modal it ies. However, not a l l  the mu lt ireceptive neurons are sensit ised, 
some actual ly become desensit ised upon repeated stimu lation and th is has been 
shown by d i rectly apply ing g lutamate or kainate to the primary sensory neurons of 
the dorsal root gang l ia  (Szekely . ,  2002). 
Blocking N M DA receptors with ketam ine or (2R)-amino-5-
phosphonopentanoate can i nh ibit the wind-up phenomenon of spinal  dorsal horn 
neurons and red uce the hypersensitivity of spina l  dorsal horn neurons in  
neuropathic pa in  models (Dickenson & Su l l ivan ,  1 987) . 
I n  neuropathic pa in ,  nociceptors with unmyel inated axons (C-nociceptors) 
are sensitized such that they d ischarge spontaneously, respond to normal ly 
innocuous stimu l i ,  and have a supernormal  response to noxious stimu l i . Nociceptor 
sensitization underl ies the spontaneous pain and hypersensit ivity of the injured site. 
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The area surrounding the injured s ite a lso becomes a source of pain and 
hypersensitivity, and this is  now known to be due, at least in  part, to an NMDA 
receptor-mediated hyperexcitabi l ity in  spina l  neurons evoked by C-nociceptor mput 
from the injured s ite The chron ic pain syndromes due to periphera l  neuropathies 
are now bel ieved to be re lated , in  part, to a s imi lar  N M DA receptor-mediated 
hyperexcitab i l ity in spinal  neurons .  Axotomized C-nociceptors beg in to d ischarge 
ectopical ly,  and this has the same effect as the d ischarge of sensitized C­
nociceptors it evokes N M DA receptor-mediated central hyperexcitabi l ity. NMDA 
receptor antagonists block neuropathic pain in an imals ,  and early cl in ical tr ia ls 
suggest that they are effective d rugs for human painful peripheral neuropathies. 
High levels of activity at N M DA receptors in  the nervous system are known to lead 
to neuronal  death or dysfunct ion .  There is  evidence that pain-evoked g lutamate 
release is  excitotoxic to smal l ,  presumed inh ib itory i nterneurons, in the spinal dorsal  
horn .  
M itochondria l  dysfunction ,  which is impl icated in  d iabetic neuropathy, can 
lead to secondary excitotoxicity. Metabol ic impa irment depletes ATP, depresses 
Na+/K+-ATPase activity and can lead to graded neuronal depolarization .  This 
re l ieves the voltage-dependent Mg2+ b lock of the N M DA receptor and a l lows 
apparently innocuous levels of g lutamate to become toxic. M itochondria l  impa i rment 
a lso d isrupts cel lu lar calci um homeostasis .  I ncreased act ivation of the N M DA 
receptor, in  turn ,  leads to further mitochondria l  impairment and damage. The 
calcium that enters a neuron through N M DA receptors now has can access to 
mitochondria and lead to free rad ical product ion and mitochondrial depolarization .  
Th is  suggests the presence of  a feed-forward cycle where the m itochondrial 
dysfunction activates N M DA receptor  and to further m itochondria l  impairment .  In this 
scenario ,  NMDA receptor antagonists could possibly be neuroprotective 
(Ankarcrona,  1 995) 
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4 .6 .3  Kai nate l o notropic  G l utamate Receptors and N e u ro pathic P a i n  
I n  the  present study, there was a h igh ly s ign ificant and marked 
downreg luatlon in expression of both Grik3 and Gnk4 in a l l  the dorsal root gangl ia In  
both groups of  an imals versus the i r  control counterparts Furthermore, these 
reductions were seen at a l l  levels of the dorsal root gangl ia .  Marked Gnk3 
downregu latlon was also seen in  the thoracic sympathetic gangl ia (TSG 1 -6, TSG 7-
1 2) However, no sign ificant change was seen of Gnk4 in  these sympathetic gang l ia .  
Th iS consistent f inding IS  in  l ine with the possib i l ity that downregulation of  the genes 
expressing these receptors i s  an adaptive response. Adaptive responses are 
appropnate react ions to a cel l u lar  event and at the gene level ,  th is is very important 
for the neuronal  cel l  bod ies to cope with sustained stress. Kainate receptor 
activation IS l i nked to neuronal excitabi l ity and subsequent reduction in fir ing 
threshold and KA antagon ists reduce mechan ica l a l lodynia and thermal 
hyperalgesia The location of KARs i n  DRG neurons,  specifica l ly in  neurons that 
g ive rise to th in ly myel inated or unmyel inated Ao and C fibers is  h igh ly suggestive of 
the role that these receptors play in pa in .  The presynaptic locat ion of KARs also 
suggests a role In  inh ibit ion of neurotransmission.  S ince pre-synapt ic KA receptors 
IS also expressed on spinal  cord inh ibitory interneurons and activate inh ibitory 
transmission , a downregulat ion i n  the production of KARs could further propagate 
the phenomenon of sens itization a long the pain pathway and increase the 
perception of pain to the l ightest stimu l i .  Th is  is manifested as hyperalgesia and 
al lodynla .  
Kainate receptors are specifica l ly local ized on smal l  to intermediate diameter 
DRG neurons that g ive rise to th in ly myel inated or unmyel i nated Ao and C fibers 
including nociceptive fibers .  This information paved the way to study the role of KA 
receptors in  the transmission of nociception and the perception of pa in .  Behavioural 
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studies also show anti nociceptive effects of specific KA receptor antagonists in 
models of persistent pain.  SYM208 1 , a KA antagonist, reduces mechanical a l lodynia 
and thermal hypera lgesia in  the chronic constrict ion inj u ry model and cold inju ry 
model of neuropathic pain .  L Y293558 has been shown in  human studies to reduce 
spontaneous pain and mechan ical a l lodynia after capsaicin inject ion into the sk in .  
The permeabi l ity to ca lc ium of some KA receptors increases the intracel lu lar  
concentration of ca lcium.  This brings about reactions such as excitoxicity and 
synaptic plasticity . 
The Kainate receptors show funct ional d iversity from the subunit composit ion 
and a lso their association with aux i l iary subun its such as the neuropi l i n  and tol lo id­
l i ke prote ins .  
Besides depolarizing neuronal membranes when g lutamate b inds,  there is a 
second s ignal l ing mode un ique to KARs and this is med iated by G protein-coupled 
activation of protei n  k inases. Although the metabol ic pathways are not clearly 
understood it is known that this dua l  mode of s igna l l ing ,  ionotropic and 
metabotropic, p lays a role i n  modulat ing neura l  c ircuits. Some of the mechanisms of 
this modulation arise from postsynaptic depolar izing of a subset of synapses, 
presynaptic modu lation of g lutamate and GABA releases as wel l  as d i rect a lteration 
of voltage gated ion channels that reg ulate action potentia l  firi ng.  
Kainate receptors located on the centra l  endings of dorsal  root gangl ia 
neurons regu late g lutamaterg ic transmission . Kainate receptors are located both 
postsynaptica l ly  (ma in ly mediat ing excitatory neurotransmission) and presynaptical ly 
(modulating excitatory and i nhi bitory transmissions) .  Pre-synaptic KA receptors 
expressed on spina l  cord inh ibitory interneurons activate inh ibitory transmission (F .  
Wang, Stefano,  & Kream,  201 4) .  
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Pain beg ins from a series of s ignal l ing events that occurs at mu lt iple levels of 
the nervous system Acute pain s ignals beg in when the periphera l  stimulation of A 
delta and C-fiber noclceptors are activated These action potentia ls are propagated 
through the cel l  soma of the DRG neurons to the dorsal horn of the spinal  cord, 
tha lamus and higher order processing centers . Th iS pathway a lso plays a role in  
ana lgesia through the st imu lation of  endogenous opiod receptors and modulating 
the i nh ibitory GABA tone on nociceptive dorsal horn neurons. This sensory 
transduction pathways a l lows noclceptors to respond to noxious stimu l i  and assists 
us In protecting ourselves The perception of pain is a ltered by modulat ing the s ignal  
transduction In  peripheral and nociceptive pathways.  Persistent pain ar ises from 
patholog ic  Increases in excitabi l ity, or sensitizat ion,  of one or more of the periphera l  
or centra l parts of  pa in  pathways. Periphera l  sensit ization is due to  a reduction i n  
firing threshold and  an  increased responsiveness of  peripheral nociceptors . Th is  i s  
l i nked to  neurogenic factors such as inflammatory factors; ca lciton in  gene re lated 
peptide, substance P, ATP and seroton in .  Central sensitization can be when the 
dorsal horn neurons in the spinal  cord become hyperexcitable and th is can be 
because of pre and postsynaptic changes and changes in the postsynaptic 
membrane excitab i l ity. Long-term a lteration in  neuronal  excitabi l ity is l inked to 
persistent pain and can be from adaptive changes in structure and function of 
several bra in  reg ions that are impl icated in  the h igher processing of pain re lated 
Input (Bhangoo & Swanson,  201 3) . 
Activat ion of ionotropic g lutamate receptors increases energy consumption 
because the resu ltant infl ux of Na+ and Ca2+ requ i res energy to be pumped out of 
the ce l l  aga in .  Neurons become more vu lnerable to g lutamate after energy 
deprivation or after inh ibit ion of the Na+K+ -ATPase. Early mitochondrial  damage 
plays a key role in  induct ion of g lutamate neurotoxicity and g lucose level fluctuations 
that result in hypoglycaemia and hyperg lycaemia are also harmful (Nove l l i ,  Rei l ly ,  
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Lysko, & Henneberry 1 988) Too h igh g lucose levels a lso increase the neuronal  
vu lnerabi l ity to Ischemia (Kel leher, Chan,  Chan,  & Gregory , 1 993) Glutamate 
receptor activation also enhances the rates of generation of reactive oxygen species 
and potentiates the tOXIC effects of H202 and of mutant superoxide d lsmutase 
Metabol ic Inh ibit ion predisposes neurons to g lutamate mediated damage and 
pathologica l  condit ions such as d iabet iC neuropathy can be associated with a 
hypersensitivity to g lutamate d ue to for example impai red cel lu lar  energy 
metabol ism or aberrant expression of g lutamate receptors (J .  G .  Greene & 
Greenamyre, 1 996) Several d ifferent pnmary events or changes may share a fina l  
common pathway 
VICIOUS cycles can ensue if the g lutamaterg ic  system malfunct ions.  High 
extracel lu lar  g lutamate can activate g lutamate receptors causing further g lutamate 
re lease. G lutamate receptor activation increases energy consumption and free 
rad ica l production which may impair  energy production and g lutamate uptake and 
lead to even revers ing the transporters and causing even more g lutamate to be 
released The Ion Influx can lead to cel l  edema, ischemia  and a compromised 
energy supply and so on 
4.6.4 l onotro p i c  G l utamate Receptor - D e lta 2 
Expression of Grid2 was s ign ificantly in  TDRG 5-8 of the G K  rats. The 
receptor that th is gene codes for forms heteromeric assemblies with other types of 
IGluRs Including AMPA and Kainate receptors to form funct ional  channels .  Since it 
requ i res the i nvolvement of the types of iG luRs that are impl icated in neuropath ic 
pa in ,  It i s  tempting to speculate the increased expression of  this gene m ig ht a lso 
contnbute to neuropathic pa i n .  
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4 . 7  T h e  Role of G l utamate Tra n s p o rters i n  G l uta mate Toxic ity 
Some changes were seen In expression of the genes coding for g lutamate 
transporter proteins S Ic1  a 1  expression was sign ificantly Increased In  TDRG 1 -4 ,  5-
8, 9- 1 2  LDRG and SDRG We found the mRNA levels of S Ic1  a3 to be s ignificantly 
upregulated In  TDRG 1 -4 , TDRG 5-8 and TSG 1 -6 of GK animals and TDRG 5-8, 
TDRG9- 1 2  and SDRG of GK Sucrose an imals I t  was a lso s ign ificantly upregu lated 
In TDRG5-8 of both GK and GK Sucrose an imals .  Expression of S Ic1  a2 was not 
a ltered SIc1 a6 was downregulated in  TDRG 1 -4 ,  5-8, 9- 1 2  In  GK animals and i n  
TDRG 1 -4 and LDRG of  G K  Sucrose. 
Besides the essent ia l  g lutamate removal ro le ,  the g lutamate transporters 
also play a role In  neurotransmisslon modulat ion.  These transporters modify the 
t ime course of synaptic events, the extent and pattern of activation and 
desensitization of receptors outside the synaptic cleft and at neighboring synapses 
( Intersynaptlc cross-ta lk) . The g lutamate transporters provide g lutamate for 
synthesis of Important molecules such as GABA and g lutath ione.  G lutamate uptake 
can be modulated on a l l  possible levels i . e .  DNA transcript ion,  mRNA spl ic ing and 
degradation , prote in  synthesis and target ing, and actual  amino acid transport activity 
and associated Ion channel activit ies. A variety of molecules besides g lutamate 
(such as cytokines and growth factors) a lso influence g lutamate transporter 
expression and activ it ies . 
A decrease in  expression of g lutamate transporters would lead to an 
extrace l lu lar  bui ld-up of g lutamate which would ,  v ia g lutamate receptors, i ncrease 
Na+ and Ca2+ i nflux ,  energy  consumption and free radical product ion.  
However, extrace l lu lar  g lutamate overload occurs after CNS tra umatic inj u ry 
and causes excessive Ca2+ inf lux into neurons through overactivation of neuronal  
lonotroplc g lutamate receptors, leading to neuronal  excitotox icity. Additiona l ly ,  
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numerous g lutamate-Induced CNS neurodegeneratlve d isorders , such as  
amyotrophic latera l sclerosIs (ALS) ,  epi lepsy, ischemia and traumatic bra in  InJ u ry, 
have been reported to associate With dysfunction of astrocytlc g lutamate 
transporters Therefore, the function of g lutamate transporters , especia l ly astrocytlc 
g lutamate transporters especia l ly the astrocytic g lutamate transporters (g lutamate 
aspartate transporter; G LAST/EAAT- 1 )  and g lutamate transporter- 1 (GLT-1 /EATI-2) 
IS of great Importance for protect ing neurons from g lutamate- induced excitotoxicity. 
Studies demonstrate that rat penphera l  sensory term inals and dorsal root 
gangl ia (DRG) express molecules which are invo lved in glutamate s igna l l ing ,  
inc lud ing h igh-affin ity membrane-bound g lutamate transporters S Ic1  a 1  (EAAC 1 ,  
EAAT3),  S Ic1 a2 (GLT- 1 , EAAT2), S Ic1 a3 ( EAAT 1 , G LAST) and SIc1 a6 
(EAA T 4)(Berger & Hediger, 2000) .  Evidence suggests in  DRG, satel l ite cel ls 
express SIc1 a2 whereas sensory neurons were posit ive for S Ic1  a 1 .  S Ic1  a3 is  
local ized In  both neurons and sate l l ite ce l ls  (V. A. Carozz i ,  2008). EAAC 1 ,  G LAST, 
and GL T- 1 are particularly relevant for regu lat ing g lutamate uptake in  many of the 
centra l  nervous system reg ions inc lud ing the sp ina l  cord (Danbolt ,  200 1 ) . 
Transporters located i nside the synaptic cleft d i rectly affect the g lutamate 
concentration there and transporters located outside the cleft, such as on g l i a  or 
non-synaptic parts of neurons ind i rectly affect g lutamate concentrations by reducing 
or Increasing the amount of extrasynaptic g lutamate that can d iffuse back into the 
synaptic clefts. 
Defects in  g l utamate uptake due to alterations in  the function and/or in  the 
expression of these transporters have been impl icated in  several neurolog ic and 
neurodegeneratlve d isorders i n  the central nervous system (V. Carozz i ,  201 1 )  but 
there are not extensive studies a bout the uptake activity of the g lutamate receptors 
In the penpheral nervous system in d iabetic neuropathy. 
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Depending on whether transporters are located In re lation to the synapse , 
these transporters either take up g lutamate to concentrate Into presynaptic veSicles 
or recycle g lutamate through I ntrace l lu lar  metabolic reactions to return back to the 
neurons (nerve endings) In the form of a precursor such as g lutamine .  The transport 
of g lutamate and precursors of g lutamate across plasma membranes IS a 
strateg ical ly pos it ioned mechanism to term inate g lutamate and a lso be part of ItS 
recycl ing Several prote in  molecules act as g lutamate transporters and regulate the 
function of the g lutamaterg lc synapses. Glutamaterg ic neurotransmission can be 
weakened If g lutamate is removed/inactivated before it can adequately interact with 
Its postsynaptic receptors . Thus, hyperactive g lutamate transport can contribute to 
temper excessive g lutamate neurotransmission.  The expression of g lutamate 
transporters IS Influenced by a number of neuropeptides and growth factors (F ig ie l ,  
Maucher, Rozyczka ,  8ayatt i ,  & Engele ,  2003). 
Alterat ions in  the expression and/or funct iona l ity of g lutamate transporters 
have been Impl icated In  severa l models of peripheral neuropathy, neuropathic pain 
and hyperalgeSia Thus the effects of a ltered expression and g lutamate uptake 
activity of g lutamate transporters in  dorsal root gangl ia is  l ike ly to be mediated via 
changes in  regional  g lutamate homeostasis .  Evidence demonstrates that 
funct ional ly active g lutamate transporters can be stud ied in  dorsal  root gangl ia and 
help to further understand the role of g lutamaterg ic transport in the periphera l 
nervous system (V Carozzi . ,  20 1 1 ) .  
U nder physiological condit ions,  the extracel lu lar  concentration of  g lutamate 
strongly depends on ItS re-uptake into cel ls through specific transporters located in  
neurons such as SIc1 a1  and on the membrane of  g l ia l  ce l ls  S Ic1  a2 and SIc1 a3 (V. 
A. Carozz i ,  2008). 
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SIc1 a1  IS considered to be the predominant transporter in  neural t issues 
outside the blood-bra in  barner and In  the periphera l  nervous system.  SIc1 a 1  
expression has been observed In  the sate l l ite ce l ls  surrounding the gangl ion 
neurons and these cel ls are the coro l lary to astrocytes In the peripheral nervous 
system Expression of SIc1 a1 In  ORG has been loca l ized in  the nuclei and 
cytoplasm of sensory neurons (V. A.  Carozz l ,  2008). The function of SIc1 a 1  
expression by the dorsal root gangl ia neurons i s  l ikely to take up the g lutamate that 
IS released from g lutamaterg ic nerve termina ls i nnervating the gang l ion neurons 
( Berger & Hediger, 2000) 
PrevIous stud ies have demonstrated SIc1 a3 m RNA was expressed by 
satel l ite cel ls In  ORG ( Berger & Hediger, 2000). 
The overact ivlty of g luta mate transporters has been impl icated in the 
pathophysiology of schizophren ia and other  mental i l lnesses, whi lst underactivity is 
seen in  Ischemia  and traumatic bra in  i njury. Severa l  mechanisms could contribute to 
Increased expression of the g lutamate transporters. The pathological release of 
g lutamate from pnmary afferents may serve as a positive feedback on g lutamate 
transporter expression.  Expression of neurotrophic factors in dorsal  root gangl ia and 
spina l  cord is  a lso upregulated dramatica l ly under patholog ical condit ions. 
Neurotrophic factors such as Brain derived neurotrophic factor which modulate N­
methyl-O-aspartate ( N M OA)-evoked responses and nociceptive sensory inputs in  
the sp ina l  cord (Ha ,  K im ,  Hong,  K im , & Cho,  200 1 ) .  
Gl ia l  ce l ls that express these transporters are found between neighboring 
synapses and may prevent the released g lutamate from activating receptors at 
neighboring synapses (cross-ta lk) . However a pathological increase in  the density of 
g lutamate transporters can g ive rise to paradoxical effects .  A h igh density of 
transporters on g l ia l  cel ls can actual ly trap the g lutamate and prevent it from leaving 
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the cleft and a l low g lutamate the opportun ity to re-enter the cleft upon unbind ing 
from these transporters The transporters can a lso mediate release of g lutamate via 
reversed uptake (Oanbolt, 200 1 ) Reversed uptake IS when diss ipation of the Ion 
g radients that are driving force for the uptake causes the high intracel lu lar 
concentrat ion of g lutamate to d rive the transporters backwards re leasing g lutamate. 
This has been observed In Ischemia (Oanbolt, 200 1 ) .  So though g lutamate binding 
to the transporter reduces the extrace l lu lar  concentration of free g lutamate, the 
binding a lso s lows down the d iffusion of g lutamate away from the re lease site.  
Glutamate escaping from the synaptic cleft may then reach and activate 
presynaptic receptors thus modu lating its own release, th is suggests an ind irect 
Involvement of g lutamate transporters because of they control the amount of 
g lutamate that can access the presynaptic receptors. G lutamate bound to G LAST 
has a h igher probabi l ity of unb ind ing than of being transported but it is the opposite 
case for g lutamate bound to GL T and EAA T 4. Thus,  the paradoxical  effects may be 
more Important in those locations where G LAST rather than G LT- 1 is the 
predominant transporter (Oanbolt , 200 1 ) . 
Before being re leased into the synaptic cleft, cytosol ic g l utamate first need 
cross the vesicu lar  membrane via the activity of vesicular g lutamate transporters 
(VGLUTs).  These transporters also belong to the fami ly  of glutamate transporters 
and their  expression IS up-regu lated in  the ORG neurons after peripheral nerve 
inju ry and eVidence suggests that there is an increase in g lutamate release by 
VGLUT u p-regulation that contributes to the e levated g lutamaterg ic transmission 
(Moechars, 2006). 
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Figure 37'  G lutamate transporters in  astrocytes are responsible for synaptic 
g lutamate homeostasis .  
Mod ified from (Y P LIU ,  Yang , & Tzeng , 2008) 
4.8 The Role of E nzymes I nvolved in the G l u tamate Cyc l e  a n d  G l utam ate 
Receptor I n teracti n g  P rote i n s  in D i a betic N e u ropathy 
We found the m RNA expression of Grip 1  to be sign ificantly decreased in 
TDRG 1 -4 of GK and a lso in  the LDRG and TSG 1 -6 of both GK and GK Sucrose 
an imals In compa rison to contro l .  
S ince a decrease in  inte ractions of  Grip 1  with its respective AMPA receptors 
could reduce sensitizat ion,  these fi ndings suggest a compensatory mechanism is in  
place to help reduce the increase in  neuronal  sensit ivity and hyperexcitabi l ity that 
man ifests as some of the symptoms of d iabetic neuropathy. 
G lutamate is toxic in  increased concentrations because of how important it 
is  S ince it i s  the ma in  mediator of excitatory s igna ls and also involved in  nervous 
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system plasticity including cel l  e l im ination , It fol lows that g lutamate should be 
present at the correct concentrations In the right places and at the right t ime Cel ls 
should have the correct sensitivity to g lutamate and be able to withstand normal 
stimulation ,  and that g lutamate shou ld be removed with the nght speed from the 
nght locations 
Glutamaterg lc neurotransmisslon IS  not an independent process. I t  regulates 
other processes and IS regu lated by other systems including itself. Many,  if not a l l ,  
structures that are Important for g lutamaterg ic neurotransmission such as cel ls ,  
synapses and dendnt lc spines are dynamic and subject to regulat ion .  I n  patholog ical 
Situations,  a change In  one area of the nervous system often leads to changes at 
other sites In consequence of this, the primary cause of a d isease may induce 
several secondary changes. These changes can be part of adaptive responses that 
affect the progression of the d isease and the compensatory a lterations try to 
counteract the primary defect or changes . The secondary changes themselves can 
aggravate the condit ion and thereby become problems i n  themselves. 
G lutamine expression showed some minor changes which were statistica l ly  
sign ificant However, s ince these are not reproduced between the G K  group and the 
G K-Sucrose group and because these changes are genera l ly  very m inor these are 
probably of l ittle biological importance . Glutamine is recycled form the g l ia l  ce l l  back 
to the presynaptic nerve term ina l  where the enzyme g lutaminase converts it to 
g lutamate for packag ing into secretory g ranules ready to be re leased at the synapse 
(Bradford , 1 978) .  The astrocyt ic export of g lutamine impl ies a cont inuous loss of 
alpha ketog lutarate from the astrocytic TCA cycle but th is is  not the case. The 
Intermediates of the TCA cycle have restricted access across the blood-bra in  barrier 
and so the anaplerotic process of pyruvate carboxylation continua l ly  replenishes the 
loss. Anaplerosis is the process of convert ing pyruvate , which is derived from 
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glucose via g lycolysIS to oxaloacetate or malate Astrocytes express the enzymes 
pyruvate carboxylase and cytosol lc and mitochondrial malic enzyme (Kurz,  1 993, 
Salgan lcoff & Koeppe, 1 968, A C Yu, 1 983) Observations that neurons and 
subpopulatlons of neurons have the ab i l ity to replenish their TCA cycle by 
carboxylating pyruvate can explain why some g lutamatergic pathways have a low 
level of g lutaminase, whereas others have h igh levels ,  and it expla ins how 
transmitter g lutamate can be formed from neuronal  precursors (Hassel & Brathe, 
2000a, 2000b) Neurons can thus carboxylate pyruvate and not completely depend 
on g lutamine as a precursor for transmitter g lutamate. 
The g lutamine cycle,  the 1 : 1 exchange between astrocytes and neurons of 
g lutamine for g lutamate and GABA was conceptua l ized in  the 1 970s (van den Berg 
& Garfi nkel ,  1 97 1 ) . I n  th is cycle ,  astrocytes take up g lutamate re leased from 
neurons, convert It to g lutamine in an energy dependent process and then supply 
g lutamine to the extrace l lu lar  fl u id to mainta in a high concentration of g lutamine 
which IS approximately 0 3mM.  Neurons consume g lutamine and convert it to 
g lutamate by g lutaminase. 
In dorsal root gangl ia g lutamine and g lutamine re lated enzymes are enriched 
In  the satel l ite cel ls  that surround the neurons. In the periphera l  nervous system,  the 
g l ia l  tricarboxyl ic and g lutam ine cycles produces g lutamine for neuronal  ce l l  uptake 
and conversion to g lutamate for synapt ic transmission.  These cycles may a lso 
function In periphera l  g l i a  s imi lar  to centra l nervous system astrocytes in  terms of 
provid ing support for the energy  demands of the neurons (M i l le r, Richards,  & 
Knebel ,  2002) 
The g lutamine cycle is often described occurri ng at the synaptic term i na l  but 
eVidence suggests that g lutamine is a lso taken up and converted to g lutamate for 
synaptic use in the cel l  bodies and axons of DRG neurons.  G lutamine and re lated 
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enzymes In  the satel l ite cel l s  of the DRG may facI l itate g lutamate production In  DRG 
neurons for synaptic transm ission In  the spinal dorsal horn (Johnson, 1 974) 
There IS a trend for reduction In expression of GAD2 in the DRG which 
reaches statistical sign ificant i n  TDRG 1 -4,  9- 1 2  of GK group and In  TDRG 5-9 and 
LDRG In  the G K-Sucrose group The decrease In  mRNA expression may be due to 
a reduced transcription/translat ion of GAD65 The consequence of th is would be a 
decrease I n  GABA concentrations and could contribute to neuropathic pa in .  
G lutamic acid decarboxylase (GAD) IS  an enzyme that catalyzes the 
decarboxylation of g lutamate to GABA and CO2. GAD exists in  two Isoforms 
encoded by two d ifferent genes - GAD 1  and GAD2 . These isoforms a re GAD67 and 
GAD65 and have molecular weights of 67 and 65 kDa,  respectively (Erlander, 
T i l iakaratne, Feldblum,  Pate l ,  & Tobin, 1 99 1 ) .  GAD65 and GAD67 synthesize GABA 
at d ifferent locations in the ce l l ,  at d ifferent t imes during development and for 
functiona l ly  d ifferent reasons .  Th is expla ins why GAD67 is spread even ly throughout 
the ce l l  whi le  GAD65 is loca l ized to nerve term inals .  GAD67 synthesizes cytosol ic 
GABA for neuron activity that is not re lated to neurotransmission such as 
synaptogenesis and protect ion from neural inju ry .  GAD65, however, synthesizes a 
synaptic GABA for vesicu lar release and neurotransmiss ion and would be requ i red 
at nerve termina ls  and synapses. Post trans lation regulat ion of Gad65 involves 
activation by phosphorylat ion and thus regu lated by prote in  k inase C synapses(Pinal  
& Tobin,  1 998). 
Gamma-aminobutyric acid (GABA) , the product by g lutamic acid 
decarboxylase (GAD), is a pri ncipal inh ibitory neurotransm itter and plays a crucial 
role in  modulating synapt ic c ircuits. The loss of GAD65-producing GABAerg ic 
neurons in  the dorsal horn of the spinal  cord that resu lts in  GABA hypo-function has 
been wel l  documented in var ious pain models .  The exogenous introduct ion of the 
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GAD gene to the dorsal  root gangl ia (DRG) I n  genetic therapy has been shown to 
Increase GASA concentrations in the spinal  dorsal  horn and helped to reduce 
symptoms of paIn (J K im,  K im,  Lee, & Chang,  2009; S. Lee, K im,  Kim Lee, & 
Chang,  200?) 
Transfect Ing DRG neurons with vectors that express GAD65 and GAD6? 
have been found to reduce d iabetes- induced mechanical a l lodynia more effectively 
than gabapent in .  Studies suggest that either GAD65 or GAD6? vectors are the most 
effective In the treatment of d iabetic pain (Y. Wang,  20 1 3) .  
We observed an  increase in  the m RNA expression of Gclc in  the TDRG1 -4 
and 5-8, LDRG and SDRG in both G K  and G K  Sucrose rats compared to controls .  
This would be expected if there was an  increase in  production of th is enzyme to 
counteract the oxidat ive stress that is imp l icated in  d iabetic neuropathy. 
C l in ical and experimental studies have documented that chronic 
compl icat ions,  inc luding d iabetic neuropathy, persist and progress even with good 
g lycaemic contro l .  Hyperg lycaemia induced oxidative stress has been impl icated in  
d iabetic neuropathy (Andrea M Vincent . ,  2004) .  Glutamate cysteine l igase 
cata lyzes the first and rate-l im it ing step in  de novo g lutathione synthesis and the 
regu lation of expression and activity of Gclc is crit ical for g lutathione 
homeostasis(Meister, 1 983) .  This enzyme is responsible for ma inta in ing 
homeostasis of the intrace l lu lar  antioxidant status .  M itochondria are vu lnerable to 
damage by reactive oxygen and n itrogen species . Reactive oxygen species are 
produced by the mitochondria and usual ly  removed by cel lu lar  agents such as 
g lutath ione,  cata lase and superoxide d ismutase. Hyperg lycaemia accentuates ROS 
production in  the cel l  v ia m itochondrial activity (F riederich , 2009; Leinn inger, 2006; 
Andrea M Vincent, 2004). 
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(y-Glutamyl cycle,  1 Glutamate cysteine l igase (GCl) ,  2 G lutathione synthetase 
(GS), 3 Glutath ione peroxidase, 4 Glutath ione reductase, 5 Glutath ione-S-
transferases (detoxificat ion react ions) ,  6 y-g lutamyl-transferase (GGT), 7 y-g lutamyl 
cyclotransferase (GCT), 8 5-0xoprol inase,  9 Di pept idase, R Prote i n ,  FAD,  FADH2 
Flavin-adenine d inucleotide, NAD, NAD+ N icoti nam ide-adenoside dinucleotide, 
NADP, NADPH+ N icoti nam ide-adenoside d inucleotide phosphate , ADP,  ATP 
Adenosine d iphosphate, Adenosine tr iphosphate(Main ,  Angley, O'Doherty, Thomas, 
& Fenech , 201 2) .  
Glutaminase (Gclc or GlS) is  an  enzyme that generates g lutamate from 
g lutamine The enzyme plays an important role in g l ia l  cel ls .  The g lutamate re leased 
Into the synapse for neurotransmiss ion is rapid ly taken up by nearby g l ia l  cel ls and 
converted to g lutamine .  This g lutam ine is suppl ied to the presynaptic termina ls  of 
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t he  neurons, where g lutaminase converts I t  back to g lutamate for load ing Into 
synaptic vesicles GLS IS also expressed in the bra in ,  spinal  cord, and dorsal root 
gangl ia neurons 
We observed a decrease In  mRNA leve ls of Gis in TDRG9- 1 2  In GK and in 
LDRG and TSG 1 -6 In  the GK Sucrose an imals compared to control rats. Decrease 
levels  of mRNA of Gis from the cel l  body can translate i nto decreased amounts of 
Gis produced from the DRG cel l  bodies to axons. This could be a compensatory 
mechanism to counteract the patholog ical levels of g lutamate Impl icated in  neuronal 
hyperexcitabi l ity and centra l sensitizat ion .  We postu late that a decrease in the 
amount of GLS during chron ic d iabetic neuropathy leads to decreased production 
and release of g lutamate . Decreased production and re lease of these substances 
could adaptive mechanisms to amel iorate neuronal hypersensit ivity that contributes 
towards many of the symptoms of d iabetic neuropathy. A decrease in G LS 
product ion could affect the peri pheral termina ls  as well because g lutamate that is  
released from the peripheral afferents that a lso have g lutamate receptors . A 
decrease In  g lutamate production and re lease could reduce the activation of these 
term ina ls to com pensate for the sensit ization of pr imary afferents . A cycle of 
decrease g lutamate production a nd re lease, decrease in numbers of axons with 
g lutamate receptor expression on axons could lead to a decrease in  sensitization of 
peripheral nerve terminals and help to amel iorate the process of chronic pain and 
hyperag lesia that is  prevalent in  d iabetic neuropathy. G lutaminase inh ibit ion has 
been postu lated to represent an  'upstream' mechanism of g lutamate regulat ion that 
cou ld reduce transmission at a l l  g l utamaterg ic  receptors and antagonists for th is 
enzyme have been been shown to provide ana lgesia which further supports the 
theory that a reduction in  g lutamate production by inh ibit ing g lutaminase enzyme 
activity mig ht provide pain rel ief in  neuropath ic pain (Hoffman & M i l ler, 20 1 0) .  
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Glutamate carboxypeptldse I I  (N-acetylasparatylg lutamate peptidase) IS a 
membrane bound metal loenyzme that cleaves the abundant neuropeptide NAAG to 
N-acetylaspartate (NAA) and g lutamate. GCP I I  is abundant In  the spinal  cord and 
DRG NAAG IS one of the most common peptide transm itters In  the bra in and IS also 
a type 3 metabotroplc g lutamate receptor (mGluR3) agonist .  GCP I I  inh ibitors 
Increase extracel lu lar  NAAG, decrease g lutamate and have been impl icated in 
reducing excess g lutamate transmission In  pathological condit ions such as 
Ischemia/stroke, motoneuron d isease, bra in and spina l  cord injury and periphera l 
neuropathy 
I t  showed that da l ly  oral intake of the d rug protected against the sensory and 
motor loss and neurodegeneration that p lauges neuropathy. Admin istering GCP I I  
I nh ibitor Improved the locomotor, sensory and thermal sensitivity deficits. GCP I I  
Inh ibit ion a lso protects against neurodegeneration .  The mechanism could be by 
reducing excltoxiclty that IS induced by excess g lutamate concentrat ions.  GCP I I  
I nh ibit ion a lso increases NAAG levels .  NAAG partial ly antagon izes N M DA receptors 
and could also provide neuroprotect ion .  GCP I I  inh ibit ion has also been protective In  
d iabetic and chemotherapy induced neuropathy. GCP I I  inh ibitors have been wel l  
tolerated in  humans and appears t o  affect increased g lutamate concentration leve ls 
rather than basel ine levels(Potter, Wozniak ,  Cal l izot, & S lusher, 201 4) .  
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This d iagram i l lustrates that g lutamine,  g lutamine synthetase, g lutamate 
dehydrogenase, and pyruvate carboxylase are located in the peripheral nervous 
system In  sate l l ite cel ls of the DRG and Schwann  cel ls  of the periphera l nerve. 
These enzymes have major roles in  supporting peripheral neuronal metabol ism and 
neurotransmlsslon.  Gl ia l  cel l s  take up g lutamate from the extrace l lu lar  mi l ieu v ia 
transporters (GLAST, GL T- 1 )  and g lutamate synthetase converts i t  to g lutamine .  
Glutamine can be shuttled out  of  g l ia l  ce l ls by the S N 1  g lutamine transporter a nd 
taken up by neurons via the SAT/ATA g lutamine transporters for use by g lutaminase 
(GT) in  the g lutam ine cycle .  I n  addit ion ,  g l utamine is an  important branch point 
substrate for purine synthesis v ia GPATase.  G lutamate dehydrogenase is  a 
bidirect ional  enzyme that can either add g lutamate for GS in  the g lutamine cycle or 
convert g lutamate to 2-oxoglutarate for the TCA cycle .  2-0xog lutarate and other 
TCA intermediates such as malate can be shuttled from g l ia  for use in  neurons. 
Ma late also can be converted to pyruvate via mal ic enzyme (ME) .  Pyruvate can be 
1 64 
converted to lactate and used in neuronal  metabol ism.  Pyruvate carboxylase is an 
anaplerotic enzyme that ref i l ls the g l ia l  TCA cycle with carbon as TCA intermediates 
are used for other purposes (M i l ler, 2002). 
The Gri p 1  gene encodes for a member of the g lutamate receptor interact ing 
prote in  fami ly  This encoded scaffold protein binds to and mediates the t rafficking 
and membrane organ ization of several transmembrane prote ins .  Prototypical 
scaffold ing prote ins such as the g lutamate receptor i nteracting protein 1 (GRI P 1 )  
conta in  several PSO-95/0iscs-large/lO- 1 homology (POl) domains operate as 
molecular adapters in  neuronal  synapses. The POl-conta in ing scaffolds assemble 
specific prote ins into large molecular complexes at defined locations in  the ce l l  and 
In  the postsyna ptic density of neuronal excitatory synapses organ ize g lutamate 
receptors and their associated s ignal l ing prote ins .  This helps to determine the s ize 
and strength of synapses. The POl scaffo lds a lso play a role in  the dynamic 
trafficking of synaptic proteins by assembl ing cargo complexes that are then 
transported by molecular motors (E .  Kim & Sheng, 2004) .  
G R I P 1  has been impl icated i n  playing a role i n  the synaptic clustering of 
AMPA receptors and unmasking si lent g l utamatergic synapses in somatosensory 
inputs (P .  L i ,  1 999) .  I ts role i n  neuropathic pain has been suggested by studies that 
showed reducing interact ions of the Grip 1  protein with the product of Gria2 (GluR2 
AMPA receptor) has inh ibited the neuropathic reflex sensit izat ion .  This suggests an  
involvement of  Grip 1 , i f  expressed,  in  neuropathic pa in  (Garry, 2003). 
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C h a pte r 5 :  C o n c l u s i o n  
Diabetic neuropathy IS the most common and debi l itating compl ication of 
d iabetes It manlfp.sts Itself as pa in ,  decreased moti l ity, and often resu lts In  
amputation Diabetic neuropathy encompasses a variety of  forms whose impact 
ranges from discomfort to death 
Amongst the mYriad of therapeutic options avai lable,  g lucose control remains 
the s ing le most Important factor that can mod ify the d isease (Leinn inger, 2006). 
Despite the wide reaching implication of d iabetic neuropathy when considering the 
number  of people affl icted,  the pathogenesis of d iabetic neuropathy has many 
theories that surround it .  Despite extens ive i nvestigat ions and development of 
mu lt iple theories the mechanism involved I n  the development of d ia betic neuropathy 
are sti l i  not complete ly understood . When severa l theories orbit a condit ion, it 
suggests that there is no un ifying hypothesis.  
The expression and regulat ion of genes g ives the cel l  control over cel lu lar  
structure and function .  I t  i s  the bas is  for ce l l u lar  d ifferentiation ,  morphogenesis and 
IS a lso crucia l for the versati l ity and adaptabi l ity of  any organ ism.  The t iming,  
location and amount of gene expression can have a profound effect on the functions 
of the gene. Analysing genomic and proteomic data from su itable an imal  models 
and diabetic neuropathy patients can provide ins ight into disease pathogenesis and 
possibly Identify therapeutic targets for d isease modify ing treatments. Developi ng 
symptomatic and d isease-modifying therapeutic interventions depends on a 
com prehenSive and pert inent understanding of the pathogenesis and 
pathophysiology of d iabetic neuropathy. 
The genes that are invo lved in  human pathology requ ire study to improve the 
outcome of d isease processes and reveal therapeutic targets . S ince genes and 
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gene functions have been so h igh ly conserved throughout evolution , the study of 
less complex model organisms reveals critical information about s imi lar  genes and 
processes In  humans.  The selection of appropriate an imal  models for gene 
expression stud ies is of the utmost importance. Animal models a l low control in vivo 
the genetic and environmental factors that i nfluence the development of d iabetes 
and ItS compl icat ions.  Rodents are preferable due to advantages such as short 
generation i ntervals , economic viabi l ity, ease of care and housing compared to 
larger models. I n  our study we included the Goto-Kakizaki (GK) and Goto-Kakizaki 
Sucrose (GK Sucrose) an ima l  g roups.  The Goto-Kakizaki (GK) rat is a non-obese 
Wistar substra in  which develops Type 2 diabetes mel l i tus early in  l i fe .  The GK rat is 
one of the best characterized an imal  models of spontaneous T20M and has proved 
to be a valuable tool offering sufficient commona lit ies to study this aspect. 
Comprehensive studies of gene expression provide a layer of information 
that is usefu l for predict ing gene funct ion .  I nformation about a gene's function can 
be deduced by identify ing genes that share its expression pattern.  Gene expression 
stud ies that focus on sensory and sympathetic neurons from d ifferent an imal  models 
of d iabetic peripheral neuropathy and autonomic neuropathy wi l l  show different ial ly 
regu lated transcripts. These expression profi les wi l l  a l low data to define categories 
of genes that are funct ional ly regu lated in d iabetic neuropathy such as genes 
Invo lved in  metabol ism or nerve regenerat ion . 
On a broad level it can help to ga in  g reater knowledge about how ind iv idual  
mechanisms of the d isease fit together as a whole and generate novel hypotheses 
concerning the pathogenesis, d iagnosis and progression of d iabetic neuropathy. 
This can also help pinpoint targets for d isease regu lat ion and therapeutic 
intervention .  Relevant pathways related to functiona l  gene categories can be 
pinpointed for new information of d isease mechanisms and targets . Genes that are 
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different ia l ly expressed between hea lthy and d iseased tissue can be put into the 
context of cel lu lar  pathways and used to predict regu latory elements that control the 
changes observed . Those reg ulatory elements that are identified can be uti l ized 
later as drug targets and a lso used to predict the downstream effects of gene 
expression These can a lso pave the way for developing biomarkers. 
For expression profi l ing ,  or  h igh-throughput analysis of many genes with in a 
sample,  quantitative peR is a popular and re l iable method to study hundreds of 
genes s imu ltaneously. I n  pre l im inary studies, low density arrays revealed many 
Interest ing find ings but i t  was not possible to fo l low a l l  of  these changes. Once a set 
of genes involved in a particular biological process has been identified, the next 
logica l  step is to further study the genes ind ividual ly .  Determ in ing when a gene acts 
can faci l itate the reconstruction of entire genetic or biochemical pathways, and such 
studies have been centra l to our understand ing of pathological processes. The focus 
was honed to the genes i nvolved in  the g lutamate s igna l l ing pathway because of 
there were several changes in the pathways of these genes. Genes for g lutamate 
receptor express ion,  g lutamate processing enzymes and g lutamate transporter 
prote ins showed s ign ificant changes in  expression.  This was also i n  l ight of the 
l iterature that ind icated the g lutamate pathway was involved in neuropathic pain 
including d iabetic neuropathy. 
The presence of excess g lucose activates mu lt ip le biochemical pathways 
that lead to damage. Amongst the myriad of therapeutic opt ions ava i lable ,  g l ucose 
control remains the s ing le most important factor that can modify the d isease 
(Leinn inger, 2006). However, no therapeutic agent aids in  e l im inating the root cause 
of d iabetic neuropathy. Understanding the root cause of neuropathy wi l l  i l l um inate 
the path towards therapeutic intervention at a stage when compl ications have not 
been ful ly establ ished.  
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Observ ing patterns of changes in  gene express ion using d ifferent an imal  
models of d iabetes wi l l  he lp pave the way for further stud ies in  ind iv idual  gene 
ana lys is , prote in  characterization and funct ional studies . 
Using informatics to ana lyze genomic and proteomic data from su itable 
an imal models and ON patients can provide ins ight into disease pathogenesis and 
possibly Identify therapeutic targets for d isease mod ifying treatments. Developing 
symptomatic and disease-modifying therapeutic interventions depends on a 
comprehensive and pertinent understanding of the pathogenesis and 
pathophysiology of d iabetic neuropathy. 
The low density arrays showed severa l  interest ing resu lts of which the most 
prominent changes were the genes that are involved in the glutamate pathway. 
Changes in gene expression were confi rmed by fast real-t ime RT -PCR.  In GK rats, 
these studies showed consistent changes in expression, part icularly in the lumbar 
and sacra l dorsal root gangl ia of the spina l  cord and in  the sympathetic gangl ia .  The 
changes were consistent between the d ifferent g roups of an ima ls as wel l  as 
between adjacent g roups of gang l ia .  The most prom inent changes in  both the GK 
groups included marked upregulation of  Gria4 ( ionotropic AMPA receptor) , 
downregulat ion of Grik3 and G rik4 (both ionotropic, ka in ite receptors) and Gr in1  and 
Grin2A (both ionotropic, N M DA receptors) ,  activat ion of a l l  of which has been shown 
to induce hyperalgesia ;  downregu lat ion of S Ic1  a6 (excitatory amino acid transporter 
4)  and upregu lat ion of S Ic1 a 1  (excitatory amino acid transporter 3), both of which 
mediate neural reuptake of g lutamate from the synaptic cleft; and upregu lation of 
Gclc (g lutathione synthase), which reflects a response to protect aga inst oxidative 
damage. 
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The immense physica l , psychologica l ,  and economic cost of d iabetic 
neuropathy underscore the need for better understanding of the pathogenesis at an 
early Interventlonal  level .  
The patholog ical s igna l l ing pathways associated with d iabetic neuropathy 
are complex and this influences the development of targeted therapies. 
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C h a pte r 6 :  F utu re d i rections 
The most prominent and interesti ng changes in  these an imal  groups were 
those involving ;  Gna4 ( ionotropic AMPA receptor), Grik3 and Grik4 (both ionotropic, 
ka in lte receptors) and Grin2A (both ionotropic, N M DA receptors) .  Future studies 
could be focused in  many d irections such as incorporating more an imal  models , 
further gene ana lysis and i nvolving human stud ies. Obvious d i rections include 
confirmation in  other d iabetic an ima l  models for example Zucker fatty rats. Zucker 
an imals have been obta ined and these studies are now underway. Earl ier time 
POints of the GK model can also be investigated.  Characterization of protein  
expression needs to  be investigated by western blot and/or immunohistochemistry. 
I n  addit ion, it would be worthwhi le to broaden the investigation of gene expression to 
include genes that are coloca l ized with g lutamate in the secretory granules.  These 
include those that code for genes such as CGRP,  tachykin ins (substance P, 
neurok in in A etc) which are known to be i nvolved in the pain pathways. 
Analyzing gene expression patterns can provide clues about gene function 
but further understanding requ i re m utants that lack a part icu lar gene may qu ickly 
revea l  the function of the protein that it encodes. Other d i rections i nclude 
mani pu lation of gene expression using knockout m ice and also overexpression of 
the respective genes and investigat ing the effects of that on d iabetes in  these 
an imal  g roups. 
I t  may a lso be possible to undertake l im ited investigation us ing autopsy 
t issues from patients with and without d iabetic neuropathy. 
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